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Background: The principal diagnosis/indication for this assessment is chronic diarrhoea due to bile acid
malabsorption (BAM). Diarrhoea can be defined as the abnormal passage of loose or liquid stools more
than three times daily and/or a daily stool weight > 200 g per day and is considered to be chronic if it
persists for more than 4 weeks. The cause of chronic diarrhoea in adults is often difficult to ascertain and
patients may undergo several investigations without a definitive cause being identified. BAM is one of
several causes of chronic diarrhoea and results from failure to absorb bile acids (which are required for the
absorption of dietary fats and sterols in the intestine) in the distal ileum.
Objective: For people with chronic diarrhoea with unknown cause and in people with Crohn’s disease
and chronic diarrhoea with unknown cause (i.e. before resection): (1) What are the effects of selenium-75-
homocholic acid taurine (SeHCAT) compared with no SeHCAT in terms of chronic diarrhoea, other health
outcomes and costs? (2) What are the effects of bile acid sequestrants (BASs) compared with no BASs in
people with a positive or negative SeHCAT test? (3) Does a positive or negative SeHCAT test predict
improvement in terms of chronic diarrhoea, other health outcomes and costs?
Data sources: A systematic review was conducted to summarise the evidence on the clinical effectiveness
of SeHCAT for the assessment of BAM and the measurement of bile acid pool loss. Search strategies were
based on target condition and intervention, as recommended in the Centre for Reviews and Dissemination
(CRD) guidance for undertaking reviews in health care and the Cochrane Handbook for Diagnostic Test
Accuracy Reviews. The following databases were searched up to April 2012: MEDLINE; MEDLINE In-Process
& Other Non-Indexed Citations; EMBASE; the Cochrane Databases; Database of Abstracts of Reviews of
Effects; Health Technology Assessment (HTA) Database; and Science Citation Index. Research registers and
conference proceedings were also searched.
Review methods: Systematic review methods followed the principles outlined in the CRD guidance for
undertaking reviews in health care and the National Institute for Health and Care Excellence (NICE)
Diagnostic Assessment Programme interim methods statement. In the health economic analysis, the
cost-effectiveness of SeHCAT for the assessment of BAM, in patients with chronic diarrhoea, was
estimated in two different populations. The first is the population of patients with chronic diarrhoea with
unknown cause and symptoms suggestive of diarrhoea-predominant irritable bowel syndrome (IBS-D) and
the second population concerns patients with Crohn’s disease without ileal resection with chronicv
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ABSTRACT
vidiarrhoea. For each population, three models were combined: (1) a short-term decision tree that models
the diagnostic pathway and initial response to treatment (first 6 months); (2) a long-term Markov model
that estimates the lifetime costs and effects for patients initially receiving BAS; and (3) a long-term Markov
model that estimates the lifetime costs and effects for patients initially receiving regular treatment
(IBS-D treatment in the first population and Crohn’s treatment in the second population). Incremental
cost-effectiveness ratios were estimated as additional cost per additional responder in the short term (first
6 months) and per additional quality-adjusted life-year (QALY) in the long term (lifetime).
Results: We found three studies assessing the relationship between the SeHCAT test and response to
treatment with cholestyramine. However, the studies had small numbers of patients with unknown cause
chronic diarrhoea, and they used different cut-offs to define BAM. For the short term (first 6 months),
when trial of treatment is not considered as a comparator, the optimal choice depends on the willingness
to pay for an additional responder. For lower values (between £1500 and £4600) the choice will be no
SeHCAT in all scenarios; for higher values either SeHCAT 10% or SeHCAT 15% becomes cost-effective.
For the lifetime perspective, the various scenarios showed widely differing results: in the threshold range of
£20,000–30,000 per QALY gained we found as optimal choice either no SeHCAT, SeHCAT 5% (only
IBS-D) or SeHCAT 15%. When trial of treatment is considered a comparator, the analysis showed that for
the short term, trial of treatment is the optimal choice across a range of scenarios. For the lifetime
perspective with trial of treatment, again the various scenarios show widely differing results. Depending on
the scenario, in the threshold range of £20,000–30,000 per QALY gained, we found as optimal choice
either trial of treatment, no SeHCAT or SeHCAT 15%.
Conclusions: In conclusion, the various analyses show that for both populations considerable decision
uncertainty exists and that no firm conclusions can be formulated about which strategy is optimal.
Standardisation of the definition of a positive SeHCAT test should be the first step in assessing the
usefulness of this test. As there is no reference standard for the diagnosis of BAM and SeHCAT testing
provides a continuous measure of metabolic function, diagnostic test accuracy (DTA) studies are not the
most appropriate study design. However, in studies where all patients are tested with SeHCAT and all
patients are treated with BASs, response to treatment can provide a surrogate reference standard; further
DTA studies of this type may provide information on the ability of SeHCAT to predict response to BASs.
A potentially more informative option would be multivariate regression modelling of treatment response
(dependent variable), with SeHCAT result and other candidate clinical predictors as covariates. Such a
study design could also inform the definition of a positive SeHCAT result.
Study registration: The study is registered as PROSPERO CRD42012001911.
Funding: The National Institute for Health Research Health Technology Assessment programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Bile acid malabsorption One of several causes of chronic diarrhoea, resulting from failure to absorb bile
acids (which are required for the absorption of dietary fats and sterols in the intestine) in the distal ileum.
Bile acid sequestrant Intervention for the treatment of BAM, which can cause significant reduction in
bowel frequency and therefore a better quality of life. There are currently three bile acid sequestrants
available: cholestyramine, colestipol and colesevelam.
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes the
costs for additional health gain.
Crohn’s disease A chronic, severe condition characterised by inflammation, ulcers and bleeding which may
affect any part of the gastrointestinal tract, mostly the terminal ileum.
Decision modeling A mathematical construct that allows the comparison of the relationship between costs
and outcomes of alternative health-care interventions.
False-negative Incorrect negative test result: number of diseased persons with a negative test result.
False-positive Incorrect positive test result: number of non-diseased persons with a positive test result.
Geometric centre The geometric centre analysis is often used for evaluating colonic transit data obtained
by scintigraphy.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Inflammatory bowel disease The most common types of IBD are ulcerative colitis and Crohn’s disease.
Both ulcerative colitis and Crohn’s disease directly cause chronic diarrhoea.
Irritable bowel syndrome One of the most common functional gastrointestinal disorders, characterised by
the presence of abdominal pain/discomfort associated with defecation, a change in bowel habit together
with disordered defecation (constipation or diarrhoea or both), the sensation of abdominal distension, and
can include associated non-colonic symptoms.
Markov model An analytic method particularly suited to modelling repeated events, or the progression of a
chronic disease over time.
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
Meta-regression Statistical technique used to explore the relationship between study characteristics and
study results.
Opportunity costs The cost of forgone outcomes that could have been achieved through
alternative investments.ix
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GLOSSARY
xPublication bias Bias arising from the preferential publication of studies with statistically significant results.
Quality-adjusted life-year A measure of health gain, used in economic evaluations, in which survival
duration is weighted or adjusted by the patient’s quality of life during the survival period.
Quality of life An individual’s emotional, social and physical well-being, and their ability to perform the
ordinary tasks of living.
Receiver operating characteristic curve A graph which illustrates the trade-offs between sensitivity and
specificity which result from varying the diagnostic threshold.
Reference standard The best currently available diagnostic test, against which the index test is compared.
SeHCAT A radiopharmaceutical that is licensed for use in the investigation of BAM and measurement of bile
acid pool loss.
Sensitivity Proportion of people with the target disorder who have a positive test result.
Specificity Proportion of people without the target disorder who have a negative test result.
True-negative Correct negative test result: number of non-diseased persons with a negative test result.
True-positive Correct positive test result: number of diseased persons with a positive test result.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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CRD Centre for Reviews and
Dissemination
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DARE Database of Abstracts of Reviews
of Effects
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EAG External Assessment Group
EVPI expected value of perfect
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FN false-negative
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GE gastric emptying
GP general practitioner
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IBD inflammatory bowel disease
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MD mean difference
MeSH medical subject heading
NA not applicable
ND no diarrhoea
NHS EED NHS Economic Evaluation Database
NICE National Institute for Health and
Care Excellence
NR not reported
OR odds ratio
QALY quality-adjusted life-year
RE random effects
ROC receiver operating characteristic
RR relative risk
SCI Science Citation Index
SD standard deviation
SeHCAT selenium-75-homocholic acid
taurine
SMD standardised mean difference
SMR standardised mortality ratio
SSRI selective serotonin reuptake
inhibitor
TCA tricyclic antidepressant
TN true-negative
TNF-α tumour necrosis factor alpha
TP true-positivexi
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The principal diagnosis/indication for this assessment is chronic diarrhoea due to bile acid malabsorption
(BAM). BAM is one of several causes of chronic diarrhoea and results from failure to absorb bile acids
(which are required for the absorption of dietary fats and sterols in the intestine) in the distal ileum.
Selenium-75-homocholic acid taurine (SeHCAT; GE Healthcare) is a radiopharmaceutical that is licensed
for use in the investigation of BAM and measurement of bile acid pool loss. Current diagnostic options
include analysis of a patient’s history, investigations to exclude ‘red flag’ symptoms and a variety of other
diagnostic tests such as blood tests and lactose tolerance tests. Trial of treatment is used, with mixed
results, to diagnose BAM. It is, however, not widely used in current practice [National Institute for Health
and Care Excellence (NICE). Diagnostics Assessment Programme: SeHCAT (Tauroselcholic [75Selenium]
acid) for the investigation of diarrhoea due to bile acid malabsorption: final scope. London: NICE; 2011].
The main comparator for the assessment includes tests and clinical observations contained in the British
Society of Gastroenterology (BSG) guidelines for the investigation of chronic diarrhoea. As mentioned in
the NICE scope, there is no direct comparator for SeHCAT.
In consultation with NICE and clinical experts during early scoping it was agreed that the review should
focus on two populations:
1. people presenting with chronic diarrhoea with unknown cause and symptoms suggestive of
functional disease
2. people with Crohn’s disease and chronic diarrhoea with unknown cause (i.e. before resection of the
terminal ileum).Objectives
To evaluate the clinical effectiveness and cost-effectiveness of selenium-75-homocholic acid taurine
(SeHCAT), a bile acid analogue that is used as a test for investigating BAM and the measurement
of bile acid pool loss in patients referred to a gastrointestinal clinic for investigation and diagnosis
of BAM.
This can be translated into the following research questions. For people with chronic diarrhoea with
unknown cause and in people with Crohn’s disease and chronic diarrhoea with unknown cause
(i.e. before resection):
1. What are the effects of SeHCAT compared with no SeHCAT in terms of chronic diarrhoea, other health
outcomes and costs?
2. What are the effects of bile acid sequestrants (BASs) compared with no BASs in people with a positive
or negative SeHCAT test?
3. Does a positive or negative SeHCAT test predict improvement in terms of chronic diarrhoea, other
health outcomes and costs?xiii
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xivMethods
A systematic review was conducted to summarise the evidence on the clinical effectiveness of SeHCAT for
the assessment of BAM and the measurement of bile acid pool loss. Search strategies were based on
target condition and intervention. Nine databases were searched up to April 2012:
l MEDLINE (1946–week 1 April 2012) (OvidSP)
l MEDLINE In-Process & Other Non-Indexed Citations and Daily Update (inception up to 17 April 2012)
(OvidSP)
l EMBASE (1980–week 15 2012) (OvidSP)
l Cochrane Database of Systematic Reviews (The Cochrane Library Issue 3:2012) (Wiley Online Library)
l Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4:2012) (Wiley
Online Library)
l Database of Abstracts of Reviews of Effects (inception up to 19 April 2012) [Centre for Reviews and
Dissemination (CRD) website]
l Health Technology Assessment (HTA) Database (inception up to 19 April 2012) (CRD website)
l Science Citation Index (1970–18 April 2012) (Web of Science)
l National Institute for Health Research HTA (inception up to 19 April 2012) (internet).
Research registers and conference proceedings were also searched. Systematic review methods followed
the principles outlined in the CRD guidance for undertaking reviews in health care and the NICE
Diagnostic Assessment Programme interim methods statement.
The methodological quality of included studies was assessed using standard tools.
Results were summarised in tables and text, stratified by principal diagnosis (chronic diarrhoea/IBS or
Crohn’s disease), as appropriate. The review included only three assessments of the relationship between
the SeHCAT test and treatment with BAS (cholestyramine). These three studies used different SeHCAT
cut-off points to define BAM and pooling of results was deemed inappropriate.
In the health economic analysis, the cost-effectiveness of SeHCAT for the assessment of BAM in patients
with chronic diarrhoea was estimated in two different populations. The first is the population of
patients with chronic diarrhoea with unknown cause and symptoms suggestive of diarrhoea-predominant
irritable bowel syndrome (IBS-D) and the second population concerns patients with Crohn’s disease
without ileal resection with chronic diarrhoea.
For both populations the cost-effectiveness of SeHCAT compared with no SeHCAT was assessed. For the
SeHCAT option we defined various strategies based on the test cut-off points used to classify patients. For
the IBS-D patient population, data were available to be able to distinguish between cut-off points of 5%,
10% and 15%. For the Crohn’s patient population, only data on a 10% and 15% SeHCAT test cut-off
were available. For the no SeHCAT strategy all patients receive regular treatment for either IBS-D or
chronic diarrhoea in Crohn’s. Additionally, in the scoping document, ‘trial of treatment with BAS’ was
mentioned as another possible strategy without specifically including it as a comparator. According to the
clinical experts at the scoping meeting, trial of treatment is rarely used as a treatment strategy and was
thus not considered relevant. However, trial of treatment could also not be completely excluded as an
option. Thus, in this report, for both populations we present two sets of results: one where trial of
treatment is not considered as a comparator and one where it is. In the trial of treatment strategy, patients
first receive a BAS and when patients do not respond they receive regular treatment for either IBS-D or
chronic diarrhoea in Crohn’s.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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1. a short-term decision tree that models the diagnostic pathway and initial response to treatment
(first 6 months)
2. a long-term Markov model that estimates the lifetime costs and effects for patients initially
receiving BAS
3. a long-term Markov model that estimates the lifetime costs and effects for patients initially
receiving regular treatment (IBS-D treatment in the first population and Crohn’s treatment in the
second population).
In the decision tree the 6-month number of responders and the expected costs were calculated for each
comparator while for the Markov models lifetime expected quality-adjusted life-years (QALYs) and
expected costs per patient were calculated for each comparator.
Where possible, input for the model was based on our SeHCAT systematic review, other published
literature and UK databases. When such evidence was not available, expert opinion was used. The impact
of uncertainty about the various input parameters on the outcomes was explored through probabilistic
sensitivity analyses and scenario analyses.
Incremental cost-effectiveness ratios (ICERs) were estimated as additional cost per additional responder in
the short term (first 6 months) and per additional QALY in the long term (lifetime).Results
Twenty of the 21 studies included studies in the systematic review were studies assessing the value of
SeHCAT in predicting the response to BAS. Of these 20 SeHCAT studies, 19 included people with
chronic diarrhoea with unknown cause and two studies included people with Crohn’s disease and
chronic diarrhoea.
Three studies were reasonably reliable in assessing the relationship between the SeHCAT test and response
to treatment with cholestyramine. However, the studies had small numbers of patients with unknown
cause chronic diarrhoea, they used different cut-offs for the assessment of BAM and between study
heterogeneity was considerable.
None of the studies looking specifically at people with Crohn’s disease presented reliable data for the
prediction of response to treatment with BAS because no data were presented for people with a negative
SeHCAT test in the two studies.
One randomised controlled trial in patients with IBS-D, which compared treatment with BAS (colesevelam)
with placebo, showed no significant differences in terms of colonic transit, bowel function or adverse
events. However, randomisation (sequence generation and allocation concealment) was not adequately
reported and groups were small (n = 12 in both arms).
For people with chronic diarrhoea, 19 studies provide data on the effectiveness of BAS given a positive
SeHCAT test; three studies also provided data on the effectiveness of BAS given a negative SeHCAT test.
For those with a positive SeHCAT test response rates were on average 85%, 73% and 72% for cut-offs at
5%, 10% and 15%, respectively. For those with a negative SeHCAT test the response rate was 14% at a
cut-off of 5% and 0% at a cut-off of 15%. For people with Crohn’s disease and a positive SeHCAT test
the response rate was 95% at a cut-off of 5% and 86% or 89% at a cut-off of 15%.
The health economic analysis showed for the IBS-D population that for the short term (first 6 months),
when trial of treatment is not considered as a comparator, that the optimal choice depends on thexv
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SCIENTIFIC SUMMARY
xviwillingness to pay for an additional responder. For lower values (base case £2400, scenarios between
£1800 and £4600) the choice will be no SeHCAT in all scenarios; for higher values either SeHCAT 10% or
SeHCAT 15% becomes cost-effective.
For the lifetime perspective, we did not define a base case, as we had no information of any kind to
inform the transition probabilities between the health states diarrhoea and no diarrhoea and vice versa.
Thus, only scenario analysis was performed. The various scenarios showed widely differing results.
Depending on the scenario, in the threshold range of £20,000 to £30,000 per QALY gained, we found as
optimal choice either no SeHCAT, SeHCAT 5% or SeHCAT 15%; only SeHCAT 10% never had the highest
probability of being cost-effective.
When trial of treatment is considered a comparator, the analysis showed for the IBS-D population that for
the short term, trial of treatment is the optimal choice across a range of scenarios. In the base-case
scenario, trial of treatment dominated all other strategies and had a 95% probability of being the most
cost-effective option. In the various scenarios, trial of treatment was dominant compared with all
strategies. For all scenarios trial of treatment had the highest probability of being cost-effective; this
probability was for most scenarios around 90%, decreasing for some scenarios to 50%.
For the lifetime perspective, for all but two scenarios, trial of treatment was the strategy with the highest
probability of being cost-effective for thresholds above £5000–15,000, with no SeHCAT the most
favourable strategy for lower-threshold ICERs. In the two scenarios where the transition probability from
diarrhoea to no diarrhoea in the BAM model was 5% per cycle while all others were 0, we observed that
for thresholds > £15,000 SeHCAT 15% had the highest probability of being cost-effective.
For the Crohn’s population, the short-term evaluation without trial of treatment as comparator showed for
the short term that the optimal choice depends on the willingness to pay for an additional responder. For
lower values (base case £2300, scenarios between £1500 and £4000) the choice will be no SeHCAT in all
scenarios; for higher values SeHCAT 10% becomes cost-effective.
For the long term, the various scenarios show widely differing results. Depending on the scenario, in the
threshold range of £20,000–30,000 per QALY gained, we found as optimal choice either no SeHCAT
or SeHCAT 15% while some scenarios found that all three strategies had the same probability of
being cost-effective.
When trial of treatment is considered a comparator, the analysis showed for the Crohn’s population that
for the short term, trial of treatment dominated all other strategies (in terms of number of responders) and
had an almost 100% probability of being the most cost-effective option. In the various scenarios, trial of
treatment was dominant compared with all strategies. For all scenarios trial of treatment had the highest
probability of being cost-effective; for most scenarios this probability was around 90%.
For the lifetime perspective in Crohn’s with trial of treatment, again the various scenarios show widely
differing results. Depending on the scenario, in the threshold range of £20,000–30,000 per QALY gained,
we found as optimal choice either trial of treatment, no SeHCAT or SeHCAT 15%.Conclusions
We found three studies assessing the relationship between the SeHCAT test and response to treatment
with cholestyramine. However, the studies had small numbers of patients with unknown cause chronic
diarrhoea, and they used different cut-offs to define BAM. None of the studies looking specifically at
people with Crohn’s disease presented reliable data for the prediction of response to treatment with BAS
because no data were presented for people with a negative SeHCAT test in the two studies.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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with placebo, showed no significant differences in terms of colonic transit or adverse events.
The health economic analysis has shown similar results for both patient populations considered.
For the short term (first 6 months), when trial of treatment is not considered as a comparator, the optimal
choice depends on the willingness to pay for an additional responder. For lower values (between £1500
and £4600) the choice will be no SeHCAT in all scenarios; for higher values either SeHCAT 10% or
SeHCAT 15% becomes cost-effective.
For the lifetime perspective, the various scenarios showed widely differing results: in the threshold range of
£20,000 to £30,000 per QALY gained we found as optimal choice either no SeHCAT, SeHCAT 5% (only
IBS-D) or SeHCAT 15%.
When trial of treatment is considered a comparator, the analysis showed that for the short term, trial of
treatment is the optimal choice across a range of scenarios.
For the lifetime perspective with trial of treatment, again the various scenarios show widely differing
results. Depending on the scenario, in the threshold range of £20,000–30,000 per QALY gained, we
found as optimal choice either trial of treatment, no SeHCAT or SeHCAT 15%.
In conclusion, the various analyses have shown that for both populations considerable decision uncertainty
exists, and that no firm conclusions can be formulated about which strategy is optimal.Suggested research priorities
Standardisation of the definition of a positive SeHCAT test should be the first step in assessing the
usefulness of this test. As there is no reference standard for the diagnosis of BAM and SeHCAT testing
provides a continuous measure of metabolic function, diagnostic test accuracy (DTA) studies are not the
most appropriate study design. However, in studies where all patients are tested with SeHCAT and all
patients are treated with BAS, response to treatment can provide a surrogate reference standard; further
DTA studies of this type may provide information on the ability of SeHCAT to predict response to BAS.
A potentially more informative option would be multivariate regression modelling of treatment response
(dependent variable), with SeHCAT result and other candidate clinical predictors as covariates. Such a
study design could also inform the definition of a positive SeHCAT result.
The limited evidence identified means that the effectiveness of BAS, both in unselected patients with
chronic diarrhoea and where treatment decisions are based on SeHCAT test results, remains uncertain.
Two possible randomised controlled designs are, therefore, potentially useful:
1. Patients with chronic diarrhoea receive SeHCAT testing and all patients are then randomised to
treatment with BAS or placebo. This study design can provide information on the effectiveness of BAS
in all patients with relevant symptoms. If the analysis is then stratified by test result, information can be
obtained on any difference in effectiveness between SeHCAT-positive and SeHCAT-negative patients,
or variation in the effectiveness of BAS with levels of SeHCAT absorption.
2. Patients with chronic diarrhoea receive SeHCAT testing and only patients with a positive SeHCAT test
are randomised to treatment with BAS or placebo. This study design can provide information on the
effectiveness of BAS in SeHCAT-positive patients. This design might be considered more ethical if
it is believed that current evidence is sufficient to indicate no or minimal effectiveness of BAS in
SeHCAT-negative patients.
The inclusion criteria for such a trial are important to make sure that patients are not unnecessarily
subjected to BAS treatment and at the same time, all patients suitable for a SeHCAT test are included.
Treatment strategies should be clearly described in the study protocol. Long-term follow-up is needed toxvii
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SCIENTIFIC SUMMARY
xviiifully assess the effectiveness of BAS in all relevant patient groups. Outcomes should include all relevant
bowel function and transit outcomes, as well as quality of life (including utility) and adverse events of
testing and treatment. Additionally, such trials should enable the collection of resource use data related to
the chronic diarrhoea problems.
Moreover, the large variation in outcomes between the scenarios considered for the Markov models make
it clear that long-term data are important for patients with IBS-D, patients identified as having BAM and
Crohn’s patients with chronic diarrhoea. These data do not necessarily need to come from a randomised
controlled trial; it might be possible to set up a retrospective study using existing databases, patient
records, etc., to find relevant long-term data. If those sources of information do not provide enough
information, prospective observational studies could collect data on treatment and treatment switches and
resource use.
It was also shown in the various scenarios that the assumption about utility values for BAM health states
have an important impact on the results. For reliable utility estimates for the various health states, a
cross-sectional study in the relevant patient populations would be a relatively easy way to inform these
important parameters.Study registration
This study is registered as PROSPERO CRD42012001911.Funding
The National Institute for Health Research Health Technology Assessment programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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decision problem(s)Conditions and aetiologies
Bile acid malabsorption
The principal diagnosis/indication for this assessment is chronic diarrhoea due to bile acid malabsorption
(BAM). Diarrhoea can be defined as the abnormal passage of loose or liquid stools more than three times
daily and/or a daily stool weight greater than 200 g per day and is considered to be chronic if it persists for
more than 4 weeks.1 The cause of chronic diarrhoea in adults is often difficult to ascertain and patients
may undergo several investigations without a definitive cause being identified.2 Chronic diarrhoea is one of
the most common reasons for referral to a gastrointestinal clinic,3 and could account for as many as 1 in
20 referrals. Estimates of the prevalence of chronic diarrhoea in a Western population are 4–5%.4 Some of
the causes of chronic diarrhoea are given in Box 1.
Bile acid malabsorption is one of several causes of chronic diarrhoea (see Box 1) and results from failure to
absorb bile acids (which are required for the absorption of dietary fats and sterols in the intestine) in the
distal ileum. Normally, more than 90% of the acids are reabsorbed in the distal ileum. BAM results in excess
bile acids in the colon where they cause diarrhoea by various mechanisms. These mechanisms include:
l inducing secretion of sodium and water, particularly at a concentration above 3 mmol/l
l increase colonic motility
l stimulating defecation
l inducing mucus secretion
l causing damage to mucosa, thereby increasing mucosal permeability.
Bile acid malabsorption has been divided into three types depending on aetiology:
1. type 1: following ileal resection, disease or bypass of the terminal ileum
2. type 2: primary idiopathic malabsorption
3. type 3: associated with cholecystectomy, peptic ulcer surgery, chronic pancreatitis, coeliac disease and
diabetes mellitus.Irritable bowel syndrome
People with chronic diarrhoea are often diagnosed as having diarrhoea-predominant irritable bowel
syndrome (IBS-D) if a definitive cause has not been identified. There is evidence that suggests a high
prevalence of BAM (up to one-third) in patients previously diagnosed with IBS-D.3,5 On this basis,
approximately half a million patients in the NHS who are currently treated for IBS-D actually have BAM, for
which potential diagnosis and effective treatment are available.6
Irritable bowel syndrome is one of the most common functional gastrointestinal disorders. It is a chronic,
relapsing and often life-long disorder, characterised by the presence of abdominal pain/discomfort associated
with defecation, a change in bowel habit together with disordered defecation (constipation or diarrhoea or
both), the sensation of abdominal distension, and can include associated non-colonic symptoms. These
morbidities can cause dehydration, lack of sleep, anxiety and lethargy, with consequences such as time taken
off work, avoidance of stressful or social situations and significant reduction in quality of life.7
Irritable bowel syndrome most commonly affects people between the ages of 20 and 30 years and is twice
as common in women as in men. People with IBS are the largest group of patients seen in a general1
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BOX 1 Causes of diarrhoea (from Thomas et al.1)
Colonic
l Colonic neoplasia.
l Ulcerative and Crohn’s colitis.
l Microscopic colitis.
Small bowel
l Coeliac disease.
l Crohn’s disease.
l Other small bowel enteropathies (e.g. Whipple’s disease, tropical spruce, amyloid,
intestinal lymphangiectasia).
l Bile acid malabsorption.
l Disaccharidase deficiency.
l Small bowel bacterial overgrowth.
l Mesenteric ischaemia.
l Radiation enteritis.
l Lymphoma.
l Giardiasis (and other chronic infections).
Pancreatic
l Chronic pancreatitis.
l Pancreatic carcinoma.
l Cystic fibrosis.
Endocrine
l Hyperthyroidism.
l Diabetes.
l Hypoparathyroidism.
l Addison’s disease.
l Hormone-secreting tumours (VIPoma, gastrinoma, carcinoid).
Other
l Factitious diarrhoea.
l ‘Surgical’ causes (e.g. small bowel resection, internal fistulae).
l Drugs.
l Alcohol.
l Autonomic neuropathy.
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM(S)
2gastroenterology clinic (1 in 20 referrals). The prevalence of the condition in the general population is
estimated at between 10% and 20%.7 Recent trends indicate that there is also a significant prevalence of IBS
in older people, and therefore IBS diagnosis should be a consideration when an older person presents with
unexplained abdominal symptoms. The true prevalence of IBS in the whole population may be higher than
estimated, because it is thought that many people with IBS symptoms do not seek medical advice; NHS Direct
online data suggest that 75% of people using this service who have IBS symptoms rely on self-care. In England
and Wales, the number of people consulting for IBS is extrapolated to between 1.6 million and 3.9 million.7NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Ulcerative colitis and Crohn’s disease are the two most common forms of inflammatory bowel disease
(IBD). Together these long-term conditions are estimated to affect about 240,000 people in the UK:
approximately 400 per 100,000 population.8 Both ulcerative colitis and Crohn’s disease directly cause
chronic diarrhoea.
Crohn’s disease is a chronic severe condition characterised by inflammation, ulcers and bleeding which
may affect any part of the gastrointestinal tract but mostly the terminal ileum. There are approximately
60,000 people in the UK with this condition (Figure 1).9 Crohn’s disease is sometimes treated by ileal
resection. In a study carried out by Smith et al.3 BAM was found in 97% of people with Crohn’s disease
with ileal resection who were in clinical remission and in 54% of people in clinical remission with
unoperated Crohn’s disease.
Description of technologies under assessment
(selenium-75-homocholic acid taurine)Selenium-75-homocholic acid taurine (SeHCAT) (GE Healthcare) is a radiopharmaceutical that is licensed
for use in the investigation of BAM and measurement of bile acid pool loss. It may also be used in
assessing ileal function, in the investigation of IBD and chronic diarrhoea and in the study of
enterohepatic circulation.
SeHCAT product information lists its applications as follows:FIGU
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Park, STauroselcholic acid is a bile acid analogue which shows identical physiological behaviour with naturally
occurring bile acid conjugates. Following oral administration in normal subjects, approximately 95%
of the labelled bile acid is absorbed, mainly by the terminal ileum during each enterohepatic cycle.
The distribution of activity is almost entirely confined to the lumen of the biliary ducts, gut and liver.
Whole body retention data from normal subjects showed 97 to 100% of [75Se]tauroselcholic was
excreted with a biological half-life of 2.6 days and that, in most cases, a small component of about
3% was eliminated with a mean half time of 62 days. GE Healthcare Ltd.11
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RE 1 Venn diagram with approximate population sizes in the UK. 1, 3 million in the UK (prevalence of chronic
rhoea in a Western population: 4–5%);1 2, unknown; 3, 1.3 million in the UK (there are up to 3.9 million adults
e UK being treated for IBS, with one-third of these having IBS-D);10 4, unknown (there are approximately
00 people in the UK with Crohn’s disease);9 5, unknown (BAM was found in 54% of people in clinical remission
unoperated Crohn’s disease);3 6, 500,000 in the UK.10
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BACKGROUND AND DEFINITION OF THE DECISION PROBLEM(S)
4ComparatorsThere is no direct comparator for this diagnostic test. Current diagnostic options include analysis of a
patient’s history, investigations to exclude ‘red flag’ symptoms and a variety of other diagnostic tests such
as blood tests and lactose tolerance tests. Trial of treatment is used, with mixed results, to diagnose BAM.
It is, however, not widely used in current practice.12
The main comparator for the assessment will be tests and clinical observations contained in the
British Society of Gastroenterology (BSG) guidelines for the investigation of chronic diarrhoea
(see Care pathways).1Care pathways
Diagnosis
Patients with undiagnosed BAM are likely to present with chronic diarrhoea. The BSG guideline states that
bile salt malabsorption occurs when normal active uptake from the ileum is disrupted by ileal inflammation
or resection. It also states that the degree of malabsorption depends on the length of ileal involvement or
resection. According to the BSG guidelines, diagnosis of BAM can be made via SeHCAT scanning.
During early scoping, two issues arose regarding the BSG pathway. First, all experts agreed that SeHCAT
needs to be placed earlier in the pathway to help patients gain a firm diagnosis at an earlier stage.
However, expert opinion varied as to where SeHCAT should be placed on the pathway. Some felt that it
should be available to general practitioners (GPs) for use in all patients with chronic, erratic bowels
with a tendency to diarrhoea, while others felt that it is more appropriate for use in secondary care.
Second, the BSG guideline does not take into account the prevalence of BAM in people diagnosed with
IBS. The BSG guideline place SeHCAT at the end of the diagnostic algorithm (position C in Figure 2).
Possible alternatives are:
1. SeHCAT as part of the basic investigations for all patients presenting with chronic diarrhoea (position A
in Figure 2)
2. SeHCAT for all patients presenting with chronic diarrhoea and symptoms suggestive of functional
disease (i.e. age < 45 and normal basic investigations) (position B1 in Figure 2); and also for patients
with a history of findings suggestive of colonic or terminal ileal disease (position B2 in Figure 2).
Selenium-75-homocholic acid taurine as part of the basic investigations (position A in Figure 2) means that
all patients presenting with chronic diarrhoea will be tested with SeHCAT. However, during the scoping
workshop clinical experts advised that a positive SeHCAT test at this stage does not rule out the possibility
of organic disease. As no subsequent tests for organic disease are made redundant, it is unlikely that
SeHCAT in position A will be more cost-effective than in position B1. Therefore, this assessment will focus
on position B1.
The same applies to SeHCAT in position B2. A positive SeHCAT test in position B2 is not thought likely to
stop clinicians from doing subsequent tests such as sigmoidoscopy, barium enema or colonoscopy.
Therefore, in the assessment, using SeHCAT in position B2 and in position C will be considered as having
the same effect on the care pathway.
This leaves two possible populations for investigation:
1. people presenting with chronic diarrhoea with unknown cause and symptoms suggestive of
functional disease
2. people with Crohn’s disease and chronic diarrhoea with unknown cause (i.e. before resection of the
terminal ileum).NIHR Journals Library www.journalslibrary.nihr.ac.uk
Basic investigations
FBC, LFT, Ca, B12,
folate, Fe status,
thyroid function,
coeliac serology
History suggestive of
organic diarrhoea
Abnormal basic
investigations
History or findings
suggestive of
malabsorption
History or findings
suggestive of
colonic or terminal
ileal disease
‘Difficult diarrhoea’
Suspicion of laxative
abuse
Persistent symptoms
with negative
investigations
High–volume diarrhoea
Consider inpatient
assessment
24 – 72 hours
stool weights
Stool osmolality/
osmotic gap
Laxative screen
Flexible simoidoscopy
if < 45 years
Complement with
barium enema
if > 45 years
Colonoscopy preferred
if > 45 years
A: SeHCAT
Pancreatic
CT pancreas
Faecal elastase or
chymotrypsin
Pancreolauryl test
Small bowel
D2 biopsy
Barium follow–through
Enteropathy
Review histology?
Enteroscopy
Bacterial overgrowth
Glucose hydrogen
breath test
Jejeunal aspirate and
culture
Further structural
tests ERCP or
MRCP
Terminal diseases
excluded?
Barium follow through
99mTc-HMPAO
C: 75SeHCAT
Gut hormones
Serum gestrin, VIP
Urinary 5-HIAA
Symptoms suggestive
 of functional disease
Age < 45 years + normal
basic investigations = 
 IBS
B2: SeHCAT
B1: SeHCAT
IGURE 2 British Society of Gastroenterology’s guideline for the investigation of chronic diarrhoea (adapted from
homas et al.1). B12, vitamin B12; Ca, calcium; FBC, full blood count; LFT, liner function tests.
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TTreatment
Following a definitive diagnosis, patients may be treated with bile acid sequestrants (BASs), which can
cause significant reduction in bowel frequency and therefore a better quality of life.13 There are currently
two types of BAS available:
1. Bile binding resins (cholestyramine and colestipol): although they are tolerated by some, most people
dislike these treatments because of side effects and the difficulty of administration, but take them in
the long term because they can help in managing the condition. One in four patients cannot take more
than a single dose.
2. Colesevelam (Cholestagel,® Genzyme) (gel matrix): two-thirds of patients take this treatment for at least
4 years and most of those who stop do so because they found no benefit initially.
The response to BAS therapy varies among people with bile acid diarrhoea. For those with Crohn’s disease
with ileal resection and BAM (assessed with SeHCAT), the response to BAS was 60%; response was 40%
in those with Crohn’s disease without ileal resection and BAM and 70% in those with a diagnosis of IBS-D
and BAM.35
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The objective of this project is to evaluate the clinical effectiveness and cost-effectiveness of SeHCAT, abile acid analogue which is used as a test for investigating BAM and the measurement of bile acid pool
loss in patients referred to a gastrointestinal clinic for investigation and diagnosis of BAM.
This can be translated in the following research questions. For people with chronic diarrhoea with
unknown cause and in people with Crohn’s disease and chronic diarrhoea with unknown cause
(i.e. before resection):
1. What are the effects of SeHCAT compared with no SeHCAT in terms of chronic diarrhoea, other health
outcomes and costs?
2. What are the effects of BASs compared with no BASs in people with a positive or negative
SeHCAT test?
3. Does a positive or negative SeHCAT test predict improvement in terms of chronic diarrhoea, other
health outcomes and costs?7
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A systematic review was conducted to summarise the evidence on the clinical effectiveness of SeHCATfor the assessment of BAM and the measurement of bile acid pool loss. Systematic review methods
will follow the principles outlined in the Centre for Reviews and Dissemination (CRD) guidance for
undertaking reviews in health care,14 and National Institute for Health and Care Excellence (NICE)
Diagnostic Assessment Programme interim methods statement.15Inclusion and exclusion criteria
Participants
Study populations eligible for inclusion will be all patients (including children) referred to a gastrointestinal
clinic for investigation and diagnosis of BAM which is a common underlying cause of chronic diarrhoea
and the measurement of bile acid pool loss.3,5
As explained above, this report will focus on two specific populations:
1. people presenting with chronic diarrhoea with unknown cause and symptoms suggestive of
functional disease
2. people with Crohn’s disease and chronic diarrhoea with unknown cause (i.e. before resection of the
terminal ileum).Setting
The relevant setting is secondary care.Interventions
The intervention is SeHCAT.Comparators
The comparator will be no SeHCAT test (the current situation).Outcomes
The following outcomes are considered:
l effect of testing on treatment plan (e.g. surgical or medical management), where information on the
appropriateness of the final treatment plan is also reported
l effect of testing on clinical outcome (e.g. morbidity and adverse events)
l prognosis – the ability of test result to predict clinical outcome (e.g. response to treatment).
For included studies reporting any of the above outcome measures, the following outcomes will also be
considered if reported:
l acceptability of tests to patients or surrogate measures of acceptability (e.g. waiting time and
associated anxiety)
l adverse events associated with testing (e.g. pain/discomfort experienced during the procedure and
waiting times before results).9
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ASSESSMENT OF CLINICAL EFFECTIVENESS
10Study design
The following study designs were eligible for inclusion:
l Randomised or non-randomised controlled trials, where participants are assigned to the intervention or
comparator tests, for treatment planning, and outcomes are compared at follow-up.
l Observational studies which report the results of multivariable regression modelling with clinical
outcome as the dependent variable and index test result as an independent variable. Included studies
should control adequately for potential confounders (e.g. age, sex, disease, etc.).
The following study/publication types were excluded:
l pre-clinical and animal
l reviews, editorials, and opinion pieces
l case reports
l studies reporting only technical aspects of the test, or image quality
l studies with < 10 participants.
As no studies were found with either of the above-mentioned study designs, it was decided to broaden
the inclusion criteria by allowing lower levels of evidence (change to protocol). Therefore, observational
studies reporting data to calculate the accuracy of SeHCAT in predicting treatment response and studies
reporting data on the clinical effectiveness of treatment given a positive and/or negative SeHCAT test
will also be included.Search strategySearch strategies were based on principal diagnosis and intervention, as recommended in the CRD
guidance for undertaking reviews in health care and the Cochrane Handbook for Diagnostic Test Accuracy
Reviews.14,16,17
The following databases were searched for relevant studies. No date limit was used and searches were
limited to remove animal studies:
l MEDLINE (1946–week 1 April 2012) (OvidSP)
l MEDLINE In-Process & Other Non-Indexed Citations and Daily Update (up to 17 April 2012) (OvidSP)
l EMBASE (1980–week 15 2012) (OvidSP)
l Cochrane Database of Systematic Reviews (CDSR) (The Cochrane Library Issue 3:2012) (Wiley
Online Library)
l Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4:2012) (Wiley
Online Library)
l Database of Abstracts of Reviews of Effects (DARE) (up to 19 April 2012) (CRD website)
l Health Technology Assessment Database (HTA) (up to 19 April 2012) (CRD website)
l Science Citation Index (SCI) (1970–18 April 2012) (Web of Science)
l NIHR HTA (up to 19 April 2012) (internet).
Supplementary searches were undertaken on the following resources to identify grey literature, completed
and ongoing trials:
l National Institutes of Health (NIH) Clinicaltrials.gov (internet) www.clinicaltrials.gov
l Current Controlled Trials (internet) www.controlled-trials.com
l WHO International Clinical Trials Registry Platform (ICTRP) (internet) www.who.int/ictrp/en
l EU Clinical Trials Register (EU CTR) (internet) www.clinicaltrialsregister.eu.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Original clinical effectiveness and trials searches undertaken between 9th and 16th January 2012 retrieved
5142 records. Update searches undertaken between 17th and 20th April 2012 found an additional
82 records (after deduplication), but no new includes.
Searches were undertaken to identify studies of SeHCAT in the diagnosis of BAM. The main EMBASE
strategy for each set of searches was independently peer reviewed by a second information specialist,
using the PRESS-EBC checklist.18 Search strategies were developed specifically for each database and the
keywords associated with BAM were adapted according to the configuration of each database. Searches
took into account generic and other product names for the intervention. No restrictions on language or
publication status were applied. Limits were applied to remove animal studies. Full search strategies are
reported in Appendix 1.
Electronic searches were undertaken for the following conference abstracts:
l British Society of Gastroenterology Annual Meetings 2008–2011: www.bsg.org.uk/education/meeting/
index.html
l Advances in Clinical Oesophageal Investigation Conference (ASCONA ESSENTIALS 2011). Online
Learning in Gastroenterology (OLGa): http://olga.uegf.org/portal/documents-explore.html#solr0
l Eighth Summer School of Gastroenterology (ASNEMGE-SS-PRAGUE2011). Online Learning in
Gastroenterology (OLGa): http://olga.uegf.org/portal/documents-explore.html#solr0
l GASTRO2009. Online Learning in Gastroenterology (OLGa): http://olga.uegf.org/portal/documents-
explore.html#solr0
l 18th United European Gastroenterology Week (UEGW2010). Online Learning in Gastroenterology
(OLGa): http://olga.uegf.org/portal/documents-explore.html#solr0
l 19th United European Gastroenterology Week (UEGW2011). Online Learning in Gastroenterology
(OLGa): http://olga.uegf.org/portal/documents-explore.html#solr0
l Conference Proceedings Citation Index-Science (CPCI-S) (1990–2012/04/18) (Web of Knowledge).
Identified references were downloaded in EndNote X4 software (Thomson Reuters, CA, USA) for further
assessment and handling.
References in retrieved articles were checked for additional studies. The final list of included papers was
also checked on PubMed for retractions and errata.19–21
Figure 3 depicts the flow of searches for clinical effectiveness.
Inclusion screening and data extraction
Two reviewers independently screened the titles and abstracts of all reports identified by searches and any
discrepancies were discussed and resolved by consensus. Full copies of all studies deemed potentially
relevant, after discussion, were obtained and the same two reviewers independently assessed these for
inclusion; any disagreements were resolved by consensus. Details of studies excluded at the full paper
screening stage are presented in Appendix 5.
Data relating to study details, participants, intervention and comparator tests, reference standard, and
outcome measures were extracted by one reviewer, using a piloted, standard data extraction form.
A second reviewer checked data extraction and any disagreements were resolved by consensus.Quality assessmentThe evidence-based Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool22–24 is
recommended for assessing the methodological quality of test accuracy studies.14,17 A revised version of11
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DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61QUADAS (QUADAS-2) has recently been published (www.QUADAS.org).25 QUADAS-2 more closely
resembles the approach and structure of the Cochrane risk of bias tool. It is divided into four key domains
covering participant selection, index test, reference standard, and the flow of patients through the study
(including timing of tests). Each domain is rated for risk of bias (low, high or unclear) and the tool provides
signalling questions, in each domain, to aid reviewers in reaching a judgement. The participant selection,
index test and reference standard domains are also, separately, rated for concerns regarding the
applicability of the study to the review question (low, high or unclear). Thus, QUADAS-2 separates bias
from external validity (applicability) and does not include any items that assess only reporting quality. The
QUADAS-2 tool does not currently include domains specific to the assessment of studies comparing
multiple index tests, such as those included in this assessment. Further development of QUADAS-2 in this
area is planned. A modified version of the QUADAS-2 tool, which includes an additional domain for the
comparator test and additional signalling questions in the ‘flow and timing’ domain, has been used in this
assessment. Review-specific guidance was produced for the use of the modified version of QUADAS-2 and
is reported in Appendix 2.
The results of the quality assessment are summarised and presented in tables and graphs in the results
of the systematic review (see Chapter 4, Results) and are presented in full, by study, in Appendix 3.
No diagnostic accuracy data set included in this assessment was of sufficient size to allow statistical
exploration of between-study heterogeneity based on aspects of risk of bias. The findings of the quality
assessment were used to inform recommendations for future research.
The risk of bias in the controlled clinical trial was assessed using a table based on the Cochrane
Collaboration’s tool for assessing risk of bias.16
The methodological quality of included effectiveness studies was assessed using standard tools.14 The
Cochrane Collaboration quality assessment checklist was used to assess the methodological quality of each
included study as detailed in Table 1.16
Each study was awarded a ‘yes’, ‘no’ or ‘unclear/unknown’ rating for each individual item in the checklist.
Any additional clarifications or comments were also recorded.
The quality of case–control and cohort studies was assessed using specific checklists for the
methodological quality assessment of these studies. In addition, we used an adapted version of the quality
assessment checklist by Wedlake et al.6 (see Appendix 2).
Quality assessment was carried out independently by two reviewers. Any disagreements were resolved by
consensus. The results of the quality assessment were used for descriptive purposes to provide an
evaluation of the overall quality of the included studies and to provide a transparent method of
recommendation for design of any future studies. In addition, where enough data were available from
the included studies, each of the quality components were included as explanatory variables in a
meta-regression analysis to investigate the association of each of these components with study results
as a way of explaining possible heterogeneity. Based on the findings of the quality assessment,
recommendations are made for the conduct of future studies.Methods of analysis/synthesisMeta-analysis was considered inappropriate, owing to the small number of test accuracy studies with
varying diagnostic thresholds and between-study heterogeneity in other study design categories (principal
diagnosis, treatment dose, definition of response, follow-up period and SeHCAT administration); we
therefore employed a narrative synthesis. Typically, this involved the use of text and tables to summarise
data. Studies were organised by clinical application (diagnosis of BAM in those with chronic diarrhoea
and those with Crohn’s disease) and study design (DTAs, observational studies of treatment effect in13
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TABLE 1 The Cochrane Collaboration’s Tool for Assessing Risk of Bias16
Domain Item Description
Sequence generation Was the allocation sequence
adequately generated?
The method used to generate the allocation
sequence should be described in sufficient detail
to allow an assessment of whether it should
produce comparable groups
Allocation concealment Was allocation adequately
concealed?
The method used to conceal the allocation
sequence should be described in sufficient detail
to determine whether intervention allocations
could have been foreseen in advance of, or
during, enrolment
Blinding of participants,
personnel and outcome
assessors
Was knowledge of the
allocated intervention
adequately prevented during
the study?
All measures used, if any, to blind study
participants and personnel from knowledge of
which intervention a participant received, should
be described. Any information relating to
whether the intended blinding was effective
should also be reported
Assessments will be made for
each main outcome (or class
of outcomes)
Incomplete outcome data Were incomplete outcome
data adequately addressed?
The completeness of outcome data for each main
outcome should be described, including attrition
and exclusions from the analysis. The authors
should report any attrition and exclusions, the
numbers in each intervention group (compared
with total randomised participants), reasons
for attrition/exclusions and any re-inclusions
in analyses
Assessments will be made for
each main outcome (or class
of outcomes)
Selective outcome reporting Are reports of the study free
of suggestion of selective
outcome reporting?
The study should be free of the possibility of
selective outcome reporting
Other sources of bias Was the study apparently free
of other problems that could
put it at a high risk of bias?
Overall, the study should be free from any
important concerns about bias (i.e. bias from
other sources not previously addressed by the
other items)
ASSESSMENT OF CLINICAL EFFECTIVENESS
14SeHCAT-positive patients, and RCT of BAS treatment in patients without SeHCAT testing). Text summaries
were supported by tables and figures as appropriate.Test accuracy
The results of DTA studies included in this review were summarised by clinical indication (chronic diarrhoea
only). For all included studies, the absolute numbers of true-positive (TP), false-negative (FN), false-positive
(FP) and true-negative (TN) test results of SeHCAT compared with the reference standard of treatment
response, as well as sensitivity and specificity values, with 95% confidence intervals (CIs) were presented in
results tables. The results of individual studies were plotted in the receiver operating characteristic (ROC)
plane, with the diagnostic threshold used for the SeHCAT test indicated.
As no studies were found for the assessment of SeHCAT’s test accuracy and very few studies for the
accuracy of SeHCAT to predict treatment response, it was decided to include studies reporting response to
BAS given a positive test to estimate the probability of a positive BAS response at different SeHCAT cut-off
points. Based on the data retrieved, a random-effects meta-analysis was performed to find a pooled
estimate for each of the three cut-off values.Dichotomous outcomes
Dichotomous data were analysed by calculating the relative risk (RR) for each trial using the random-effects
DerSimonian and Laird method and the corresponding 95% CIs.26NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Continuous outcomes
Continuous data were analysed by calculating the standardised mean difference (SMD) between groups
and the corresponding 95% CI, due to the different types of outcome measures. Where the standard
deviations and means were not determinable, they were estimated from the data that were provided or
from a representative value from other studies.
Systematic differences between studies (heterogeneity) are likely; therefore, the random-effects model was
used for the calculation of RRs or SMDs. Heterogeneity was initially to be assessed by measuring the
degree of inconsistency in the studies’ results (I2). This measure (I2) describes the percentage of total
variation across studies that were due to heterogeneity rather than the play of chance. The value of I2 can
lie between 0% and 100%. Low, moderate and high I2 values correspond to 25%, 50% and 75%.
Where important heterogeneity was identified, we planned to formally investigate this using
meta-regression. In addition, a funnel plot (plots of logarithm of the RR for efficacy against the precision
of the logarithm of the RR) was planned to be generated in order to estimate potential asymmetry, which
is indicative of small study effects. In addition, we wanted to use the Egger regression asymmetry test in
order to facilitate the prediction of potential publication biases. This test detects funnel plot asymmetry
by determining whether or not the intercept deviates significantly from zero in a regression of the
standardised effect estimates against their precision. However, due to the lack of data this was
not possible.
Statistical analyses were performed using the following software: RevMan (version 5, The Cochrane
Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark), Comprehensive Meta-Analyses
(CMA version 2, Biostat, Englewood, NJ, USA: www.meta-analysis.com/pages/about_us.html) and Stata
(version 10, StataCorp LP, College Station, TX, USA).
A detailed commentary on the major methodological problems or biases that affected the studies was
also included, together with a description of how this may have affected the individual study results.
Recommendations for further research were made based on any gaps in the evidence or
methodological flaws.ResultsThe literature searches of bibliographic databases identified 4240 references. After initial screening of titles
and abstracts, 185 were considered to be potentially relevant and ordered for full-paper screening. Five
additional papers were ordered based on information from the manufacturer; one of these studies had
already been identified by bibliographic database searches (see Appendix 6). One additional study was
identified from searches of clinical trials registries. Of the total of 191 publications considered potentially
relevant, three could not be obtained within the time scale of this assessment: two possibly because the
reference details were not correct27,28 and one was held in British Library stacks which are currently closed
for asbestos removal.29 Figure 4 shows the flow of studies through the review process, and Appendix 5
provides details, with reasons for exclusions, of all publications excluded at the full-paper screening stage.
Based on the searches and inclusion screening described above, 24 publications of 21 studies were
included in the review. One of the included studies was reported as a conference abstract,30,31 and another
included study was reported as a student’s project under supervision of Professor McLaughlin at the
University of Manchester.32
All but one of the included studies were studies providing data on the accuracy of SeHCAT in predicting
treatment response (where treatment response is treated as the reference standard), or studies providing
data on treatment effects in SeHCAT-positive and -negative patient groups. Out of the 20 SeHCAT studies,
19 included people with chronic diarrhoea with unknown cause2,3,5,31–45 and two studies included15
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Full papers ordered after
screening industry
submissions
(n = 5)
Full papers ordered after
screening trial registry
entries
(n = 1)
Could not be obtained
(n = 3)
Excluded at title and
abstract screening
(n = 4055)  
Excluded at full-paper
screening
(n = 141)
Background papers,
excluded after checking
references
(n = 23)
Titles and abstracts identified from
bibliographic databases and
screened for potential relevance
(n = 4240)  
Total potentially relevant
publications obtained as full text
(n = 188) 
Potentially relevant publications
(n = 185) 
Total number of studies included
in the review
(n = 21; 24 publications) 
FIGURE 4 Flow of studies through the review process.
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16people with Crohn’s disease and chronic diarrhoea.3,46 The remaining study was a RCT which compared
treatment with BAS (colesevelam) with placebo for patients with IBS-D.47 This study reported the
following patient-relevant outcomes: colonic transit, bowel function, colonic mucosal permeability and
adverse events.
Three included studies were published between 1985 and 1987, nine studies were published in the 1990s,
four in 2000, 2001, 2003 and 2007 and five in 2010 and 2011. Twenty of the 21 included studies were
conducted in Europe (eight in the UK, five in Scandinavia, three in Spain and Italy each, and one in France)
and the remaining study was conducted in the USA. Nineteen of the 21 included studies were single-
centre studies and two were multicentre studies. Funding was not reported in most studies, and in one
study Amersham International supplied SeHCAT.39
Table 2 shows the details of included studies. Further details of the characteristics of study participants
and the technical details of the conduct of the index test (SeHCAT), comparator test(s) and reference
standard (where applicable) and their interpretation are reported in the data extraction tables presented
in Appendix 4.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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ASSESSMENT OF CLINICAL EFFECTIVENESS
26In the following sections we will discuss the results we found for the accuracy of SeHCAT for the detection
of BAM, the accuracy of SeHCAT for the assessment of response to treatment in people with chronic
diarrhoea and in people with Crohn’s disease; and the effectiveness of BAS for the treatment of BAM in
people with chronic diarrhoea and in people with Crohn’s disease.
Accuracy of selenium-75-homocholic acid taurine for the detection of bile
acid malabsorption
As mentioned in the NICE scope, there is no direct comparator for SeHCAT. Current diagnostic options
include analysis of a patient’s history, investigations to exclude ‘red flag’ symptoms and a variety of other
diagnostic tests such as blood tests and lactose tolerance tests. Trial of treatment and measurement of
faecal bile acids are two methods used, with mixed results, to diagnose BAM. They are, however, not
widely used in current practice.
In addition, the clinical effectiveness of BASs in people with chronic diarrhoea with unknown cause and in
people with Crohn’s disease and chronic diarrhoea of unknown cause is not known. Therefore, this
assessment will focus on the value of a SEHCAT test in predicting the response to treatment with BASs.
Any studies described in the literature as accuracy studies (Sciaretta42 in Johnston et al.;52 Merrick39 and
Sciaretta42 in Kurien et al.;53 and Sciaretta42 in Wedlake et al.6), will be included in this review under
studies predicting the response to BAS, if treatment response was assessed.
None of the studies evaluated in this report, including the studies described in the literature as accuracy
studies, was included in this review as diagnostic test accuracy (DTA) studies, because they either do not
use an acceptable reference standard or they include a population not in line with the scope (i.e. healthy
volunteers or people with ileal resection).Accuracy of selenium-75-homocholic acid taurine for the assessment of
response to treatment in people with chronic diarrhoea
Nineteen of the 20 studies with information on the relationship between SeHCAT and response to
treatment were in patients with chronic diarrhoea. These can be divided in different groups, depending on
the reliability of the results.
Most studies (12 out of 19) have no information about respondents with a negative SeHCAT test.2,3,5,31–33,
37,38,40,44,45,49 Therefore, these studies should be regarded as flawed design for the purposes of this review
and cannot be used to reliably asesess the relationship between SeHCAT and response to treatment.
Another three studies34,35,41 have very limited data for respondents with a negative SeHCAT test.
Four studies36,39,42,43 have data for all respondents with a negative SeHCAT test. However, in two of these
studies36,39 it is unclear why certain patients are treated and others not. In Fellous et al.,36 16 out of
53 patients with functional diarrhoea were treated with cholestyramine; 11 of these had a positive
SeHCAT test and 5 a negative SeHCAT test. It is not clear why the other 37 patients with functional
diarrhoea did not receive cholestyramine.
This leaves three studies to assess the relationship between the SeHCAT test and treatment
with cholestyramine:
l Merrick et al.39 estimated the sensitivity of SeHCAT in predicting a positive response as 0.667 (95% CI
0.223 to 0.957), and the specificity as 0.971 (95% CI 0.847 to 0.999) using a cut-off of 8% for the
test. Using a cut-off of 15%, the sensitivity is 1.000 (95% CI 0.541 to 1.000) and the specificity is
0.912 (95% CI 0.763 to 0.981).
l Sciaretta et al.42 estimated the sensitivity of SeHCAT in predicting a positive response as 0.857 (95% CI
0.421 to 0.996), and the specificity as 1.000 (95% CI 0.541 to 1.000) using a cut-off of 5% for the
test. However, only 13 patients were included in this analysis.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61l Sciaretta et al.43 estimated the sensitivity of SeHCAT in predicting a positive response as 0.950
(95% CI 0.751 to 0.999), and the specificity as 0.962 (95% CI 0.804 to 0.999) using a cut-off of 8%
for the test.
It should be noted here that in the study by Merrick et al.,39 31 patients were considered TNs. This
assessment was based on long-term follow-up: ‘None of the 31 patients with irritable bowel disease who
retained more than 15% at seven days showed any evidence of small bowel disease, and none appeared
during a follow-up of at least 12 months, and in some up to 24 months. Simple conservative treatment
resolved or eased most symptoms’ (p. 266). The remaining nine patients were treated with cholestyramine;
five of these had a SeHCAT test result < 8%, one of whom did not respond to treatment and four had an
equivocal (between 8% and 15%) SeHCAT test result; two of these patients responded to cholestyramine
and two did not.
In the study by Sciaretta et al.,43 the cut-off for a positive SeHCAT was 8% based on a 7-day SeHCAT
retention measurement. However, in the study by Sciaretta et al.,42 the cut-off for a positive SeHCAT was
most likely based on a 3-day retention measurement, which was according to the authors equivalent to
5% at 7 days. These issues and possible overlap in populations in both Sciaretta papers are discussed in
more detail in the quality assessment (QUADAS-2, see Appendix 3) of these studies.
As can be seen in Figure 5, the sensitivity is highest with a cut-off of 15% and decreases with lower
cut-offs; while the specificity is less clearly related to the cut-off used.
The between-study heterogeneity in these three studies is considerable. The principal diagnosis, treatment
dose, the definition of response, follow-up period and SeHCAT administration was different between
trials. Most of these differences were between Merrick and the two Italian studies, but even the two Italian
studies were not completely similar (see Appendices 3 and 4 for details).
Three studies were included in the QUADAS-2 assessment; all three studies were rated as ‘unclear’ risk of
bias for the patient selection domain. Merrick et al.39 was rated ‘high’ risk of bias for the ‘flow and timing’
domain of QUADAS-2 because only test positive and equivocal patients received the reference treatment.
The test-negative patients were followed up and hence all patients did not receive the same reference
standard. Sciaretta et al.42 was rated ‘high’ risk of bias for the ‘index test’ domain of QUADAS-2 because a
threshold was not prespecified. Sciaretta et al.43 was rated as ‘low’ risk of bias for all the QUADAS-2
domains in this assessment except for ‘patient selection’ domain, where it was rated ‘unclear’ risk of bias0.8
0.9
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FIGURE 5 ‘Accuracy’ of SeHCAT to predict a response to treatment at different cut-offs. The centre dots represent the
point estimates for sensitivity and specificity of SeHCAT in predicting response to treatment in the three studies at
different cut offs (5%, 8% and 15%). The vertical and horizontal lines represent the 95% CIs for sensitivity and
specificity respectively; see data in Table 4.
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ASSESSMENT OF CLINICAL EFFECTIVENESS
28because the study did not clearly state whether the patient enrolment was prospective or retrospective.
The applicability concerns were high in two studies for the ‘patient selection’ domain because some
patients had cholecystectomy and < 90% of patients had unknown-cause diarrhoea.42,43 Merrick et al.39
had low applicability concerns for the ‘patient selection’ domain.
Table 3 provides a summary of the quality assessments for studies in this section and Table 4 summarises
individual study results.
Accuracy of selenium-75-homocholic acid taurine for the assessment of
response to treatment in people with Crohn’s disease
None of the studies looking specifically at people with Crohn’s disease presented reliable data for the
prediction of response to treatment with BAS. Only two studies looked at this population.3,46 Neither of
these studies presented data for people with a negative SeHCAT test. In addition, it was not clear why
certain people were treated and others not. In the study by Nyhlin et al.,46 34 out of 51 patients had a
positive SeHCAT test at a 10% cut-off, while 22 patients were treated, of whom one had a negative
SeHCAT (at 10%). In the study by Smith et al.,3 24 out of 44 patients had a positive SeHCAT test at a
10% cut-off; 11 of these were successfully treated with conventional treatment (prednisolone with or
without 5-ASA) and a further nine patients were treated with BAS after conventional treatment had failed.
Finally, Nyhlin et al.46 included patients with or without resection.Effectiveness of bile acid sequestrants for the treatment of bile acid
malabsorption in patients with chronic diarrhoea
One controlled clinical trial compared colesevelam with placebo for patients with IBS-D.47,50,51
All participants had fasting plasma 7α-C4 (C4) measured to assess for underlying BAM and had serum
FGF-19 measured. However, it is not certain whether or not this was used as an inclusion criterion.
SeHCAT was not used in this trial.
No controlled trials were found to assess the clinical effectiveness of cholestyramine in terms of bowel
function in patients with chronic diarrhoea of unknown cause, nor were any such trials found for other BASs.
This randomised trial was considered to have ‘risk of bias’ in a number of areas: sequence generation was
described as independently generated by a statistician at the Mayo Clinic, no further details were reported,
allocation concealment was not described, and results for some of the outcomes were not reported.
According to the authors, ‘colesevelam modestly affected overall colonic transit (24 hours, p = 0.22).
Emptying of the ascending colon took an average four hours longer in patients given colesevelam
compared with placebo. Colesevelam was associated with greater ease of stool passage (p = 0.048) and
somewhat firmer stool consistency (p = 0.12). No effects on mucosal permeability or safety were identified’
(p. 160).47 Our analyses using Cochrane’s Review Manager software identified no significant differences
between colesevelam and placebo for all outcomes.ABLE 3 QUADAS-2 results for studies of the accuracy of SeHCAT for the assessment of treatment response
Study ID
Risk of bias Applicability concerns
Patient
selection
Index
test
Reference
standard
Flow and
timing Patient selection
Merrick 198539 ? ☺ ? ☹ ☺
Sciaretta 198642 ? ☹ ? ? ☹
Sciaretta 198743 ? ☺ ☺ ☺ ☹
☹, high risk;☺, low risk; ?, unclear risk.TNIHR Journals Library www.journalslibrary.nihr.ac.uk
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ASSESSMENT OF CLINICAL EFFECTIVENESS
30Table 5 provides a summary of the risk of bias assessment for this study and Table 6 summarises results.
In addition to the RCT reported above, information about the clinical effectiveness of BAS for the
treatment of BAM can be derived from the 19 studies reported in Chapter 4 (see Accuracy of SeHCAT for
the assessment of response to treatment in people with chronic diarrhoea). All 19 studies provide data on
the clinical effectiveness of BAS given a positive SeHCAT test; three studies39,42,43 also provide data on the
effectiveness of BAS given a negative SeHCAT test. Table 7 provides a summary of the risk of bias
assessment for these studies; the results are reported in Tables 8 and 9. In these tables we have used data
for the population defined in the scope where we could find them and we have included only patients
who were actually treated, ignoring those with a positive SeHCAT test who were not treated.
Meta-analysis of test accuracy studies was considered inappropriate, owing to the small number of studies
with varying diagnostic thresholds and between-study heterogeneity in other study design categories
(principal diagnosis, treatment dose, definition of response, follow-up period and SeHCAT administration);
therefore, we employed a narrative synthesis in Chapter 4 (see Accuracy of selenium-75-homocholic acid
taurine for the assessment of response to treatment in people with Crohn’s disease). As mentioned
previously, the between-study heterogeneity in the 19 studies included in this section is also considerable.
The principal diagnosis, treatment dose, the definition of response, follow-up period and SeHCAT
administration were different between trials (see Appendix 4 for details). However, for the economic
model we need estimates for the probability of a positive SeHCAT test in people with IBS-D or Crohn’s
disease and the probability of a positive BAS response given a positive test result (see Chapter 5,
Model parameters). These probabilities can be derived from the data in these studies. Despite the
heterogeneity between studies, we decided to combine the results from different studies to derive an
estimate for these probabilities. As no studies could be classified as superior based on risk of bias, we
decided to include all studies in the meta-analysis. We chose a random-effects model, as this would ensure
that the CI would be wide enough to capture most uncertainties. However, given the large heterogeneity,
these results should be treated with appropriate caution.
For those with a positive SeHCAT test response rates ranged from 74% to 100% at a cut-off of 5% and
from 62% to 86% at a cut-off of 15%. For those with a negative SeHCAT test the response rate was
14% at a cut-off of 5% and 0% at a cut-off of 15%.ABLE 5 Quality assessment of Odunsi-Shiyanbade47,50,51
Items Judgement Description
Adequate sequence generation? Unclear ‘An independent Mayo Clinic statistician generated the
randomisation codes. Mayo Research Pharmacy
maintained the randomisation schedule in case of
emergency.’ No further details reported
Allocation concealment? No No details reported
Blinding? Yes Double blind. ‘All clinical and laboratory study personnel
were blinded throughout the study until all data were
locked and analysed’
Were patient characteristics comparable
at baseline?
Yes See table 1 in paper
Incomplete outcome data addressed? Yes All outcomes assessed appear to be reported for all patients
Free of selective reporting? No Some outcomes assessed were not reported [HAD and
SCL-90 (somatisation)]
Free of other bias? YesTNIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 7 Quality assessment for studies of SeHCAT for the assessment of treatment response
Study ID
Q1:
prospective
Q2:
diarrhoea
Q3:
known
cause
Q4:
SeHCAT
test
Q5:
cut-off
Q6:
reason
treatment
Q7:
neg.
test
Q8:
treatment
Q9:
response
Borghede
201133
R N N (57),
Y (298)
Y Y N N N Y
Dyson 201131
(abstract only)
R N Y N Y Y N N Y
Eusufzai 199334 Unclear Y N Y Y N Y:
2/15
Y Y
Eusufzai 199335 P N Y Y N N Y:
1/13
N N
Fellous 199436 P Y N (36),
Y (53)
Y Y N Y:
all
Y Y
Fernandez-
Banares 200137
P Y N Y Y Y N Y Y
Fernandez-
Banares 200749
P Y N Y Y Y N N Y
Ford 199238 R Y Y Y Y Y N Y Y
Galatola 19925 P Y N Y Y Y N Y Y
Merrick 198539 P Y N (43),
Y (106)
Y Y N Y:
all
N Y
Notta 201140 P N Unclear Y Y Y N N Y
Rudberg 199641 P Y N Y Y N Y:
4/10
Y Y
Sciaretta 198642 P Y N (13) Y Y Y Y:
all
N Y
Sciaretta 198743 Unclear Y Y (46) Y Y Y Y:
all
Y Y
Sinha 19982 R Y N N Y Y N Y Y
Smith 20003 R N Unclear Y N N N Y Y
Tunney 201132 R N N (136) Y Y N N N N
Wildt 200344 R Y Y N Y Y N Y Y
Williams 199145 R Y N Y Y N N Y Y
N, no; P, prospective; R, retrospective; Y, yes.
Q1: Does the study have a retrospective ‘R’ or prospective ‘P’ study design? (R/P/unclear.)
Q2: Has a clear definition of diarrhoea in the presenting population been given or a validated tool for assessing chronic
diarrhoea been used? (Y/N.)
Q3: Does the population include people with known causes of chronic diarrhoea? (Y/N/unclear.)
Q4: Has an adequate description of the SeHCAT test procedures been provided? (Y/N.)
Q5: Are the cut-off values used for establishing severity of BAM clearly reported? (Y/N.)
Q6: Are the reason for treating people clearly described (e.g. ‘all with a positive test’) (Y/N.)
Q7: Are data provided for people with a negative SeHCAT test (> 15%)? (Y-all/Y-some/N.)
Q8: Is the treatment clearly described, including dose and duration of treatment and follow-up? (Y/N.)
Q9: Has an objective measure of response to treatment been provided? (Y/N.)
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ASSESSMENT OF CLINICAL EFFECTIVENESS
40Table 10 shows the average response rates given a positive or negative SeHCAT test at all different cut-offs
using all available data for patients with unknown cause chronic diarrhoea. This analysis combines results
from different studies weighted by population size.
Using the random-effects analysis,26 the results are very similar (Table 11). Data are now grouped in cut-off
bands of 5%, 10%, and 15% plus or minus 2% points. These are the data used in the economic model.
Effectiveness of bile acid sequestrant for the treatment of bile acid
malabsorption inpatients with Crohn’s disease
As reported earlier in this chapter (see Accuracy of selenium-75-homocholic acid taurine for the
assessment of response to treatment in people with Crohn’s disease), none of the studies looking
specifically at people with Crohn’s disease presented reliable data for the prediction of response to
treatment with BAS. Only two studies looked at this population.3,46 Neither of these studies presented data
for people with a negative SeHCAT test. In addition, it was not clear why certain people were treated and
others not. In Nyhlin et al.,46 34 out of 51 patients had a positive SeHCAT test at a 10% cut-off, while
22 patients were treated, of whom one had a negative SeHCAT (at 10%). In Smith et al.,3 24 out of
44 patients had a positive SeHCAT test at a 10% cut-off; 11 of these were successfully treated with
conventional treatment (prednisolone with or without 5-ASA) and a further nine patients were treated
with BAS after conventional treatment had failed. Finally, Nyhlin et al.46 included patients with or without
resection. Nevertheless, information about the effectiveness of BAS for the treatment of BAM given a
positive SeHCAT test can be obtained from the two studies.TABLE 11 Treatment response at different cut-offs given a positive SeHCAT test
Cut-off bands
Positive SeHCAT test
Response rate, % (n, N)
5% 88, 95% CI 75 to 100 (79, 4)
10% 76, 95% CI 65 to 86 (226, 9)
15% 73, 95% CI 66 to 81 (138, 6)
n, number of respondents; N, number of studies.
TABLE 10 Treatment response at different cut-offs given a positive or negative SeHCAT test
Cut-off
Positive SeHCAT test Negative SeHCAT test
Response rate, % (n, N)
5% 85 (79, 4) 14 (7, 1)
8% 80 (5, 1) 5 (51, 2)
10% 73 (143, 6)
11% 76 (37, 1)
11.7% 95 (41, 1)
15% 72 (138, 6) 0 (31, 1)
Unclear 80 (10, 1)
n, number of respondents; N, number of studies.
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DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Table 12 provides a summary of the quality assessments for studies in this section and Table 13 summarises
individual study results.
For those with a positive SeHCAT test the response rate was 95% at a cut-off of 5% and 86% or 89% at
a cut-off of 15%.
Table 14 shows the average response rates given a positive SeHCAT test at two different cut-offs using all
available data.
Summary
Twenty of the 21 included studies in the systematic review were considered for the assessment of the
value of SeHCAT in predicting the response to BAS. Of these 20 SeHCAT studies, 19 included people with
chronic diarrhoea with unknown cause2,3,5,31–45 and two studies included people with Crohn’s disease and
chronic diarrhoea.3,46
Three studies were reasonably reliable in assessing the relationship between the SeHCAT test and
treatment with cholestyramine.39,42,43 However, the studies had small numbers of patients with unknown
cause chronic diarrhoea, they used different cut-offs for the assessment of BAM and between-study
heterogeneity was considerable.
Sensitivity ranged from 0.67 (at a cut-off of 8%) to 1.00 (at a cut-off of 15%) and specificity ranged from
0.91 (at a cut-off of 15%) to 1.00 (at a cut-off of 5%) (Table 15).
None of the studies looking specifically at people with Crohn’s disease presented reliable data for the
prediction of response to treatment with BAS because no data were presented for people with a negative
SeHCAT test in the two studies.
One randomised controlled trial in patients with IBS-D which compared treatment with BAS (colesevelam)
with placebo showed no significant differences in terms of colonic transit [e.g. geometric centre at
48 hours: mean difference (MD) = 0.18 (95% CI –0.29 to 0.65)], bowel function [e.g. stool frequency per
day: MD = –0.11 (95% CI –1.01 to 0.79)] or adverse events [e.g. uterine cramps: OR = 0.45 (95% CI 0.04ABLE 12 Quality assessment for studies of SeHCAT for the assessment of treatment response
Study
ID
Q1:
prospective
Q2:
diarrhoea
Q3:
known
cause
Q4:
SeHCAT
test
Q5:
cut-off
Q6:
reason
treatment
Q7:
negative
test
Q8:
treatment
Q9:
response
Nyhlin
199446
R N Y Y Y N N N N
Smith
20003
R N Unclear Y N N N Y Y
N, no; R, retrospective; Y, yes.
Q1: Does the study have a retrospective ‘R’ or prospective ‘P’ study design? (R/P/unclear.)
Q2: Has a clear definition of diarrhoea in the presenting population been given or a validated tool for assessing chronic
diarrhoea been used? (Y/N.)
Q3: Does the population include people with known causes of chronic diarrhoea? (Y/N/unclear.)
Q4: Has an adequate description of the SeHCAT test procedures been provided? (Y/N.)
Q5: Are the cut-off values used for establishing severity of BAM clearly reported? (Y/N.)
Q6: Are the reason for treating people clearly described (e.g. ‘all with a positive test’) (Y/N.)
Q7: Are data provided for people with a negative SeHCAT test (> 15%)? (Y-all/Y-some/N.)
Q8: Is the treatment clearly described, including dose and duration of treatment and follow-up? (Y/N.)
Q9: Has an objective measure of response to treatment been provided? (Y/N.)T41
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TABLE 14 Treatment response at different cut-offs given a positive SeHCAT test
Cut-off
Positive SeHCAT test
Response rate (n)
5% 95% (19)
10% 87% (30)
TABLE 15 Accuracy of SeHCAT in predicting a response to BAS
Study ID Cut-off bands Sensitivity (95% CI) Specificity (95% CI)
Merrick 198539 (n = 40) 8% 0.667 (0.223 to 0.957) 0.971 (0.847 to 0.999)
15% 1.000 (0.541 to 1.000) 0.912 (0.763 to 0.981)
Sciaretta 198642 (n = 13) 5% 0.857 (0.421 to 0.996) 1.000 (0.541 to 1.000)
Sciaretta 198743 (n = 46a) 8% 0.950 (0.751 to 0.999) 0.962 (0.804 to 0.999)
a Including eight patients with cholecystectomy.
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61to 5.81)]. However, randomisation (sequence generation and allocation concealment) was not adequately
reported and groups were small (n = 12 in both arms).
For people with chronic diarrhoea, 19 studies provided data on the clinical effectiveness of BAS given a
positive SeHCAT test; three studies also provided data on the effectiveness of BAS given a negative
SeHCAT test. For those with a positive SeHCAT test response rates were on average 85%, 73% and 72%
for cut-offs at 5%, 10% and 15%, respectively. For those with a negative SeHCAT test the response rate
was 14% at a cut-off of 5% and 0% at a cut-off of 15%. For people with Crohn’s disease and a positive
SeHCAT test the response rate was 95% at a cut-off of 5% and 86% or 89% at a cut-off of 15%.43
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DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Chapter 4 Assessment of cost-effectivenessSearch strategySearches were undertaken to identify cost-effectiveness studies of SeHCAT in the diagnosis of BAM and
BASs used to treat BAM. As with the clinical effectiveness searching, the main EMBASE strategy for each
set of searches was independently peer reviewed by a second information specialist, using the PRESS-EBC
checklist.18 Search strategies were developed specifically for each database and searches took into account
generic and other product names for the BASs and SeHCAT. No restrictions on language or publication
status were applied. Limits were applied to remove animal studies. Full search strategies are reported
in Appendix 1.
The following databases were searched for relevant studies with no date limits:
l MEDLINE (1946–week 1 January 2012) (OvidSP)
l MEDLINE In-Process & Other Non-Indexed Citations and Daily Update (up to 13 January 2012) (OvidSP)
l EMBASE (1980–week 2 2012) (OvidSP)
l NHS Economic Evaluation Database (EED) (up to 16 January 2012) (CRD website)
l Health Economic Evaluation Database (HEED) (Wiley Online Library) (up to 6 March 2012)
http://onlinelibrary.wiley.com/book/10.1002/9780470510933
l EconLit (1886–16 January 2012) (EBSCOhost)
l SCI (1970–12 January 2012) (Web of Science).
Supplementary searches on SeHCAT, BAM, IBS, Crohn’s disease and chronic diarrhoea were undertaken
on the following resources to identify guidelines and guidance:
l National Guidelines Clearinghouse (NGC) (up to 28 November 2011) (internet) www.guideline.gov
l International Guidelines Library (GIN) (up to 28 November 2011) www.g-i-n.net
l NICE Guidance (up to 28 November 2011) (internet) http://guidance.nice.org.uk
l Turning Research Into Practice (TRIP) database (limited to Guidelines) (up to 28 November 2011)
(internet) www.tripdatabase.com
l HTA Database (up to 28 November 2011) (CRD website)
l NIHR HTA (up to 9 December 2011) (internet).
Owing to the lack of studies found that matched all the criteria, an additional keyword search of the
Clinical Effectiveness EndNote Library was performed to identify potentially relevant cost/economic studies.
After deduplication, 121 records were identified (see Appendix 1).
As described by the NICE Methods Guide, the information process that supports the development of a
model is ‘a process of assembling evidence and this reflects an iterative, emergent process of information
gathering’.54 The following additional searches were requested by the health economists as part of
this process:
l Searches for utility weights for BAM, IBS, Crohn’s disease and chronic diarrhoea were conducted on
the CEA Registry: https://research.tufts-nemc.org/cear4/Home.aspx.
l Additional searches were also requested for health-related quality of life and cost-effectiveness for
both Crohn’s disease and IBS on the following resources:
¢ NHS EED (CRD website)
¢ MEDLINE (OvidSP).45
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ASSESSMENT OF COST-EFFECTIVENESS
46These searches were targeted to find results to inform the inputs of a model and were not intended to be
used for a comprehensive systematic literature review.
The final list of included papers was also checked on PubMed for retractions and errata.19–21
Figure 6 depicts the flow of searches for cost-effectiveness.
Search B identified three existing health economic models for IBS. Additionally, various other health
economic evaluations were found but they all assessed costs and effects alongside clinical trials.
The first model, by Suleiman et al.,55 assesses the cost-effectiveness of endoscopy in IBS. The model
considers only the diagnostic phase, and thus does not consider long-term costs and effects. The reported
outcome was test costs divided by increment in diagnostic certainty. No relevant information could be
extracted from this paper.
The second model was developed by Mein and Ladabaum56 and investigates the cost-effectiveness of
coeliac screening in patients with IBS symptoms. This model consists of a diagnostic part until final
diagnosis and a long-term part where life expectancy of patients is multiplied with overall annual costs forSearch A: Scoping search
BAM + previous/incidence + other
conditions
Resources: E
Search B: Searches to inform
model
IBS + cost/QoL
Resources: M, NE
Search C: Guidelines
(IBS or Crohn’s disease or BAM or
chronic diarhhoea or SeHCAT)
Resources: G, NG, N, H, NH, T
Total: 429
Search D: Cost-effectiveness
(SeHCAT or BAS/AH or
 BAM) + cost
Resources: E, M, MP, NE, S, EC, HE
Search D.2: Cost-effectiveness
Keyword search of clinical
effectiveness, EndNote
Library
Search E: Searches to inform
model
Crohn’s disease + cost/QoL
Resources: M, NE
Search F: Utilities
(IBS or Crohn’s disease or BAM or
chronic diarhhoea)
Resources: CEA
FIGURE 6 Flow of searches developed for SeHCAT health economics. Records retrieved 3292 prior to deduplication;
total 2975 after deduplication. AH, aluminium hydroxide. Resources: E, EMBASE; EC, EconLit; C, CENTRAL; CEA,
Tufts CEA register; D, DARE; G, GIN; H, HTA; HE, HEED; M, MEDLINE; MP, MEDLINE In-Process & Other Non-Indexed
Citations and Daily Update; NE, NHS EED; NG, National Guidelines Clearing House; NH, NIHR HTA; SR, CDSR. For
the full search strategies
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a utility of 0.689 was applied to IBS patients, which is slightly lower than the value we derived from the
utility studies we identified (see Diagnostic and initial treatment model IBS-D).
The final model, by Spiegel et al.,57 also considers the cost-effectiveness of testing for coeliac disease in
patients with IBS-D symptoms. This model consists of a diagnostic part and a Markov model. The Markov
model consists of two health states: ‘symptoms improve’ and ‘symptoms recur’. The model does not
include utilities; the main outcome measure is incremental costs per additional symptomatic improvement.
We carefully considered both the cost of IBS treatment included in this model and the initial therapeutic
benefit of IBS-D treatment that was included. The model applied a cost estimate of US$45 per month for
IBS-D treatment. No details were presented to explain this estimate other than the remark that this
estimate represents the monthly costs in the USA for therapies such as loperamide, fiber supplements or
antispasmodics. As we will see later in this chapter (see Diagnostic and initial treatment model for
diarrhoea-predominant irritable bowel syndrome), based on expert opinion the costs of medication in the
UK are estimated to be much lower at approximately £5 per month. The estimate for the initial therapeutic
response that was included in the study was based on data from studies with alosetron, yielding an
estimate of 75%. However, they also reported a range from a study by Brandt et al.58 from 35% to 75%.
This latter study presents the probability of response for the various treatment options for IBS per
treatment. However, it does not present the probability that a patient will eventually be responsive (after
trying several treatments).
Additionally, we also considered how this model estimates long-term transition probabilities. The authors
indicate a lack of data to support these estimates and then describe how data from patients receiving
tegaserod reveal that up to 85% develop symptomatic recurrence after discontinuing a successful
therapeutic course, of whom 80% achieve symptomatic remission following a second therapeutic course.
Although these data apply to patients with constipation-predominant IBS, Speigel et al.57 adopted these
favourable results to their population of IBD-D patients. To bias the model against CS testing, they
assumed that only 50% (instead of 85%) of IBS-D patients developed symptomatic recurrence
following successful therapy and adopted the tegaserod data of 80% remission following a second
therapeutic course.
In addition to health economic models, search B also provided the literature for the utility estimates used
in the models (see Diagnostic and initial treatment model for diarrhoea-predominant irritable bowel
syndrome and Diagnostic and initial treatment model for Crohn’s disease without ileal resection for
further details).
The guidelines search (search C) provided mainly general information about diagnosis, treatments and
prognosis in IBS and Crohn’s disease. The most relevant document was the clinical practice guideline for
IBS in adults in primary care from the National Collaborating Centre for Nursing and Supportive Care.59
This report included various health economic searches on, for example, utilities and long-term prognosis,
some of which have been used in this report.
Search D did not lead to any relevant papers; no economic evaluations of SeHCAT or treatment of BAM
were found.
Search E did not yield any papers assessing costs or utility of chronic diarrhoea in Crohn’s patients. Some
health economic models for medical treatment of Crohn’s disease were found, especially relating to
treatment with anti-tumour necrosis factor alpha (TNF-α). However, none of these models considered
diarrhoea as a health state and no useful data could be extracted from these studies.
Finally, search F did not reveal any new relevant studies on utilities for our models.47
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48Model structure and methodologyIn this section, we describe the models used for the economic evaluation. As no relevant models were
identified in the searches, a de novo model was developed for each population. This model consists of two
parts: a decision model reflecting the diagnostic and initial treatment phase and a Markov model to
estimate long-term costs and effects. We compare various strategies.
The scoping document clearly defined SeHCAT and no SeHCAT as strategies. The option of trial of
treatment was also mentioned without specifically including it as a comparator. According to the clinical
experts at the scoping meeting, trial of treatment is rarely used as a treatment strategy and was thus not
considered relevant. However, trial of treatment can also not be completely excluded as an option. Thus,
in this report we will present two sets of results: one where trial of treatment is not considered as a
comparator and one where it is.
For the IBS-D population we compare first the SeHCAT strategy using three different cut-off points
(absorption < 5%, < 10% and < 15%) with no SeHCAT testing, that is to say treating patients as IBS-D
patients. In the second set of results, trial of treatment is added as a strategy.
For the Crohn’s disease population, we include the same strategies, with the exception of SeHCAT 5% as
no data were available for this strategy. In this population, no SeHCAT entails treatment for chronic
diarrhoea (which may or may not be a direct result of a disease relapse).
The models used in the analyses are described, in detail, below. The stochastic analyses are based on
cohort simulations. To investigate decision uncertainty, second-order uncertainty microsimulations were
run. All costs and effects were discounted by 3.5%. The model incorporated a lifetime time horizon to
estimate outcomes in terms of quality-adjusted life-years (QALYs) and costs from the perspective of the
NHS. Only health effects of patients were included.Diagnostic and initial treatment model for diarrhoea-predominant irritable
bowel syndrome
Given the fact that no data are available on the accuracy of SeHCAT, the model uses response to
treatment, dependent on the test outcome (see also Chapter 3, Accuracy of selenium-75-homocholic acid
taurine for the detection of bile acid malabsorption). We compare two no SeHCAT strategies with three
SeHCAT strategies. Figure 7 presents the decision tree used.
In the SeHCAT strategies, patients may have a positive or negative test result. If the test is positive, that is
to say the percentage resorption of bile acids is below a certain cut-off, patients are treated with
cholestyramine (a BAS) and they may or may not respond to that treatment. If the test is negative, the
patient is diagnosed as IBS-D and treated accordingly. Again, patients may or may not respond to that
treatment. The first no SeHCAT strategy assumes that all patients are treated with IBS-D treatment and
patients may or may not respond to that treatment. Finally, in the trial of treatment, all patients receive
cholestyramine. If patients do not respond to this, they receive IBS-D treatment and again, patients may
respond or not respond to this treatment.Diagnostic and initial treatment model for Crohn’s disease without
ileal resection
For the Crohn’s disease population, the outline of the model is in essence the same as for the IBS-D
population (Figure 8). However, here, if no SeHCAT test is used, if the test result is negative or if patients
do not respond to a trial of cholestyramine, patients will receive treatment for diarrhoea. This treatment
can vary between patients, as the diarrhoea may be a result/symptom of a relapse of the disease, and thus
focus could be on treating the relapse, but it may also occur in patients who are in remission.3 Chronic
diarrhoea in patients in remission has been suggested to be the result of repeated relapses, which have led
to fibrosis.46 For these patients, treatment is targeted at controlling the diarrhoea.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 8 Decision tree for Crohn’s disease population.
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ASSESSMENT OF COST-EFFECTIVENESS
50This model assesses only two SeHCAT strategies; no data on the probability of a positive test result were
available for a cut-off absorption of < 5%, and so this strategy was not evaluated in this assessment.Markov model
To assess the long-term costs and effects of the various strategies, patients enter into a three-state Markov
model (Figure 9). Patients who had a treatment response enter the Markov model into the ‘no diarrhoea’
state and patients who did not respond enter into the ‘diarrhoea’ state. As the model has a lifetime time
horizon, the third state included is death.
In theory, patients can either move between the ‘no diarrhoea’ state and the ‘diarrhoea’ state from one
cycle to another, stay in the same state or die. The cycle length used is 6 months. The general Markov
model is parameterised according to treatment; that is to say, in the IBS-D population, patients who
receive(d) BAS enter the BAS Markov model and patients who receive(d) IBS-D treatment enter the IBS-D
Markov model. Likewise, in the Crohn’s disease population, patients who receive(d) BAS enter the
BAS Markov model and patients who receive(d) treatment for Crohn’s disease with chronic diarrhoea
(non-BAM diarrhoea) enter the Crohn’s disease Markov model.Model parametersThis section describes the parameters used in the decision trees and the Markov models and how their
values were estimated.Diagnostic and initial treatment model for diarrhoea-predominant
irritable bowel syndrome
The diagnostic model estimates the initial costs of diagnosis and initial treatment. We assume that the
diagnostic model reflects the first 6 months after the moment the patient is seen by a specialist.Probabilities
The first probability encountered in the decision tree (see Figure 7) is that of a positive SeHCAT test.
To estimate this we used the studies listed in Tables 9 and 10. Based on the data retrieved, a random-
effects meta-analysis was performed to find a pooled estimate for each of the three cut-off values
(Tables 16–18).26 Note that studies with cut-off points between 8% and 12% have all been grouped as
10%. In some studies, patients with a history of cholecystectomy were included in the ‘IBS-D-like’
population. As we are interested in patients with idiopathic BAM, we excluded the patients with a
cholecystectomy from the calculations.
Patients with a positive SeHCAT test result, that is to say those who are classified as having idiopathic
BAM, are assumed to be treated with BASs (cholestyramine). The response rate to BASs differs between
the various cut-off points. Again, using the studies described in Chapter 3, we have estimated theDiarrhoea No diarrhoea
Death
IGURE 9 Outline Markov model.FNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 16 Probability of positive SeHCAT result for IBS-D, cut-off 5%
Study n Number SeHCAT positive Probability SeHCAT positive
Borghede33 114 41 0.36
Ford38 74 3 0.04
Sciaretta42 13 6 0.46
Wildt44 56 13 0.23
Williams45 181 23 0.13
RE mean 0.22
SD 0.06
n, sample size of study; RE, random effects; SD, standard deviation.
TABLE 17 Probability of positive SeHCAT result for IBS-D, cut-off 10%
Study n Number SeHCAT positive Probability SeHCAT positive
Borghede33 114 55 0.48
aEusufzai34 17 10 0.59
aFellous36 36 10 0.28
aFernandez-Banares37 23 b 0.65
Fernandez-Banares49 62 37 0.60
Ford38 74 15 0.20
Galatola5 98 56 0.57
Kurien53 102 37 0.36
Merrick39 43 5 0.12
Notta40 37 16 0.43
aRudberg41 18 3 0.17
aSciaretta43 38 13 0.34
Smith3 197 65 0.33
Tunney32 136 33 0.24
Wildt44 56 21 0.38
Williams45 181 39 0.22
RE mean 0.36
SD 0.04
n, sample size of study; RE, random effects; SD, standard deviation.
a Patients with a cholecystectomy were excluded from the calculation.
b No number of patients was reported in paper, only probability.
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TABLE 18 Probability of positive SeHCAT result for IBS-D, cut-off 15%
Study n Number SeHCAT positive Probability SeHCAT positive
Borghede33 114 68 0.60
Ford38 74 20 0.27
Merrick39 43 12 0.28
Rossel60 150 30 0.20
aRudberg41 18 8 0.44
Sinha2 17 9 0.53
Tunney32 136 59 0.43
Wildt44 56 24 0.43
Williams45 181 60 0.33
RE mean 0.38
SD 0.05
n sample size of study; RE, random effects; SD, standard deviation.
a Patients with a cholecystectomy were excluded from the calculation.
ASSESSMENT OF COST-EFFECTIVENESS
52response rate to BASs using random-effects meta-analysis (Tables 19–21). It is important to note that it is
a well-known fact that compliance is usually not optimal when patients are treated with cholestyramine.
We studied the various papers included into Tables 19–21 to see if compliance or drop-out were reported.
Most studies do not report any information about these issues. The study by Borghede et al.33 reports (at
15% cut-off) 43 out of 57 patients responding to treatment. They also report that 49 out of 57 patients
used cholestyramine continuously, indicating that the response rate is already based on a less-than-100%
compliance. Additionally, the study by Notta et al.40 reports that many patients used cholestyramine on
demand after achieving an initial response to counteract side effects. Thus, again this study reports a
response rate that is already based on reduced compliance. As other studies did not report anything about
compliance, we will assume that they also implicitly include the impact of reduced compliance on the
response rate. The drop-out of treatment is only considered in the Markov model after the initial phase.
The next important probability is that of a positive response to IBS-D treatment in patients with no
SeHCAT test (i.e. the whole initial population is receiving this treatment). IBS-D treatment varies greatly
between patients. Patients may receive a variety of drugs, diet advice or even psychological treatment.
Owing to the large array of treatment options and the various orders in which they are attempted, we
could not find clear data from the literature regarding how many IBS-D patients will eventually, after trying
various options, respond to treatment. We therefore sent out a questionnaire to approximately 20
specialists, seven of whom returned it. In the questionnaire we asked what percentage of patients would
eventually be successfully treated with the usual IBS-D treatment options, and the plausible range for
this percentage. We have included the full questionnaire in Appendix 9. The responses are presented in
Table 22.
We assume that the percentage of IBS-D patients considered successfully treated follows a triangular
distribution with the point estimate given by the experts representing the mode of the distribution. For
example, for the data provided by expert 1, 0.4 is the mode, and the associated mean and standard
deviation are 0.366 and 0.102, respectively. By simulating from these triangular distributions we estimated
the pooled mean and standard deviation of the probability of responding to IBS-D medication when no
SeHCAT test is available, which is assumed to have a beta distribution. We found a mean of 52% and a
standard deviation of 10%.NIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 19 Probability of a positive BAS response given a positive test result, cut-off 5%
Study n Number positive response Probability positive response
Borghede33 39 29 0.74
Sciaretta43 6 + 1 6 + 0.5a 0.93
Wildt44 13 11 0.85
Williams45 21 + 1 21 + 0.5a 0.98
RE mean 0.88
SD 0.06
n, sample size of study; RE, random effects; SD, standard deviation.
a 0.5 patients were added to all cells of the 2 × 2 table to allow calculation of variance of RE estimator.
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61TTABLE 20 Probability of a positive BAS response given a positive test result, cut-off 10%
Study n Number positive response Probability positive response
Borghede33 53 41 0.77
aEusufzai34 6 2 0.33
Fernandez Banares49 37 28 0.76
Galatola5 41 39 0.95
Merrick39 5 4 0.80
Notta40 16 8 0.50
aRudberg41 3 2 0.67
Smith3 34 28 0.82
Williams45 31 24 0.77
RE mean 0.76
SD 0.05
n, sample size of study; RE, random effects; SD, standard deviation.
a Patients with a cholecystectomy were excluded from the calculation.
TABLE 21 Probability of a positive BAS response given a positive test result, cut-off 15%
Study n Number positive response Probability positive response
Borghede33 57 43 0.75
Merrick39 9 6 0.67
Rudberg41 7 6 0.86
Sinha2 9 6 0.67
Wildt44 17 14 0.82
Williams45 39 24 0.62
RE mean 0.73
SD 0.04
n, sample size of study; RE, random effects; SD, standard deviation.
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TABLE 22 Probability of treating IBS-D patients successfully, per expert
Expert Patients successfully treated (%) Lowest Highest
1 40 10 60
2 50 25 75
3 40 30 50
4 40 0 50
5 90 70 95
6 80 20 100
7 50 40 80
Mean 52
SD 10
SD, standard deviation.
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54In the strategies where a SeHCAT test is performed, only patients with a negative SeHCAT test receive
IBS-D treatment. This means that most patients who actually have BAM are no longer part of the group
receiving IBS-D treatment. Thus, the response rate to IBS-D treatment in the SeHCAT-negative population
may be higher than in the ‘no SeHCAT testing’ population, especially as IBS-D treatment also includes
antidepressants, psychological therapy and other treatments unlikely to benefit BAM patients.
Unfortunately, no data were available to give any indication of whether or not this assumption is correct
and, if so, how much higher the response rate should be. In the base-case analysis we will make the rather
subjective assumption that at a cut-off point of 15% (when the maximum number of BAM patients have
been removed from the IBS-D-treated population) the response rate to IBS-D treatment in the SeHCAT
negative population is 10 percentage points higher than in the ‘no SeHCAT’ population. For SeHCAT
cut-off points of 5% and 10%, these increases are assumed to be 5 percentage points and 8 percentage
points respectively.
For the trial of treatment strategy, where again the maximum number of BAM patients have been
removed from the IBS-D-treated population, we assume the same response rate as in the SeHCAT
15% strategy.
Because of the subjective nature of this estimate, we have explored its impact on the outcomes through
scenario analyses.
Finally, the model required a response rate for BAS treatment given as a trial (trial of treatment) to all
patients. Theoretically, data from the two studies by Sciaretta42,43 might be used to inform this input
parameter. When we look at those results [i.e. 54% (7/13) in one study and 44% (20/46) in the other] we
find that, on average, 46% of all patients would respond to BAS treatment regardless of test status. In the
SeHCAT 15% strategy, the percentage who test positive AND respond to treatment is only 28%
(38% × 73%). If one then assumes that the 46% is applicable to all studies then the remaining 18%
(46% – 28%) would be FNs (i.e. test negative AND would have responded to treatment if it had been
tried) (18/62). However, in the two Sciaretta studies,42,43 almost none of the SeHCAT-negative patients
responded to BAS, so using just these data for the trial of treatment strategy while using pooled data from
a much larger group of studies to inform the SeHCAT strategies leads to inconsistencies.
To avoid these inconsistencies in input values, we have chosen to assume that the 28% of patients who
responded to BAS in the SeHCAT 15% strategy is the percentage of responders that would be foundNIHR Journals Library www.journalslibrary.nihr.ac.uk
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may be patients in the SeHCAT 15% strategy with a negative test result who might have responded to
BAS, either because they were FNs or because they showed a placebo response to BAS treatment. But, at
the same time, it may also be an overestimation as it is possible that patients receiving a trial of BAS are
less compliant than patients with a definite diagnosis of BAM or that a lack of patience prevents the right
dose of BAS being achieved. Thus, as a base-case estimate we have assumed a response rate of 28%, and
this estimate was varied to 21% in scenario analyses. This value of 21% was chosen because it is the
threshold value for which trial of treatment and SeHCAT 15% result in the same proportion of responders.Quality of life
The searches B and F, as outlined in Figure 6, formed the base from which we tried to derive utility values
for both responders (no diarrhoea) and non-responders (diarrhoea) in the model. Based on a review of
titles and abstracts, papers presenting utility values in IBS patients were retrieved. This resulted in six
papers, of which four presented utility values for unspecified health states. The paper by Spiegel et al.61
described utilities (EQ-5D) for patients with IBS who showed either ‘considerable relief’ after 3 months of
usual care or ‘no considerable relief’ (Table 23). This study found no significant difference between the
subtypes of IBS. The second paper with health-state-specific utilities (Mearin et al.62) presented utility
scores for high and low severity symptoms. We aggregated these across IBS subtypes for patients with
high-frequency symptoms (present > 50% of the time) (see Table 23). We assumed that the utility gain
associated with response to treatment was equivalent to an improvement in symptom severity from
high to low.
For the BAS responders, we considered two scenarios: one where BAS responders have the same utility
gain as IBS-D treatment responders and one where we assume that the utility gain is lower, due to the
generally cited unpleasantness of cholestyramine. As we have no data to support this smaller increment,
we have assumed that BAS responders have 75% of the utility increment observed in IBS-D treatment.
Costs
The costs considered in the model can be distinguished into three groups: (1) the costs of a SeHCAT test,
(2) the costs of treatment of BAM and (3) the costs of treatment of IBS-D.TABLE 23 Utility values responders and non-responders for IBS-D model
Study Mean SE
Non-responders/diarrhoea
Mearin62 0.704 0.026
Spiegel61 0.730 0.037
RE estimate 0.712 0.021
IBS-D responders/no diarrhoea
Mearin62 0.775 0.014
Spiegel61 0.780 0.037
RE estimate 0.776 0.013
BAS responders/no diarrhoea
Assumption 0.760 0.020
RE, random effect; SE, standard error.
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ASSESSMENT OF COST-EFFECTIVENESS
56For the cost of the SeHCAT test, we used information provided by the manufacturer. SeHCAT capsules
cost £195 per patient (and therefore per treatment). The tariff for administering this diagnostic test in the
NHS is £186 (HRG RA36Z nuclear medicine cat 2, OPCS code – U172, non-mandatory national tariff
2011–12).63 Thus, we would arrive at a total cost of £381. In the scoping document it was suggested,
however, that the tariff for administration might not contain all costs associated with maintenance and
service costs. A range from £55 to £105 was suggested for these costs. In the model, we have applied the
cost estimate of £381 as a base-case value, and in scenario analyses we have explored a total cost
estimate of £55 or £105 higher.
Patients with a positive test for BAM all receive treatment with BAS. These costs were based on the unit
price for cholestyramine from the British National Formulary (BNF) 63 and the actual use observed in the
studies with SeHCAT.64
Most studies present the dosage as it could be used (see Appendix 4) but only a few present information
on the actual dosage used in the study. In the study by Fernandez-Banares,37 a median dosage of 8 g per
day was recorded, with an interquartile range of 4–12 g per day. Wildt44 reported that the most common
dosage was 5–12 g per day. Finally, Williams45 reported a mean dosage of 12 g per day. We have based
our cost estimate for BAS treatment on this latter value, as it presents a mean. Thus, we arrive at costs of
12 mg = 3 sachets = 3 × £0.21 = £0.63 per day.
For the treatment of IBS-D, we distinguish three main types of resource use: (1) medication, (2) dietitian
visits and (3) counselling and psychological therapy. All of these were estimated based on expert opinion.
To find an overall estimate, we calculated a simple mean and standard deviation of the expert’s individual
estimates. We did assess whether or not the range represented by the standard deviation did cover most
of the individual responses (including the range suggested by the experts). As these data were not
collected in a formal sample (i.e. each expert gave a subjective estimate), we opted not to use formal
meta-analysis to find an overall estimate.
Patients treated for IBS-D may use a wide variety of medication. The experts consulted listed, for example,
loperamide, codeine, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs),
mebeverine and BAS. Table 24 presents the costs of medication per expert, based on their estimates of use
of the various medications. The prices of the medications were derived from the BNF.64 Exact details on
medication use, dosage and fraction of patients receiving the treatment are presented in Appendix 10,
including the ranges suggested by the experts. The experts’ responses ranged from £0.02 to £0.64 perTABLE 24 Costs of medication per day for IBS-D; each row represents the estimate of an expert
Patients receiving medication (%)
Average cost per treated
patient per day (£)
Average cost per
patient per day (£)
60 0.45 0.27
100 0.19 0.19
75 0.23 0.17
80 0.20 0.16
100 0.11 0.11
80 0.29 0.24
100 0.08 0.08
Mean 0.17
SD 0.068
SD, standard deviation.
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estimate in the probabilistic sensitivity analysis.
Table 25 presents the responses of the experts to the question of how many patients would visit a dietitian
and how many visits would be involved. The cost price of one visit to a dietitian was £67.63
Table 26 presents the response of the experts to the question of how many patients would receive some
form of psychological therapy and how many visits would be involved. The cost price of cognitive
behavioural therapy and cognitive analytical therapy is £121 per visit, of counselling is £60 per visit and of
hypnotherapy is £88 per visit.63
Markov model for diarrhoea-predominant irritable bowel
syndrome population
Probabilities
As mentioned in Markov model, patients who receive(d) BAS in the decision tree enter the BAS Markov
model and patients who receive(d) IBS-D treatment enter the IBS-D Markov model.
Each Markov model consists of six transition probabilities: from diarrhoea to no diarrhoea and vice versa,
from diarrhoea (D) to death, from no diarrhoea (ND) to death and to stay in diarrhoea or no diarrhoea.
Regarding the probability of death, we have assumed that only overall mortality in the UK population is
relevant, as no excess mortality is associated with IBS-D and BAM.65 This also implies that both of these
transition probabilities are the same. We derived these from England and Wales Interim Life Tables
1980–82 to 2008–10.66 Using the studies listed in Appendix 4, we found that the average age in the
IBS-D population in the various SeHCAT studies was 47 years, and the ratio of male to female was 0.71.
Our model cohort was assumed to have the same age and sex distribution.
For the estimation of the transition probabilities in BAM responders two long-term follow-up studies
were available.60,67 In the study by Luman et al., the mean follow-up duration was 99.2 months. Out of
12 patients, seven were in remission, as defined by a stool frequency of < 2 per day in the absence of
BAS or anti-diarrhoeal drugs. The duration of BAS treatment in these patients ranged from 2 to 3 years.
Five patients had ‘symptomatic’ diarrhoea that was controlled by BAS or loperamide.TABLE 25 Resource use and costs of dietitian for IBS-D treatment; each row represents the estimate of an expert
Patients who visit dietitian (%) Number of visits Average cost per patient (£)
100 1 67
40 5 134
2.5 1 2
10 1 7
40 1.5 40
10 2 13
30 3 60
Mean 46
SD 56.54
SD, standard deviation.
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TABLE 26 Resource use and costs of psychological treatment for IBS-D patients, per expert
Expert Type of therapy
Patients who receive
therapy (%) Number of visits
Average cost per
patient (£)
A CAT/CBT 10 30 363
B CBT 2 15a 36
C Counselling 20b 7c 84
C CBT 8b 15c 145
C Hypnotherapy 2b 12c 21
C Total 250
D Counselling 15 7 63
D CBT 5 12 73
D CAT 3 12 44
D Total 179
E CBT 1.5 18 33
E Hypnotherapy 0.5 12 5
E Total 38
F Counselling 10 7 42
Mean 130
SD 137.28
CAT, cognitive analytical therapy; CBT, cognitive behavioural therapy; SD, standard deviation.
a This expert did not indicate number of visits; the mean of the two other CBT numbers of visits was used.
b This expert indicated that only 30% total would receive one of these three psychological therapies; an estimated guess
was made as to how that percentage was divided.
c This expert did not indicate number of visits; the values of expert D have been used.
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58The study by Rossel60 has a median follow-up time of 88 months. In total 16 patients were included, of
whom only three patients had normalised SeHCAT test and stool frequency (i.e. fewer than two per day).
The remaining 13 patients still had a non-normal SeHCAT test at follow-up despite treatment with BAS
(seven patients) and symptomatic treatment (four patients). Two of the 13 patients chose to be without
any treatment despite symptoms. Their symptoms had also not normalised, but patients treated with BAS
did show a significant improvement in stool frequency (8.7 per day before treatment, 3.6 per day at
follow-up, p < 0.05).
It is difficult to correctly interpret these findings. The study by Luman et al.67 suggests a relatively high
probability of spontaneous remission after a few years of BAS treatment. This study also suggests that if
no remission occurs patients show little improvement over their baseline stool frequency even with
treatment. The study by Rossel60 shows a much lower probability of remission, but also shows a significant
improvement in stool frequency in seven patients treated with BAS.
Overall, it is difficult to derive from this the transition probabilities from ND to D and from D to ND for the
BAS Markov model. It is possible, given the above information, that patients move from D to ND due to
remission; however, in the studies by Luman67 and Rossel,60 remission took place after a period of BAS
treatment, and it may not be possible to extrapolate this to patients not responding to BAS treatment. At
the same time, it is also possible that patients move from ND to D, for example due to lack of compliance.
For example, the study by Rossel60 showed six patients who had an initial response to BAS treatment who
had to discontinue treatment due to adverse effects or other compliance problems.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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and previous health economic studies to find long-term data. One IBS guideline68 cited only a study by
Agreus et al.69 to show that a large group of IBS patients experience spontaneous remission. However,
several difficulties exist with this study. The study comprised a random sample from the inhabitants of a
specific Swedish region. They were sent a questionnaire where they were asked to indicate which (if any)
of a list of 24 symptoms had troubled them in the last 3 months and also to indicate the type and location
of pain. Based on their answers people were classified into one of six symptom groups or as ‘symptom
free’. One of these symptom groups was IBS. The same questionnaire was sent to these people 1 year
after baseline and again 7 years after baseline. Of the 75 patients classified as IBS at baseline, 55% were
still classified as IBS after 1 year and after 7 years. Note that as a cross-section of the population was given
the questionnaire, patients ‘diagnosed’ as having IBS could have had complaints for years, or only for a
few months.
The results of this study seem to indicate that after 1 year a large group of patients showed remission;
however, between year 1 and year 7 after the first questionnaire, no such remission occurred at the group
level. The fact that this population was a cross-section of a general population makes it difficult to
extrapolate these results to an IBS-D population referred for specialist care. It is not unlikely that the
spontaneous remissions are more likely to occur in patients under GP care, and the fact that symptoms
persist over a longer period may well be the reason why patients are referred to a specialist.
Additionally, we identified a clinical practice guideline which also contained a literature review of
long-term stability of IBS diagnosis and symptoms.59 In total, 14 papers were identified as relevant, most of
which were also included in a systematic review by El-Serag et al.70 The length of follow-up ranged from
2 months to up to 32 years and the percentage of the original cohort with follow-up data available also
varied widely, from 38% to 100%. Of these 14 studies, four reported whether symptoms were worse,
unchanged or improved over the follow-up period.71–74
In these studies, between 48% and 65% of patients reported improvement, 30–50% reported no change,
and 2–14% said their symptoms were worse. Seven studies reported resolution of symptoms, yielding
widely differing estimates ranging from 7% to 48%.71,72,74–78
Overall, we must conclude that there are clear indications that patients may move from ND to D and vice
versa. However, from the data available, these transition probabilities are impossible to quantify. We will
therefore present a range of equally plausible scenarios with various values, without actually selecting one
as a base case, to show the impact of the assumptions on the outcomes.Quality of life
The IBS Markov model uses the same utility estimates as reported in Diagnostic and initial treatment
model for diarrhoea-predominant irritable bowel syndrome for the decision tree.Costs
There are four relevant health states for which a cost estimate is required: ND-IBS, D-IBS, ND-BAM and
D-BAM. The ND states are the states where the treatment responders start the Markov model. Hence, for
BAS responders we have assumed that the costs per cycle are equal to the costs used in the decision tree
(i.e. 182.5 × £0.63 = £115 per cycle), and for IBS responders we have assumed that the cost per cycle are
equal to the medication costs used in the decision tree (£31.70 per cycle, see Table 24). For the ND costs
for IBS and BAM, we assume a gradual decline in costs due to patients no longer needing the treatment,
stopping treatment due to various compliance issues or entering this health state from the diarrhoea state
as a result of spontaneous remission. This decline in the cost per cycle was rather arbitrarily set at
approximately 2% per cycle (i.e. 2% decrease of the remaining costs). For patients who did not respond to
BAM treatment or IBS-D treatment in the initial phase, that is to say the patients entering the Markov
model in the D health state, both for IBS-D and BAM, we assumed that patients use some loperamide to
at least reduce the stool frequency somewhat (£10.90 per cycle).59
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60Diagnostic and initial treatment model for Crohn’s disease without
ileal resection
Probabilities
Again, the first probability encountered in the decision tree (see Figure 8) is that of a positive SeHCAT test.
To estimate this we used the studies by Smith3 and Tunney32 as they were the only studies reporting
results specifically for patients without ileal resection. We derived pooled estimates for a 10% and a 15%
cut-off (Tables 27 and 28). No studies were available with a 5% cut-off.
No data were available on the response to BAS in patients with a positive SeHCAT test. We therefore
assumed that this response rate would be the same as in patients with idiopathic BAM, that is to say 76%
and 73% for 10% and 15% cut-off, respectively (see Tables 21 and 22).
For the probability of a positive response to treatment of diarrhoea in Crohn’s patients with no SeHCAT
test (i.e. the whole initial population is receiving this treatment), again no literature was available.
The approach to diarrhoea in Crohn’s patients varies greatly between patients, mostly because the
diarrhoea may occur as a symptom of relapse but it also may occur while the patient is in remission. In the
first case, treatment may be targeted at treating the relapse, assuming that this will decrease the
diarrhoea. In the second case, more diarrhoea-specific treatments such as the use of loperamide or
codeine may be considered. So, owing to the large range of treatment options and the various orders in
which they are attempted, we could not find data from the literature as to how many Crohn’s patients
with diarrhoea without ileal resection will eventually, after trying various options, respond to treatment.
We have therefore asked the experts what percentage of patients would eventually be successfully treated
with the usual treatment options in this Crohn’s disease population, and the plausible range for this
percentage. The responses are presented in Table 29.
We assume that the percentage of Crohn’s patients considered successfully treated follows a triangular
distribution with the point estimate given by the experts representing the mode of the distribution.TABLE 28 Probability of positive SeHCAT result for Crohn’s, cut-off 15%
Study n Number SeHCAT positive Probability SeHCAT positive
Tunney32 30 19 0.63
Mean 0.63
SD 0.09
n, sample size of study; SD, standard deviation.
TABLE 27 Probability of positive SeHCAT result for Crohn’s, cut-off 10%
Study n Number SeHCAT positive Probability SeHCAT positive
Smith3 44 24 0.55
Tunney32 30 16 0.53
RE meana 0.54
SD 0.06
n, sample size of study; RE, random effects; SD, standard deviation.
a Note that in this case, due to homogeneity of the estimates, the random-effects estimate reduces to a
fixed-effect estimate.
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TABLE 29 Probability of treating diarrhoea in Crohn’s patients successfully, per expert
Expert Patients successfully treated (%) Lowest Highest
1 70 50 90
2 70 60 90
3 50 40 80
4 70 20 80
5 60 30 70
Mean 62
SD 9
SD, standard deviation.
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Based on these triangular distributions we derived the pooled mean and standard deviation of the
probability of responding to medication for diarrhoea in Crohn’s patients when no SeHCAT test is
available, which is assumed to have a beta distribution. We found a mean of 62% and a standard
deviation of 9%.
As in the IBS-D population, we may expect that the response rate to diarrhoea treatment in the SeHCAT
negative Crohn’s patients may be higher than in the ‘no SeHCAT’ population. Again, no data were
available to give any indication of whether or not this assumption is correct and, if so, how much higher
the response rate should be. We will therefore assume the same increase as in the IBS-D population, that
is to say 10 percentage points higher than in the ‘no SeHCAT’ population for a cut-off of 15% and
8 percentage points higher for a cut-off of 10%.
For the trial of treatment strategy we assume the same response rate as in the SeHCAT 15% strategy.
Because of the subjective nature of this estimate, we have explored its impact on the outcomes through
scenario analyses.
Finally, for the response rate for BAS treatment given as a trial to all patients we use the same approach as
in the IBS-D population. That is, we have chosen to assume that the 46% patients who respond to BAS in
the SeHCAT 15% strategy is the percentage of responders that would be found when giving all patients a
trial of BAS. This estimate was varied in scenario analyses.Quality of life
No studies were identified that specifically address the issue of diarrhoea in Crohn’s patients. We have
thus assumed that the utility decrement due to diarrhoea in this patient population is the same as for the
IBS-D population. In order to calculate QALYs, we have taken the utility estimate from Buxton et al.,79
where EQ-5D utilities were estimated in a group of 3672 patients with moderate to severe active Crohn’s
disease. A mean of 0.7 was found with a standard deviation of 0.25. We have assumed that this utility
reflects the quality of life in the diarrhoea health state, and thus the utility for the no-diarrhoea health
state is 0.75.Costs
As in the IBS-D model, the costs considered in this model can be distinguished into three groups: (1) the
costs of a SeHCAT test, (2) the costs of treatment with BAS and (3) the costs of treatment of diarrhoea in
Crohn’s patients.61
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ASSESSMENT OF COST-EFFECTIVENESS
62The costs of the SeHCAT test and of treatment with BAS are the same as for the IBS-D model. Thus, the
total cost of the SeHCAT test is £381 as a base-case value, and in scenario analyses we have explored a
total cost estimate of £55 or £105 higher. Treatment with BAS is assumed to be £0.63 per day.
For the treatment of chronic diarrhoea in Crohn’s patients without ileal resection, a large variety of
medication was suggested by the experts. This variety is explained by the fact that the diarrhoea can be a
result of relapsing disease, in which case drugs to treat the relapse may be prescribed (such as mesalazine,
azathioprine, corticosteroids or adalimumab), or it can occur while the patient is in remission, in which
case anti-diarrhoeal drugs such as loperamide will more often be prescribed. Table 30 presents the costs of
medication per expert, based on their estimates of use of the various medications. The prices of the
medications were derived from the BNF.64 Exact details on medication use, dosage and fraction of patients
receiving the treatment are presented in Appendix 10. The experts’ responses ranged from £0.11 to
£5.63. Given this skewed range around the point estimate we will assume a gamma distribution for this
estimate in the probabilistic sensitivity analysis.
Markov model for Crohn’s disease without ileal resectionProbabilities
No reports were found in the literature that chronic diarrhoea itself in Crohn’s patients would lead to
excess mortality. However, patients with Crohn’s disease have a shorter life expectancy compared with
that of the general population. A meta-analysis by Canavan et al.80 showed a pooled estimate of the
standardised mortality ratio (SMR) of 1.52 (95% CI 1.32 to 1.74). Thus, we have applied this SMR to
the overall mortality in the UK population, for which we used again the England and Wales Interim Life
Tables 1980–82 to 2008–10.66 Using the study by Nyhlin et al.,46 we found an average age of 39 years
and a ratio of male to female of 0.61. Our model cohort was assumed to have the same age and
sex distribution.
For the transitions between ND and D, both in the BAS Markov model and the Crohn’s Markov model, no
data were available. As in IBS-D, it seems likely that patients will transfer between these health states over
time for various reasons, especially in patients where the relapse becomes so severe that eventually an ileal
resection becomes necessary. These patients will almost certainly develop BAM if they did not have it
before.38,44
All in all, as no evidence exists to formulate base-case values for these transition probabilities, we have
defined a range of equally plausible scenarios for the long-term analysis.TABLE 30 Costs of medication per day for diarrhoea in Crohn’s disease patients, per expert
Patients receiving
medication (%)
Average cost per treated
patient per day
Average cost per
patient per day
100 2.42 2.42
100 4.01 4.01
50 0.14 0.07
95 0.25 0.24
100 1.44 1.44
Mean 1.64
SD 1.63
SD, standard deviation.
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The same utility estimates were used as in the decision tree for Crohn’s disease.Costs
Again for four health states a cost estimate is required: ND-no BAM, D-no BAM, ND-BAM and D-BAM.
The ND states are the states where the treatment responders start the Markov model; hence, for BAS
responders we have assumed that the costs per cycle are equal to the costs used in the decision tree, that
is to say £115 per cycle (i.e. 182.5 × £0.63). For non-BAM responders we have assumed that the cost per
cycle are equal to the medication costs used in the decision tree minus the costs of anti-TNF-α as it
appears unlikely that these would be continued for life. Thus, we arrive at an estimate of £197 per cycle.
We defined two different scenarios related to these ND costs for non-BAM and BAM responders, one
where the costs per cycle remain the same for the full time horizon and another where we assume a
gradual decline in costs due to patients no longer needing the treatment or stopping treatment owing to
various compliance issues. This decline in the cost per cycle was rather arbitrarily set at approximately 2%
per cycle (i.e. 2% decrease of the remaining costs). For the D health state, both for non-BAM and BAM,
again we assumed that patients use some loperamide to at least reduce the stool frequency somewhat
(£10.90 per cycle).Uncertainty analysis
In the model many uncertainties exist with regard to the input data. The impact of these uncertainties was
explored through probabilistic sensitivity analysis. Cost-effectiveness acceptability curves (CEACs) have
been used to describe which strategy has the highest probability of being considered cost-effective given a
threshold incremental cost-effectiveness ratio (ICER). All values used are listed in Tables 31 and 32.
We also explore the value of information associated with the model uncertainty by estimating the
expected value of perfect information (EVPI), which is the amount the decision-maker should be willing to
pay to eliminate all uncertainty in the decision. For the IBS-D model we assumed a potential population of
1.3 million in the UK (see Figure 1). For the Crohn’s disease model, we do not know the size of the
population and present, therefore, the EVPI per patient.
In addition, extensive scenario analyses were performed for all those input parameters where, due to lack
of published data, assumptions had to be made.Model assumptions
Diarrhoea-predominant irritable bowel syndrome population decision tree
(first 6 months)l A positive SeHCAT test result depends on a cut-off threshold; from literature three main cut-off points
are considered: 5%, 10% and 15%.
l Studies with cut-off points between 8% and 12% have all been grouped as 10% (see Chapter 3,
Effectiveness of bile acid sequestrants for thetreatment of bile acid absorption in patients with
chronic diarrhoea).
l Response to BAS treatment for positive SeHCAT test is estimated (depending on the cut-off value)
from literature.
l Response to BAS in the trial of treatment strategy is assumed to be 28%, which is equivalent to the
percentage of BAS responders in the SeHCAT 15% strategy.
l Response to IBS-D treatment for no SeHCAT test patients is derived from experts’ answers
(question 11 – no SeHCAT available).
l For the response to IBS-D treatment when SeHCAT test (15%) is negative we assume a 10-percentage-
point higher response rate, as a large group of patients with BAM (who would be less respondent to
IBS treatment) has been excluded because they have a positive SeHCAT result.63
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TABLE 31 Model parameters: IBS-D-suspected population
Categories Descriptions
Mean
values Distributions
Distribution
parameters Sources
Branch probability
(for decision
tree only)
Probability of having a
positive SeHCAT test – cut-off
value 5%
0.22 Beta α = 9.10;
β = 33.18
L
Probability of responding to
BAS given a positive SeHCAT
test – cut-off value 5%
0.88 Beta α = 21.27;
β = 2.98
L
Probability increase (%) of
responding to IBS-D treatment
given a negative SeHCAT
test – cut-off value 5%
0.05 Uniform a = 0.025;
b = 0.075
A
Probability of having a
positive SeHCAT test – cut-off
value 10%
0.36 Beta α = 50.49;
β = 88.53
L
Probability of responding to
BAS given a positive SeHCAT
test – cut-off value 10%
0.76 Beta α = 48.00;
β = 15.27
L
Probability increase (%) of
responding to IBS-D treatment
given a negative SeHCAT
test – cut-off value 10%
0.03 Uniform a = 0.01;
b = 0.05
A
Probability of having a
positive SeHCAT test – cut-off
value 15%
0.38 Beta α = 37.25;
β = 60.51
L
Probability of responding to
BAS given a positive SeHCAT
test – cut-off value 15%
0.73 Beta α = 101.64;
β = 36.91
L
Probability increase (%) of
responding to IBS-D treatment
given a negative SeHCAT
test – cut-off value 15%
0.02 Uniform a = 0.01;
b = 0.03
A
Probability of responding to
IBS-D treatment when no
SeHCAT is available
0.52 Beta α = 13.14;
β = 12.04
E
Probability of responding to
BAS – trial of treatment
0.28 Beta α = 22.29;
β = 57.34
A
Probability increase (%) of
responding to IBS-D treatment
when response to BAS is
negative in trial of treatment
0.05 Uniform a = 0.025;
b = 0.075
A
Transition probability
(for Markov
model only)
Transition probability from
‘diarrhoea’ to ‘no diarrhoea’
0.05 Triangular a = 0.02;
b = 0.08;
c = 0.05
A
Transition probability from ‘no
diarrhoea’ to ‘diarrhoea’
0.05 Triangular a = 0.02;
b = 0.08;
c = 0.05
A
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TABLE 31 Model parameters: IBS-D-suspected population (continued )
Categories Descriptions
Mean
values Distributions
Distribution
parameters Sources
Cost Cost per day of IBS-D
medication
0.17 Gamma Shape = 6.57;
scale = 0.02
E
Diet costs per 6 months
associated with IBS-D
46.05 Gamma Shape = 46.89;
scale = 0.98
E
Psychological costs per 6
months associated with IBS-D
129.81 Gamma Shape = 145.17;
scale = 0.89
E
Cost per day of BAS
medication
0.63 Triangular a = 0.42;
b = 0.84;
c = 0.63
E
Cost SeHCAT capsule 195 Fixed –
Cost for administering
SeHCAT test
186 Fixed –
Maintenance and service costs
of SeHCAT test
0 Fixed –
Cost per day associated with
health state ‘diarrhoea’
0.06 Triangular a = 0.03;
b = 0.09;
c = 0.06
A
IBS-D medication cost per day
associated with health state
‘no diarrhoea’
0.17 Gamma Shape = 6.57;
scale = 0.02
E
BAS cost per day associated
with health state ‘no
diarrhoea’
0.63 Triangular a = 0.42;
b = 0.84;
c = 0.63
E
Utility Utility associated with health
state ‘diarrhoea’
0.71 Beta α = 317.95;
β = 128.40
L
Utility associated with health
state ‘no diarrhoea’ (IBS-D)
0.78 Beta α = 781.54;
β = 226.15
L
Utility associated with health
state ‘no diarrhoea’ (BAM)
0.76 Beta α = 345.92;
β = 109.38
A
A, assumption; E, expert opinion; L, literature.
TABLE 32 Model parameters: Crohn’s disease population
Categories Descriptions
Mean
values Distributions
Distribution
parameters Sources
Branch probability
(for decision
tree only)
Probability of having a positive
SeHCAT test – cut-off value 10%
0.54 Beta α = 39.46;
β = 33.54
L
Probability of responding to BAS
given a positive SeHCAT
test – cut-off value 10%
0.76 Beta α = 48.00;
β = 15.27
A
Probability increase (%) of
responding to Crohn’s treatment
given a negative SeHCAT test –
cut-off value 10%
0.08 Uniform a = 0.04;
b = 0.12
A
Probability of having a positive
SeHCAT test – cut-off value 15%
0.63 Beta α = 18.36;
β = 10.64
L
continued
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TABLE 32 Model parameters: Crohn’s disease population (continued )
Categories Descriptions
Mean
values Distributions
Distribution
parameters Sources
Probability of responding to BAS
given a positive SeHCAT test –
cut-off value 15%
0.73 Beta α = 101.64;
β = 36.91
A
Probability increase (%) of
responding to Crohn’s treatment
given a negative SeHCAT test –
cut-off value 15%
0.02 Uniform a = 0.01;
b = 0.03
A
Probability of responding to
Crohn’s treatment when no
SeHCAT is available
0.62 Beta α = 15.77;
β = 9.60
E
Probability of responding to BAS –
trial of treatment
0.46 Beta α = 45.24;
β = 53.11
A
Probability increase (%) of
responding to Crohn’s treatment
when response to BAS is negative
in trial of treatment
0.05 Uniform a = 0.03;
b = 0.07
A
Transition probability
(for Markov
model only)
Transition probability from
‘diarrhoea’ to ‘no diarrhoea’
0.05 Triangular a = 0.02;
b = 0.08;
c = 0.05
A
Transition probability from ‘no
diarrhoea’ to ‘diarrhoea’
0.05 Triangular a = 0.02;
b = 0.08;
c = 0.05
A
Cost Cost per day of Crohn’s medication 1.78 Gamma Shape = 2.55;
scale = 0.69
E
Cost per day of BAS medication 0.63 Triangular a = 0.42
b = 0.84
c = 0.63
E
Cost SeHCAT capsule 195 Fixed –
Cost for administering SeHCAT test 186 Fixed –
Maintenance and service costs of
SeHCAT test
0 Fixed –
Cost per day associated with health
state ‘diarrhoea’
0.06 Triangular a = 0.03;
b = 0.09;
c = 0.06
A
Crohn’s medication cost per day
associated with health state ‘no
diarrhoea’
1.08 Gamma Shape = 2.00;
scale = 0.54
E
BAS cost per day associated with
health state ‘no diarrhoea’
0.63 Triangular a = 0.42;
b = 0.84;
c = 0.63
E
Utility Utility associated with health state
‘diarrhoea’
0.70 Beta α =320.21;
β = 137.23
L
Utility associated with health state
‘no diarrhoea’ (Crohn’s)
0.76 Beta α = 802.58;
β = 253.44
L
Utility associated with health state
‘no diarrhoea’ (BAM)
0.74 Beta α = 353.08;
β = 120.85
L
A, assumption; E, expert opinion; L, literature.
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higher response rate.
l SeHCAT is assumed not to be associated with any adverse effects.
l We assumed that the utility gain for IBS-D treatment would be larger than for BAS treatment, due to
side effects caused by BAS. In the Markov models, it may lead to declining costs and transitions from
ND to D.
l We assumed that reduced compliance with BAS or IBS-D treatment in the decision tree was already
implicitly included in the response rates.
l The SeHCAT test lasts 1 week. The decision tree is assumed to cover 6 months (same as Markov cycle).
l We assume no difference in number of gastroenterologists visits between the various strategies.
l IBS-D treatment costs (no SeHCAT and SeHCAT negative) consist of medication, diet and psychological
therapy costs.
l Resource use IBS-D was based on expert opinion.
l BAM treatment (SeHCAT positive) consists of medication costs only.
l The cost estimate for the BAS treatment is based on the reported dosage of Williams.45Crohn’s population decision tree (first 6 months)l Response rate to BAS in patients with a positive SeHCAT would be the same as in patients with
idiopathic BAM.
l Percentage of Crohn’s patients considered successfully treated for their chronic diarrhoea based on
expert opinion.
l For the response to diarrhoea/Crohn’s disease treatment when SeHCAT test (15%) is negative we
assume a 10-percentage-point higher response rate, as a large group of patients with BAM (who
would be less respondent to diarrhoea/Crohn’s disease treatment) has been excluded because they
have a positive SeHCAT result, and 8 percentage points higher for a cut-off of 10%. This is similar to
the assumption in the IBS-D population.
l Response to BAS in the trial of treatment strategy is assumed to be 46%, which is equivalent to the
percentage of BAS responders in the SeHCAT 15% strategy.
l We assume that the quality of life in the diarrhoea health state is 0.7.
l We assume that the utility decrement due to diarrhoea in the Crohn’s patient population is the same
as for the IBS-D population.Markov modell Cycle length: 6 months.
l Time horizon: lifetime = 50 years = 100 cycles.
l Initial distribution of patients (from decision tree): we assume that patients responding to treatment are
in no diarrhoea and those not responding are in diarrhoea.
l No excess mortality due to chronic diarrhoea is assumed.
l Our model cohort was assumed to have the same age and sex distribution as those found in the
studies used for the probability of a positive SeHCAT test.
l In the diarrhoea state patients are assumed to use loperamide.
l Patients treated as IBS-D in the no diarrhoea state are assumed to only incur medication cost (per cycle)
as in decision tree.
l Patients treated with BAS are assumed to continue their medication.
l Patients treated as Crohn’s with chronic diarrhoea in the no diarrhoea state are assumed to only incur
medication cost (per cycle) without anti-TNF-α.67
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68ResultsIn this section we discuss the costs, effects and the cost-effectiveness of the various strategies per
population. First, the full results are given for the IBS-D population: both short-term and long-term results.
These are first presented without trial of treatment as a comparator and then with trial of treatment as a
comparator. The results are then presented for the Crohn’s population again both short-term and long-
term results and again these are first presented without trial of treatment as comparator and then with
trial of treatment as a comparator. ICERs were estimated as additional cost per additional responder in the
short term (first 6 months) and per additional QALY in the long term (lifetime).Costs, effects and cost-effectiveness for diarrhoea-predominant irritable
bowel syndrome
Short-term results for diarrhoea-predominant irritable bowel syndrome
(decision tree)
Table 33 presents the probabilistic outcomes of the base-case decision tree for the IBS-D population.
Results are presented in order of increasing number of responders. From this, it becomes clear that the
SeHCAT 15% strategy dominates the other SeHCAT strategies. Also, SeHCAT 15% is more expensive
while also generating more responders.
To investigate what the impact is of the various (statistical) uncertainties in the model, we also present the
CEAC (Figure 10). It should be noted that the outcome here is cost per responder; we cannot judge the
curve using the usual threshold, which relates to cost per QALY.
As mentioned in the methods section, various assumptions regarding probabilities had to be made
where neither literature nor expert opinion was available. Additionally, the costs of IBS-D treatment areTABLE 33 Short-term results for IBS-D population, base case (scenario A1)
Strategy
Percentage of
responders
Costs
(per patient)
Incremental
responders
Incremental
costs ICER
No SeHCAT test – treat IBS-D 0.5145 208
SeHCAT test – 5% cut-off 0.632 569 Dominated by SeHCAT 15%
SeHCAT test – 10% cut-off 0.654 555 Dominated by SeHCAT 15%
SeHCAT test – 15% cut-off 0.6596 553 0.1451 345 2378
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FIGURE 10 Cost-effectiveness acceptability curve short-term (cost per responder) results for IBS-D population,
base case (scenario A1).
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DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61very uncertain, as the experts had very differing responses, and some uncertainty exists about the total
costs of SeHCAT.
Thus, we formulated several scenarios, which are listed in Table 34. We varied the percentage point
change in the response rate to IBS-D treatment for SeHCAT-negative and BAS trial-negative patients from
10% (i.e. response rate 62%) to both 0% and 25%; we increased IBS-D treatment costs by 100% and
decreased these costs by 50%; and finally we increased SeHCAT cost by £55 and £105 and decreased it
by £95.
We found that increasing SeHCAT costs has no impact on the conclusions from the base case.
This is intuitively clear, as in the base case, the SeHCAT strategies are already the most expensive, and
these only become slightly more expensive. When we change the probability of IBS-D treatment response
in SeHCAT-negative and BAS trial-negative patients to the same value as when all patients receive IBS-D
treatment (52% response rate), we see that the number of responders in the SeHCAT strategies decreases
(Table 35). The CEAC (Figure 11) shows that now SeHCAT 10% dominates the other SeHCAT strategies
for all larger threshold ICERs.TABLE 34 Overview of scenarios explored for short-term IBS-D
Scenarios
SeHCAT service
cost (£)
Probability response
to IBS-D treatment
in SeHCAT-negative
patients
Costs IBS-D
treatment
Cost SeHCAT
capsule (£)
Results
presented?
A1 0 0.62 195 Yes
A2 55 0.62 195 No
A3 105 0.62 195 No
A4 0 0.52 195 Yes
A5 0 0.87 195 No
A6 0 0.62 × 2 195 No
A7 0 0.62 /2 195 No
A8 0 0.52 /2 195 Yes
A9 0 0.62 100 Yes
A10 0 0.52 100 No
A11 0 0.87 100 No
TABLE 35 Short-term results for IBS-D population, response to IBS-D treatment in SeHCAT-negative patients 52%
(scenario A4)
Strategy
Percentage of
responders
Costs
(per patient)
Incremental
responders
Incremental
costs ICER
No SeHCAT test 0.5202 207
SeHCAT test – 5% cut-off 0.5971 568 Dominated by SeHCAT 10%
SeHCAT test – 15% cut-off 0.6014 553 Extendedly dominated by SeHCAT 10%
SeHCAT test – 10% cut-off 0.6068 555 0.0865 348 4019
69
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1.0
0.8
0.6
0.4
0.2
0.0
0 10 20 30
λ (000)
Pr
o
b
ab
ili
ty
 t
h
at
 a
 t
re
at
m
en
t 
is
 o
p
ti
m
al
40 50
No SeHCAT – IBS-D
SeHCAT  –  cut-off 5%
SeHCAT  –  cut-off 10%
SeHCAT  –  cut-off 15%
FIGURE 11 Cost-effectiveness acceptability curve short-term (cost per responder) results for IBS-D population,
response to IBS-D treatment in SeHCAT-negative patients 52% (scenario A4).
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70When we also decrease the cost of IBS-D treatment to 50% of the base case we see costs per strategy
decrease while the incremental costs stay approximately the same (Table 36). Thus, the CEAC (Figure 12) is
similar to the previous. Clearly, the impact of the treatment costs for IBS-D for the short term is limited.
When we reduce the cost of the SeHCAT test we observe that now SeHCAT 15% again dominates the
other SeHCAT strategies (Table 37), but overall the impact is limited. This is confirmed by the CEAC where
we still find that trial of treatment is dominant. The CEAC (Figure 13) is very similar to the base-case curve,
indicating that the impact of lowering the cost of SeHCAT has little impact on the results.TABLE 36 Short-term results for IBS-D population, response to IBS-D treatment in SeHCAT-negative patients 52%
and cost of IBS-D treatment 50% of base case (scenario A8)
Strategy
Percentage of
responders
Costs
(per patient)
Incremental
responders
Incremental
costs ICER
No SeHCAT test – treat IBS-D 0.5272 104
SeHCAT test – 5% cut-off 0.6024 487 Extendedly dominated by SeHCAT 10%
SeHCAT test – 15% cut-off 0.6058 489 Dominated by SeHCAT 10%
SeHCAT test – 10% cut-off 0.6111 489 0.0839 385 4591
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FIGURE 12 Cost-effectiveness acceptability curve short-term (cost per responder) results for IBS-D population,
response to IBS-D treatment in SeHCAT-negative patients 52% and cost of IBS-D treatment 50% of base case
(scenario A8).
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ABLE 37 Short-term results for IBS-D population, costs of SeHCAT reduced to £100 (scenario A9)
Strategy
Percentage of
responders
Costs
(per patient)
Incremental
responders
Incremental
costs ICER
No SeHCAT test – treat IBS-D 0.5275 208
SeHCAT test – 5% cut-off 0.6421 474 Dominated by SeHCAT 15%
SeHCAT test – 10% cut-off 0.6627 460 Dominated by SeHCAT 15%
SeHCAT test – 15% cut-off 0.668 459 0.1405 251 1784
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FIGURE 13 Cost-effectiveness acceptability curve short-term (cost per responder) results for IBS-D population, costs of
SeHCAT reduced to £100 (scenario A9).Lifetime results for diarrhoea-predominant irritable bowel syndrome
As mentioned in the methods section, no information was available to estimate the transition probabilities
in the Markov models other than the all-cause mortality rates. Thus, we formulated various scenarios
with different transition probabilities for ND-BAM→ D-BAM, D-BAM→ ND-BAM, ND-IBS→ D-IBS and
D-IBS→ ND-IBS. Additionally, we have two scenarios regarding the utility in the no diarrhoea health state;
either this is the same for BAS and IBS-D or utility of BAS responders is lower than for IBS-D responders.
Table 38 presents an overview of all scenarios we explored. As many yielded the same results, we only
present a selection of the scenarios, as indicated in the table.
Below are the results for scenario 1. Scenario 1 assumes that all four transition probabilities are 5% per
cycle. We observe that all SeHCAT strategies are dominated by no SeHCAT (Table 39). When we look at
the CEACs (Figure 14), we notice that no SeHCAT has the highest probability of being cost-effective for
the whole range of thresholds.
Figure 15 shows the population EVPI; from this we see that at a threshold of £30,000, the value of perfect
information amounts to £10,000M.
Scenario 2 assumes that all four transition probabilities are 0% per cycle. We now observe (Table 40) that
the ICER of SeHCAT 5% compared with no SeHCAT falls well below the commonly used £30,000
threshold. The ICER of SeHCAT 15% compared with SeHCAT 5% is approximately equivalent to this
threshold. When we look at the CEAC (Figure 16), we notice that, for small thresholds, no SeHCAT – treat
IBS-D has the highest probability of being cost-effective while for larger thresholds (around £10,000)
SeHCAT 5% has the highest probability of being cost-effective.
Scenario 3 assumed that the two transition probabilities from ND to D are 5% per cycle while the other
two are 0. As can be seen in Table 41, SeHCAT 5% has a favourable ICER compared with no SeHCAT,71
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TABLE 39 Lifetime results for IBS-D population, scenario 1
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 15.273 1624 Dominated by no SeHCAT
SeHCAT test – 10% cut-off 15.2744 1611 Dominated by no SeHCAT
SeHCAT test – 5% cut-off 15.2925 1462 Dominated by no SeHCAT
No SeHCAT test 15.3006 818
TABLE 38 Overview of scenarios explored for the long-term analysis, no trial of treatment
Scenario
IBS-D P
(ND→D)
IBS-D P
(D→ND)
BAM P
(ND→D)
BAM P
(D→ND)
Utility BAS no
diarrhoea
Results
presented?
1 0.05 0.05 0.05 0.05 BAS < IBS Yes
2 0 0 0 0 BAS < IBS Yes
3 0.05 0 0.05 0 BAS < IBS Yes
4 0.05 0 0 0 BAS < IBS Yes
5 0 0.05 0 0 BAS < IBS No, same as 1
6 0 0 0.05 0 BAS < IBS No, same as 1
7 0 0 0 0.05 BAS < IBS No, same as 4
8 0.05 0.05 0.05 0.05 BAS = IBS Yes
9 0 0 0 0 BAS = IBS No, same as 2
10 0.05 0 0.05 0 BAS = IBS No, same as 3
11 0.05 0 0 0 BAS = IBS No, same as 4
12 0 0.05 0 0 BAS = IBS Yes
13 0 0 0.05 0 BAS = IBS No, same as 6
14 0 0 0 0.05 BAS = IBS No, same as 7
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FIGURE 14 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 1.
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TABLE 40 Lifetime results for IBS-D population, scenario 2
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 15.3244 823
SeHCAT test – 10% cut-off 15.4127 1783 Dominated by SeHCAT 5%
SeHCAT test – 5% cut-off 15.4133 1613 0.0889 790 8886
SeHCAT test – 15% cut-off 15.4191 1793 0.0058 180 31031
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FIGURE 16 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 2.
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FIGURE 15 Population EVPI for lifetime IBS-D population, scenario 1.
ABLE 41 Lifetime results for IBS-D population, scenario 3
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 14.8964 751
SeHCAT test – 5% cut-off 14.9272 1307 0.0308 557 18077
SeHCAT test – 10% cut-off 14.9275 1379 Extendedly dominated by SeHCAT 15%
SeHCAT test – 15% cut-off 14.93 1382 0.0028 75 26786
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74and the subsequent ICER of SeHCAT 15% versus SeHCAT 5% may also be considered acceptable given a
threshold of £30,000. The CEAC presented in Figure 17 shows that for lower threshold values (< £20,000)
no SeHCAT has the highest probability of being cost-effective while for higher threshold values
(> £30,000), all three SeHCAT strategies have a higher probability of being cost-effective than no SeHCAT.
Figure 18 shows the population EVPI; from this we see that at a threshold of £30,000 the value of perfect
information amounts to £30,000M. This is three times higher than in scenario 1, which is explained by the
fact that at that threshold value all four strategies have approximately the same probability of being the
most cost-effective.
Scenario 4 assumes that the transition probability from ND to D in the IBS model is 5% per cycle while all
others are 0. We observe that SeHCAT 15% compared with no SeHCAT yields an ICER well below the
common threshold of £30,000, while the other two SeHCAT strategies are extendedly dominated by
SeHCAT 15% (Table 42). When we look at the CEAC (Figure 19), we again observe that, for small
thresholds, no SeHCAT – treat IBS-D has the highest probability of being cost-effective while for larger
thresholds (around £5000) SeHCAT 15% has the highest probability of being cost-effective.
Scenario 8 is the same as scenario 1, but now with utilities for IBS-D and BAM the same. As can be seen in
Table 43, SeHCAT 5% has a favourable ICER compared with no SeHCAT, and the ICER of SeHCAT 15%1.0
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FIGURE 17 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 3.
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FIGURE 18 Population EVPI for lifetime IBS-D population, scenario 3.
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FIGURE 19 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 4.
TABLE 43 Lifetime results for IBS-D population, scenario 8
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 15.3034 819
SeHCAT test – 5% cut-off 15.334 1460 0.0306 642 20,976
SeHCAT test – 10% cut-off 15.3388 1610 Extendedly dominated by SeHCAT 15%
SeHCAT test – 15% cut-off 15.3408 1625 0.0068 165 24,265
TABLE 42 Lifetime results for IBS-D population, scenario 4
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 14.8939 749
SeHCAT test – 5% cut-off 15.0432 1548 Extendedly dominated by SeHCAT 15%
SeHCAT test – 10% cut-off 15.0965 1727 Extendedly dominated by SeHCAT 15%
SeHCAT test – 15% cut-off 15.1003 1736 0.2064 987 4782
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61versus SeHCAT 5% may also be considered acceptable given a threshold of £30,000. The CEAC presented
in Figure 20 shows that for lower threshold values no SeHCAT has the highest probability of being optimal
while at a threshold of between £20,000 and £30,000, the three SeHCAT strategies have approximately
the same probability of being optimal.
Figure 21 shows the population EVPI; from this we see that at a threshold of £30,000, the value of perfect
information amounts to £20,000M.
Finally, scenario 12 is the same as scenario 5, but now with utilities for IBS-D and BAM the same. As can
be seen in Table 44, due to the higher utility for BAM responders, now SeHCAT 5% has a favourable ICER
compared with no SeHCAT given a threshold of £30,000. The CEAC presented in Figure 22 shows that for
lower threshold values no SeHCAT has the highest probability of being optimal while at a threshold of
between £20,000 and £30,000, SeHCAT 5% has the highest probability of being optimal.75
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FIGURE 21 Population EVPI for lifetime IBS-D population, scenario 8.
TABLE 44 Lifetime results for IBS-D population, scenario 12
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 15.7042 1823 Dominated by no SeHCAT
SeHCAT test – 10% cut-off 15.7136 1820 Dominated by no SeHCAT
No SeHCAT test 15.7239 893
SeHCAT test – 5% cut-off 15.7539 1660 0.03 767 25,567
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FIGURE 20 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 8.
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FIGURE 22 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 12.
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syndrome with trial of treatment included
Short-term results (decision tree) for diarrhoea-predominant irritable bowel
syndrome with trial of treatment
Table 45 presents the probabilistic outcomes of the base-case decision tree for the IBS-D population when
trial of treatment is also considered as comparator. Results are presented in order of increasing number of
responders. From this, it becomes clear that the trial of treatment strategy dominates all other strategies:
it leads to the highest number of responders for the lowest costs. Thus, no ICERs should be calculated.
From the table we also notice that of the three SeHCAT scenarios, the 15% cut-off dominates the other
two cut-offs.
To investigate what the impact is of the various (statistical) uncertainties in the model, we also present the
CEAC (Figure 23). We notice that the trial of treatment strategy has the highest probability of being
considered cost-effective over the whole range of possible threshold ICERs.
As mentioned in the methods section, various assumptions regarding probabilities had to be made where
neither literature nor expert opinion was available. Additionally, the costs of IBS-D treatment are very
uncertain, as the experts had very differing responses and some uncertainty exists about the total costs of
SeHCAT. Thus, we formulated several scenarios, which are listed in Table 46. However, none of these
scenarios led to any results different from the base case; in all cases trial of treatment was the dominant
strategy. For all scenarios trial of treatment had the highest probability of being cost-effective; this
probability was for most scenarios around 90%, decreasing for some scenarios to 50%.TABLE 45 Short-term results for IBS-D population: base case with trial of treatment
Strategy
Percentage of
responders
Costs
(per patient)
Incremental
responders
Incremental
costs ICER
No SeHCAT test 0.5145 208 Dominated by trial of treatment
SeHCAT test – 5% cut-off 0.632 569 Dominated by trial of treatment
SeHCAT test – 10% cut-off 0.654 555 Dominated by trial of treatment
SeHCAT test – 15% cut-off 0.6596 553 Dominated by trial of treatment
No SeHCAT test – trial of treatment 0.6862 148
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TABLE 46 Overview of scenarios explored for short-term IBS-D with trial of treatment
Scenario
SeHCAT
service
cost
Probability
response to
BAS with trial
of treatment
Probability response
to IBS-D treatment
in SeHCAT-negative
patients
Costs IBS-D
treatment
Cost
SeHCAT
capsule
Results
presented?
B1 0 0.28 0.62 195 Yes
B2 55 0.28 0.62 195 No, same as 1
B3 105 0.28 0.62 195 No, same as 1
B4 0 0.28 0.52 195 No, same as 1
B5 0 0.28 0.87 195 No, same as 1
B6 0 0.21 0.62 195 No, same as 1
B7 0 0.21 0.52 195 No, same as 1
B8 0 0.21 0.87 195 No, same as 1
B9 0 0.28 0.62 × 2 195 No, same as 1
B10 0 0.28 0.62 /2 195 No, same as 1
B11 0 0.28 0.52 /2 195 No
B12 0 0.21 0.52 /2 195 No, same as 1
B13 0 0.28 0.62 100 No, same as 1
B14 0 0.28 0.52 100 No, same as 1
B15 0 0.28 0.87 100 No, same as 1
B16 0 0.21 0.62 100 No, same as 1
B17 0 0.21 0.52 100 No, same as 1
B18 0 0.21 0.87 100 No, same as 1
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FIGURE 23 Cost-effectiveness acceptability curve for short-term (cost per responder) results for IBS-D population,
base case with trial of treatment.
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of treatment
As in Lifetime results for diarrhoea-predominant irritable bowel syndrome, above, we have again explored
a list of 14 scenarios regarding transition probabilities of the Markov models and the utility of the no
diarrhoea health state. Again, we present only a limited number of these scenarios (Table 47).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 47 Overview of scenarios explored for the long-term analysis with trial of treatment
Scenario
IBS-D
P(ND→D)
IBS-D
P(D→ND)
BAM
P(ND→D)
BAM
P(D→ND)
Utility BAS no
diarrhoea
Results
presented?
1 0.05 0.05 0.05 0.05 BAS < IBS Yes
2 0 0 0 0 BAS < IBS Yes
3 0.05 0 0.05 0 BAS < IBS No, same as 2
4 0.05 0 0 0 BAS < IBS No, same as 2
5 0 0.05 0 0 BAS < IBS No, same as 1
6 0 0 0.05 0 BAS < IBS No, same as 1
7 0 0 0 0.05 BAS < IBS Yes
8 0.05 0.05 0.05 0.05 BAS = IBS Yes
9 0 0 0 0 BAS = IBS No, same as 2
10 0.05 0 0.05 0 BAS = IBS No, same as 3
11 0.05 0 0 0 BAS = IBS No, same as 4
12 0 0.05 0 0 BAS = IBS Yes
13 0 0 0.05 0 BAS = IBS No, same as 6
14 0 0 0 0.05 BAS = IBS No, same as 7
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Below are the results for scenario 1. Scenario 1 assumes that all four transition probabilities are 5% per
cycle. We observe that all SeHCAT strategies are dominated by no SeHCAT (Table 48). When we look at
the CEACs (Figure 24), we notice that no SeHCAT has the highest probability of being cost-effective for
the whole range of thresholds.
Figure 25 shows the population EVPI; from this we see that at a threshold of £30,000, the value of perfect
information amounts to £10,000M.
Scenario 2 assumes that all four transition probabilities are 0% per cycle. We now observe (Table 49) that
the ICER of trial of treatment compared with no SeHCAT falls well below the commonly used £30,000
threshold, while all SeHCAT strategies are dominated by trial of treatment. When we look at the CEAC
(Figure 26), we notice that for small thresholds no SeHCAT has the highest probability of being
cost-effective while for larger thresholds (around £5000) trial of treatment has the highest probability of
being cost-effective.
Scenario 7 assumes that the transition probability from D to ND in the BAM model is 5% per cycle while
all others are 0. We observe that trial of treatment compared with no SeHCAT yields an ICER well belowTABLE 48 Lifetime results for IBS-D population, scenario 1 with trial of treatment
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 15.273 1624 Dominated by no SeHCAT
SeHCAT test – 10% cut-off 15.2744 1611 Dominated by no SeHCAT
No SeHCAT test – trial of treatment 15.2863 1211 Dominated by no SeHCAT
SeHCAT test – 5% cut-off 15.2925 1462 Dominated by no SeHCAT
No SeHCAT test 15.3006 818
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FIGURE 24 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 1 with trial of treatment.
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80TABLE 49 Lifetime results for IBS-D population, scenario 2 with trial of treatment
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 15.3244 823
SeHCAT test – 10% cut-off 15.4127 1783 Dominated by trial of treatment
SeHCAT test – 5% cut-off 15.4133 1613 Dominated by trial of treatment
SeHCAT test – 15% cut-off 15.4191 1793 Dominated by trial of treatment
No SeHCAT test – trial of treatment 15.45 1459 0.1256 636 5064
FIGURE 25 Population EVPI for lifetime IBS-D population, scenario 1 with trial of treatment.the common threshold of £30,000, as is the ICER of SeHCAT 15% compared with trial of treatment
(Table 50). When we look at the CEAC (Figure 27), we again observe that for small thresholds no SeHCAT
has the highest probability of being cost-effective, for thresholds between £5000 and £15,000 trial of
treatment is optimal and for thresholds higher than £15,000 SeHCAT 15% has the highest probability of
being cost-effective.
Figure 28 shows the population EVPI; from this we see that at a threshold of £30,000, the value of perfect
information amounts to £15,000M.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 50 Lifetime results for IBS-D population, scenario 7 with trial of treatment
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 15.3192 822
SeHCAT test – 5% cut-off 15.4264 1643 Dominated by trial of treatment
No SeHCAT test – trial of treatment 15.4451 1459 0.1259 637 5060
SeHCAT test – 10% cut-off 15.4653 1894 Extendedly dominated by SeHCAT 15%
SeHCAT test – 15% cut-off 15.4797 1919 0.0346 460 13,295
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FIGURE 27 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 7 with trial of treatment.
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FIGURE 26 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 2 with trial of treatment.
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Scenario 8 is the same as scenario 1, but now with utilities for IBS-D and BAM the same. As can be seen in
Table 51, now trial of treatment has a favourable ICER compared with no SeHCAT, while all the SeHCAT
strategies are dominated by trial of treatment. The CEAC presented in Figure 29 shows that for lower
threshold values no SeHCAT has the highest probability of being optimal while for thresholds above
£10,000 trial of treatment has the highest probability of being optimal.
Figure 30 shows the population EVPI; from this we see that at a threshold of £30,000, the value of perfect
information amounts to £15,000M.81
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TABLE 51 Lifetime results for IBS-D population, scenario 8 with trial of treatment
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 15.3034 819
SeHCAT test – 5% cut-off 15.334 1460 Dominated by trial of treatment
SeHCAT test – 10% cut-off 15.3388 1610 Dominated by trial of treatment
SeHCAT test – 15% cut-off 15.3408 1625 Dominated by trial of treatment
No SeHCAT test – trial of treatment 15.3412 1210 0.0378 391 10,344
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FIGURE 29 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 8 with trial of treatment.
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FIGURE 28 Population EVPI for lifetime IBS-D population, scenario 7 with trial of treatment.
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82Finally, scenario 12 is the same as scenario 5, but now with utilities for IBS-D and BAM the same.
As can be seen in Table 52, due to the higher utility for BAM responders, now trial of treatment has a
favourable ICER compared with no SeHCAT given a threshold of £30,000. The CEAC presented in
Figure 31 shows that for lower threshold values no SeHCAT has the highest probability of being optimal
while for thresholds above £10,000 trial of treatment has the highest probability of being optimal.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 52 Lifetime results for IBS-D population, scenario 12 with trial of treatment
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 15.7042 1823 Dominated by no SeHCAT
SeHCAT test – 10% cut-off 15.7136 1820 Dominated by no SeHCAT
No SeHCAT test 15.7239 893
SeHCAT test – 5% cut-off 15.7539 1660 Dominated by trial of treatment
No SeHCAT test – trial of treatment 15.7956 1508 0.0717 615 8577
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FIGURE 31 Cost-effectiveness acceptability curve for lifetime IBS-D population, scenario 12 with trial of treatment.
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FIGURE 30 Population EVPI for lifetime IBS-D population, scenario 8 with trial of treatment.
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Costs, effects and cost-effectiveness Crohn’s without ileal resectionShort-term results for Crohn’s disease (decision tree)
Table 53 presents the probabilistic outcomes of the decision tree for the Crohn’s disease population.
Results are presented in order of increasing number of responders. From this, it becomes clear that testing
with SeHCAT leads to more costs and more responders. Note that the ICER is in costs per additional
responder and, thus, we cannot compare it with the usual threshold.83
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TABLE 53 Short-term results for Crohn’s population, base case (scenario C1)
Strategy
Percentage
of responders
Expected
costs
Incremental
responders
Incremental
costs ICER
No SeHCAT test – treat Crohn’s 0.6226 327
SeHCAT test – 15% cut-off 0.7296 573 0.1069 245 2293
SeHCAT test – 10% cut-off 0.7343 592 0.0046 19 4134
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84Figure 32 presents the CEACs. We notice that for smaller thresholds no SeHCAT is the strategy with the
highest probability of being cost-effective whereas for larger thresholds, both SeHCAT strategies are
equally likely to have the highest probability of being cost-effective.
As for the IBS-D population we had to make various assumptions regarding probabilities where neither
literature nor expert opinion was available. Additionally, the costs of treating Crohn’s patients with chronic
diarrhoea are very uncertain, as the experts had very differing responses and some uncertainty exists about
the total costs of SeHCAT.
These assumptions were explored through scenario analysis. The list of scenarios analysed is presented
in Table 54.
We found that increasing or decreasing costs related to SeHCAT did not alter the results. For most
scenarios, the CEACs were close to the base-case CEAC, except for scenarios C5 and C11. These scenarios
have a near-perfect response to Crohn’s treatment in SeHCAT-negative patients. The main difference that
is observed in the CEAC for that scenario (Figure 33) is that SeHCAT 15% and SeHCAT 10% are no
longer equally likely to be the most cost-effective strategy. This is explained by the fact that in SeHCAT
10% more patients have a negative test result and then receive Crohn’s treatment, with a 97% response
rate; thus, this strategy becomes more favourable (Table 55).
Lifetime results for Crohn’s population
As mentioned in the methods section, no information was available to estimate the transition probabilities
in the Markov models other than the all-cause mortality rates. Thus, we formulated various scenarios with
different transition probabilities for ND-BAM→ D-BAM, D-BAM→ ND-BAM, ND-Crohn→ D-Crohn,1.0
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FIGURE 32 Cost-effectiveness acceptability curve for short-term (cost per responder) results for Crohn’s population,
base case (scenario C1).
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FIGURE 33 Cost-effectiveness acceptability curve for short-term (cost per responder) results for Crohn’s population,
response to Crohn’s treatment in SeHCAT-negative patients 97% (scenario C5).
TABLE 55 Short-term (cost per responder) results for Crohn’s population, response to Crohn’s treatment in SeHCAT-
negative patients 97% (scenario C5)
Strategy
Percentage
of responders
Expected
costs
Incremental
responders
Incremental
costs ICER
No SeHCAT test – treat Crohn’s 0.6144 324
SeHCAT test – 15% cut-off 0.8108 574 Extendedly dominated by SeHCAT 10%
SeHCAT test – 10% cut-off 0.8366 593 0.2222 268 1208
TABLE 54 Overview of scenarios explored for short-term Crohn’s
Scenario
SeHCAT
service cost
Probability response
to Crohn’s treatment
in SeHCAT-negative
patients
Costs Crohn’s
treatment
Cost SeHCAT
capsule
Results
presented?
C1 0 0.72 195 Yes
C2 55 0.72 195 No
C3 105 0.72 195 No
C4 0 0.62 195 No
C5 0 0.97 195 Yes
C6 0 0.72 × 2 195 No
C7 0 0.72 /2 195 No
C8 0 0.62 /2 195 No
C9 0 0.72 100 No
C10 0 0.62 100 No
C11 0 0.97 100 No
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61
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86D-Crohn→ ND-Crohn. Additionally, we have two scenarios regarding the utility in the no diarrhoea health
state; either this is the same for BAS and Crohn’s or utility of BAS responders is lower than for Crohn’s
responders. Table 56 presents an overview of all scenarios we explored. As many yielded the same results,
we only present a selection of the scenarios, as indicated in the table.
Below are the results for scenario 1. Scenario 1 assumes that all four transition probabilities are 5% per
cycle. We observe that no SeHCAT is the most favourable strategy, with not only the highest costs but also
the highest effect (Table 57). When we look at the CEACs (Figure 34), we notice that no SeHCAT has the
highest probability of being cost-effective for thresholds above £5000.
Figure 35 shows the patient EVPI; from this we see that at a threshold of £30,000, the value of perfect
information amounts to £100.
Scenario 2 assumes that all four transition probabilities are 0% per cycle. We now observe (Table 58) that
the ICER of SeHCAT 10% compared with SeHCAT 15% falls well below the commonly used £30,000
threshold and that SeHCAT 10% dominates no SeHCAT. When we look at the CEAC (Figure 36), we
notice that for small thresholds SeHCAT 15% has the highest probability of being cost-effective while for
larger thresholds (above £8000) SeHCAT 10% has the highest probability of being cost-effective.
However, for no SeHCAT this probability is almost the same as for SeHCAT 10%.TABLE 57 Lifetime results for Crohn’s population, scenario 1
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 14.0847 2710
SeHCAT test – 10% cut-off 14.0994 2828 Extendedly dominated by no SeHCAT test
No SeHCAT test 14.1571 3023 0.0724 313 4323
TABLE 56 Overview of scenarios explored for the long-term analysis, no trial of treatment
Scenario
Crohn P
(ND→D)
Crohn P
(D→ND)
BAM P
(ND→D)
BAM P
(D→ND)
Utility BAS no
diarrhoea
Results
presented?
1 0.05 0.05 0.05 0.05 BAS < Crohn Yes
2 0 0 0 0 BAS < Crohn Yes
3 0.05 0 0.05 0 BAS < Crohn No, same as 2
4 0.05 0 0 0 BAS < Crohn Yes
5 0 0.05 0 0 BAS < Crohn No, same as 1
6 0 0 0.05 0 BAS < Crohn No, same as 1
7 0 0 0 0.05 BAS < Crohn No, same as 4
8 0.05 0.05 0.05 0.05 BAS = Crohn Yes
9 0 0 0 0 BAS = Crohn No, same as 8
10 0.05 0 0.05 0 BAS = Crohn No, same as 8
11 0.05 0 0 0 BAS = Crohn No, same as 4
12 0 0.05 0 0 BAS = Crohn Yes
13 0 0 0.05 0 BAS = Crohn No, same as 6
14 0 0 0 0.05 BAS = Crohn No, same as 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 58 Lifetime results for Crohn’s population, scenario 2
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 14.2517 3196
No SeHCAT test 14.2635 3400 Dominated by SeHCAT 10%
SeHCAT test – 10% cut-off 14.2712 3336 0.0195 140 7179
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FIGURE 35 Patient EVPI for Crohn’s population, scenario 1.
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FIGURE 34 Cost-effectiveness acceptability curve for lifetime Crohn’s population, scenario 1.
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Scenario 4 assumes that the transition probability from ND to D in the Crohn’s model is 5% per cycle
while all others are 0. We observe that SeHCAT 15% compared with no SeHCAT yields an ICER well
below the common threshold of £30,000, while SeHCAT 10% is dominated by SeHCAT 15% (Table 59).
When we look at the CEAC (Figure 37), we observe that for small thresholds no SeHCAT has the highest
probability of being cost-effective while for larger thresholds (around £5000) SeHCAT 15% has the highest
probability of being cost-effective.
Scenario 8 is the same as scenario 1, but now with utilities for Crohn’s and BAM the same. As can be seen
in Table 60, SeHCAT 15% dominates no SeHCAT, and the ICER of SeHCAT 10% versus SeHCAT 15%
would be considered too high given a threshold of £30,000. The CEAC presented in Figure 38 shows that87
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FIGURE 37 Cost-effectiveness acceptability curve for lifetime Crohn’s population, scenario 4.
TABLE 60 Lifetime results for Crohn’s population, scenario 8
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 14.1592 3031 Dominated by SeHCAT 15%
SeHCAT test – 15% cut-off 14.1865 2708
SeHCAT test – 10% cut-off 14.1876 2828 0.0011 119 108,412
TABLE 59 Lifetime results for Crohn’s population, scenario 4
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 13.8169 1972
SeHCAT test – 10% cut-off 14.042 2596 Dominated by SeHCAT 15%
SeHCAT test – 15% cut-off 14.0657 2595 0.2488 623 2504
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FIGURE 36 Cost-effectiveness acceptability curve for lifetime Crohn’s population, scenario 2.
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FIGURE 38 Cost-effectiveness acceptability curve for lifetime Crohn’s population, scenario 8.
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the curves of SeHCAT 15% and SeHCAT 10% are quite close, thus leading to more decision uncertainty.
This is reflected in the EVPI (Figure 39), which at a threshold of £30,000 amounts to £400 per patient.
Finally, scenario 12 assumes that the transition probability from D to ND in the Crohn’s model is 5%
per cycle while all others are 0 and that the utilities for IBS-D and BAM are the same. As can be seen
in Table 61, here no SeHCAT can be considered the most favourable strategy given a threshold of
£30,000. The CEAC presented in Figure 40 shows that for lower threshold values (below £7000) SeHCAT
15% has the highest probability of being optimal, for thresholds between £7000 and £14,000 SeHCAT
10% has the highest probability while for thresholds above £14,000 no SeHCAT has the highest
probability of being optimal.800
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FIGURE 39 Patient EVPI for Crohn’s population, scenario 8.
TABLE 61 Lifetime results for Crohn’s population, scenario 12
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 14.4624 3426
SeHCAT test – 10% cut-off 14.4917 3639 0.0293 213 7282
No SeHCAT test 14.5362 4246 0.0445 606 13,621
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FIGURE 40 Cost-effectiveness acceptability curve for lifetime Crohn’s population, scenario 12.
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90Figure 41 shows the patient EVPI; from this we see that at a threshold of £30,000, the value of perfect
information amounts to £400.
Costs, effects and cost-effectiveness for Crohn’s disease without ileal
resection with trial of treatment included
Short-term results for Crohn’s disease (decision tree) with trial of treatment
Table 62 presents the probabilistic outcomes of the base-case decision tree for the Crohn’s population
when trial of treatment is also considered as comparator. Results are presented in order of increasing
number of responders. From this, it becomes clear that the trial of treatment strategy dominates all other500
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FIGURE 41 Patient EVPI for Crohn’s population, scenario 12.
TABLE 62 Short-term results for Crohn’s population, base case with trial of treatment (scenario D1)
Strategy
Percentage
of responders
Expected
costs
Incremental
responders
Incremental
costs ICER
No SeHCAT test – treat Crohn’s 0.6226 327 Dominated by trial of treatment
SeHCAT test – 15% cut-off 0.7296 573 Dominated by trial of treatment
SeHCAT test – 10% cut-off 0.7343 592 Dominated by trial of treatment
No SeHCAT test – trial of treatment 0.8232 171
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be calculated.
To investigate what the impact is of the various (statistical) uncertainties in the model, we also present the
CEAC (Figure 42). We notice that the trial of treatment strategy has the highest probability of being
considered cost-effective over the whole range of possible threshold ICERs.
As for the IBS-D population, we formulated several scenarios to explore the sensitivity of the model for
various major assumptions we made. The scenarios are listed in Table 63. None of these scenarios led to
any result other than the base case; in all cases trial of treatment was the dominant strategy.1.0
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FIGURE 42 Cost-effectiveness acceptability curve for short-term (cost per responder) results for Crohn’s population,
TABLE 63 Overview of scenarios explored for short-term Crohn’s with trial of treatment
Strategy
SeHCAT
service
cost
Probability
response to BAS
with trial of
treatment
Probability response
to Crohn’s treatment
in SeHCAT-negative
patients
Costs
Crohn’s
treatment
Cost
SeHCAT
capsule
Results
presented?
D1 0 0.46 0.72 195 Yes
D2 55 0.46 0.72 195 No, same as 1
D3 105 0.46 0.72 195 No, same as 1
D4 0 0.46 0.62 195 No, same as 1
D5 0 0.46 0.87 195 No, same as 1
D6 0 0.28 0.72 195 No, same as 1
D7 0 0.28 0.62 195 No, same as 1
D8 0 0.28 0.87 195 No, same as 1
D9 0 0.46 0.72 × 2 195 No, same as 1
D10 0 0.46 0.72 /2 195 No, same as 1
D11 0 0.46 0.62 /2 195 No, same as 1
D12 0 0.28 0.62 /2 195 No, same as 1
D13 0 0.46 0.72 100 No, same as 1
D14 0 0.46 0.62 100 No, same as 1
D15 0 0.46 0.87 100 No, same as 1
D16 0 0.28 0.72 100 No, same as 1
D17 0 0.28 0.62 100 No, same as 1
D18 0 0.28 0.87 100 No, same as 1
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As above (see Lifetime results for Crohn’s), we have again explored a list of 14 scenarios regarding
transition probabilities of the Markov models and the utility of the no diarrhoea health state. Again, we
present only a limited number of these scenarios (Table 64).
Below are the results for scenario 1. Scenario 1 assumes that all four transition probabilities are 5% per
cycle. We observe that both SeHCAT strategies are dominated by trial of treatment, while no SeHCAT can
be considered cost-effective compared with trial of treatment for thresholds above £14,000 (Table 65). The
CEAC confirms this assessment (Figure 43).
Figure 44 shows the patient EVPI; from this we see that at a threshold of £30,000, the value of perfect
information amounts to £300.
Scenario 2 assumes that all four transition probabilities are 0% per cycle. We now observe (Table 66) that
no SeHCAT and SeHCAT 10% are dominated by trial of treatment and the ICER of trial of treatment
compared with SeHCAT 15% falls well below the commonly used £30,000 threshold. When we look at
the CEAC (Figure 45), we notice that for almost the whole range of thresholds trial of treatment has the
highest probability of being cost-effective, up to even 90% for thresholds above £10,000.TABLE 64 Overview of scenarios explored for the long-term analysis with trial of treatment
Scenario
Crohn P
(ND→D)
Crohn P
(D→ND)
BAM P
(ND→D)
BAM P
(D→ND)
Utility BAS no
diarrhoea
Results
presented?
1 0.05 0.05 0.05 0.05 BAS < Crohn Yes
2 0 0 0 0 BAS < Crohn Yes
3 0.05 0 0.05 0 BAS < Crohn No, same as 2
4 0.05 0 0 0 BAS < Crohn No, same as 2
5 0 0.05 0 0 BAS < Crohn Yes
6 0 0 0.05 0 BAS < Crohn No, same as 5
7 0 0 0 0.05 BAS < Crohn No, same as 3
8 0.05 0.05 0.05 0.05 BAS = Crohn No, same as 2
9 0 0 0 0 BAS = Crohn No, same as 2
10 0.05 0 0.05 0 BAS = Crohn No, same as 3
11 0.05 0 0 0 BAS = Crohn No, same as 4
12 0 0.05 0 0 BAS = Crohn No, same as 2
13 0 0 0.05 0 BAS = Crohn No, same as 6
14 0 0 0 0.05 BAS = Crohn Yes
TABLE 65 Lifetime results for Crohn’s population, scenario 1 with trial of treatment
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 14.0847 2710 Dominated by trial of treatment
SeHCAT test – 10% cut-off 14.0994 2828 Dominated by trial of treatment
No SeHCAT test – trial of treatment 14.1227 2545
No SeHCAT test 14.1571 3023 0.0343 477 13,889
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IGURE 43 Cost-effectiveness acceptability curve for lifetime Crohn’s population, scenario 1 with trial of treatment.
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FIGURE 44 Patient EVPI for Crohn’s population, scenario 1 with trial of treatment.
TABLE 66 Lifetime results for Crohn’s population, scenario 2 with trial of treatment
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 14.2517 3196
No SeHCAT test 14.2635 3400 Dominated by trial of treatment
SeHCAT test – 10% cut-off 14.2712 3336 Dominated by trial of treatment
No SeHCAT test – trial of treatment 14.3572 3213 0.1055 17 161
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FIGURE 45 Cost-effectiveness acceptability curve for lifetime Crohn’s population, scenario 2 with trial of treatment.
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94Scenario 5 assumes that the transition probability from D to ND in the Crohn’s model is 5% per cycle
while all others are 0. We observe that SeHCAT 15% compared with no SeHCAT yields an ICER well
below the common threshold of £30,000, while SeHCAT 10% is dominated by SeHCAT 15% (Table 67).
When we look at the CEAC (Figure 46), we observe that for lower threshold values (below approximately
£1000) SeHCAT 15% has the highest probability of being optimal, for thresholds between £1000 and
£13,000 trial of treatment has the highest probability while for thresholds above £13,000 no SeHCAT has
the highest probability of being optimal.
Scenario 14 assumes that the transition probability from D to ND in the BAM model is 5% per cycle while
all others are 0 and that utilities per health state are the same in the Crohn’s model and the BAM model.
In this scenario we observe (Table 68) that no SeHCAT and SeHCAT 10% are dominated by trial of
treatment and the ICER of SeHCAT 15% compared with trial of treatment falls well below the commonly
used £30,000 threshold. When we look at the CEAC (Figure 47), we notice that for thresholds up to
£10,000 trial of treatment has the highest probability of being cost-effective, whereas for higher
thresholds SeHCAT 15% has the highest probability of being cost-effective, up to 50% for thresholds
above £20,000.TABLE 67 Lifetime results for Crohn’s population, scenario 5 with trial of treatment
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
SeHCAT test – 15% cut-off 14.326 3434
SeHCAT test – 10% cut-off 14.3689 3646 Dominated by trial of treatment
No SeHCAT test – trial of treatment 14.4834 3612 0.1574 178 1131
No SeHCAT test 14.5341 4250 0.0506 637 12,581
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ABLE 68 Lifetime results for Crohn’s population, scenario 14 with trial of treatment
Strategy
Expected
QALYs
Expected
costs
Incremental
QALYs
Incremental
costs ICER
No SeHCAT test 14.2627 3379 Dominated by trial of treatment
SeHCAT test – 10% cut-off 14.4892 3490 Dominated by trial of treatment
No SeHCAT test – trial of
treatment
14.4943 3197
SeHCAT test – 15% cut-off 14.5145 3399 0.0201 202 10,020
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IGURE 46 Cost-effectiveness acceptability curve for lifetime Crohn’s population, scenario 5 with trial of treatment.
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FIGURE 47 Cost-effectiveness acceptability curve for lifetime Crohn’s population, scenario 14 with trial of treatment.
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96Summary
In this chapter we assessed the cost-effectiveness of SeHCAT in two different populations. The first is the
population of patients with chronic diarrhoea with unknown cause and symptoms suggestive of IBS-D
and the second population concerns patients with Crohn’s disease without ileal resection with
chronic diarrhoea.
For both populations the cost-effectiveness of SeHCAT compared with no SeHCAT was assessed. For the
SeHCAT option we defined various strategies based on the test cut-off points used to classify patients. For
the IBS-D patient population data were available to be able to distinguish between cut-off points of 5%,
10% and 15%. For the Crohn’s patient population, only data on a 10% and 15% SeHCAT test cut-off
were available. For the no SeHCAT strategy all patients received regular treatment for either IBS-D or
chronic diarrhoea in Crohn’s. Additionally, in the scoping document, trial of treatment with BAS was
mentioned as another possible strategy without specifically including it as a comparator. According to the
clinical experts at the scoping meeting, trial of treatment is rarely used as a treatment strategy and was
thus not considered relevant. However, trial of treatment could also not be completely excluded as an
option. Thus, in this report, for both populations we have presented two sets of results: one where trial of
treatment is not considered as a comparator and one where it is. In the trial of treatment strategy, patients
first receive a BAS and when patients do not respond they receive regular treatment for either IBS-D or
chronic diarrhoea in Crohn’s.
For each population, three models were combined
1. a short-term decision tree that models the diagnostic pathway and initial response to treatment
(first 6 months)
2. a long-term Markov model that estimates the lifetime costs and effects for patients initially
receiving BAS
3. a long-term Markov model that estimates the lifetime costs and effects for patients initially
receiving regular treatment (IBS-D treatment in the first population and Crohn’s treatment in the
second population).
In the decision tree the 6-month number of responders and the expected costs were calculated for each
comparator while for the Markov models lifetime expected QALYs and expected costs per patient were
calculated for each comparator.
Where possible, input for the model was based on our SeHCAT systematic review, other published
literature and UK databases. When such evidence was not available, expert opinion was used. The impact
of uncertainty about the various input parameters on the outcomes was explored through probabilistic
sensitivity analyses and scenario analyses.
ICERs were estimated as additional cost per additional responder in the short term (first 6 months) and per
additional QALY in the long term (lifetime).
When trial of treatment is not considered as a comparator, the evaluation for the IBS-D population showed
for the short term that the optimal choice depends on the willingness to pay for an additional responder.
For lower values (base case £2400, scenarios between £1800 and £4600) the choice will be no SeHCAT in
all scenarios; for higher values either SeHCAT 10% or SeHCAT 15% becomes cost-effective.
For the lifetime perspective, we did not define a base case, as we had no information of any kind to
inform the transition probabilities between the health states diarrhoea and no diarrhoea and vice versa.
Thus, only scenario analysis was performed. The various scenarios showed widely differing results.
Depending on the scenario, in the threshold range of £20,000–30,000 per QALY gained, we found asNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61optimal choice either no SeHCAT, SeHCAT 5% or SeHCAT 15%; only SeHCAT 10% never had the highest
probability of being cost-effective.
When trial of treatment is considered a comparator, the analysis showed for the IBS-D population that for
the short term, trial of treatment is the optimal choice across a range of scenarios. In the base-case
scenario, trial of treatment dominated all other strategies and had a 95% probability of being the most
cost-effective option. In the various scenarios, trial of treatment was dominant compared with all
strategies. For all scenarios trial of treatment had the highest probability of being cost-effective; this
probability was for most scenarios around 90%, decreasing for some scenarios to 50%.
For the lifetime perspective, for all but two scenarios, trial of treatment was the strategy with the highest
probability of being cost-effective for thresholds above £5000 to £15,000, with no SeHCAT the most
favourable strategy for lower threshold ICERs. In the two scenarios where the transition probability from
diarrhoea to no diarrhoea in the BAM model was 5% per cycle while all others were 0, we observed that
for thresholds higher than £15,000 SeHCAT 15% had the highest probability of being cost-effective.
For the Crohn’s population, the short-term evaluation without trial of treatment as comparator showed for
the short term that the optimal choice depends on the willingness to pay for an additional responder.
For lower values (base case £2300, scenarios between £1500 and £4000) the choice will be no SeHCAT in
all scenarios; for higher values SeHCAT 10% becomes cost-effective.
For the long term, the various scenarios show widely differing results. Depending on the scenario, in the
threshold range of £20,000–30,000 per QALY gained, we found as optimal choice either no SeHCAT
or SeHCAT 15% while some scenarios found that all three strategies had the same probability of
being cost-effective.
When trial of treatment is considered a comparator, the analysis showed for the Crohn’s population that
for the short term, trial of treatment dominated all other strategies (in terms of number of responders) and
had an almost 100% probability of being the most cost-effective option. In the various scenarios, trial of
treatment was dominant compared with all strategies. For all scenarios trial of treatment had the highest
probability of being cost-effective; for most scenarios this probability was around 90%.
For the lifetime perspective in Crohn’s with trial of treatment, again the various scenarios show widely
differing results. Depending on the scenario, in the threshold range of £20,000–30,000 per QALY gained,
we found as optimal choice either trial of treatment, no SeHCAT or SeHCAT 15%.
In conclusion, the various analyses have shown that, for both populations, considerable decision
uncertainty exists, and that no firm conclusions can be formulated as to which strategy is optimal.97
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Clinical effectiveness
Three studies were reasonably reliable in assessing the relationship between the SeHCAT test and
treatment with cholestyramine.39,42,43 However, the studies had small numbers of patients with unknown
cause chronic diarrhoea, they used different cut-offs for the assessment of BAM and between-study
heterogeneity was considerable.
Sensitivity ranged from 0.67 (at a cut-off of 8%) to 1.00 (at a cut-off of 15%) and specificity ranged from
0.91 (at a cut-off of 15%) to 1.00 (at a cut-off of 5%) (Table 69).
None of the studies looking specifically at people with Crohn’s disease presented reliable data for the
prediction of response to treatment with BAS because no data were presented for people with a negative
SeHCAT test in the two studies.
One RCT in patients with IBS-D which compared treatment with BAS (colesevelam) with placebo showed
no significant differences in terms of colonic transit [e.g. geometric centre at 48 hours: MD = 0.18 (95% CI
–0.29 to 0.65)] bowel function [e.g. stool frequency per day: MD = –0.11 (95% CI –1.01 to 0.79)] or
adverse events [e.g. uterine cramps: OR = 0.45 (95% CI 0.04 to 5.81)]. However, randomisation (sequence
generation and allocation concealment) was not adequately reported and groups were small (n = 12 in
both arms).
For people with chronic diarrhoea, 19 studies provide data on the clinical effectiveness of BAS given a
positive SeHCAT test; three studies also provide data on the effectiveness of BAS given a negative SeHCAT
test. For those with a positive SeHCAT test response rates were on average 85%, 73% and 72% for
cut-offs at 5%, 10% and 15%, respectively. For those with a negative SeHCAT test the response rate was
14% at a cut-off of 5% and 0% at a cut-off of 15%. For people with Crohn’s disease and a positive
SeHCAT test the response rate was 95% at a cut-off of 5% and 86% or 89% at a cut-off of 15%.
Several studies reported data on the accuracy of SeHCAT for the detection of BAM in people with chronic
diarrhoea (Table 70). However, all of these studies are flawed because they either do not use an
acceptable reference standard or include a population not in line with the scope (healthy volunteers or
people with ileal resection). Therefore, these data are not used in this review.
Cost-effectiveness
In Chapter 4 we assessed the cost-effectiveness of SeHCAT in two different populations. The first is
the population of patients with chronic diarrhoea with unknown cause and symptoms suggestive of
IBS-D and the second population concerns patients with Crohn’s disease without ileal resection with
chronic diarrhoea.
For both populations the cost-effectiveness of SeHCAT compared with no SeHCAT was assessed. For the
SeHCAT option we defined various strategies based on the test cut-off points used to classify patients. For
the IBS-D patient population data were available to be able to distinguish between cut-off points of 5%,
10% and 15%. For the Crohn’s patient population, only data on a 10% and 15% SeHCAT test cut-off
were available. For the no SeHCAT strategy all patients received regular treatment for either IBS-D or
chronic diarrhoea in Crohn’s. Additionally, in the scoping document, trial of treatment with BAS was
mentioned as another possible strategy without specifically including it as a comparator. According to the
clinical experts at the scoping meeting, trial of treatment is rarely used as a treatment strategy and was99
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TABLE 69 Accuracy of SeHCAT in predicting a response to BAS
Study Cut-off Sensitivity (95% CI) Specificity (95% CI)
Merrick 198539 (n = 40) 8% 0.667 (0.223 to 0.957) 0.971 (0.847 to 0.999)
15% 1.000 (0.541 to 1.000) 0.912 (0.763 to 0.981)
Sciaretta 198642 (n = 13) 5% 0.857 (0.421 to 0.996) 1.000 (0.541 to 1.000)
Sciaretta 198743 (n = 46a) 8% 0.950 (0.751 to 0.999) 0.962 (0.804 to 0.999)
a Including eight patients with cholecystectomy.
TABLE 70 ‘Diagnostic accuracy’ of SeHCAT for the detection of BAM
Study Sensitivity Specificity References
Balzer 199381 80% 98% Study itself
Balzer 199582 60–85% 84–100% Kruis 1987,28 Balzer 1988,83
Singe 1987,27 Merrick 198539
Brydon 199684 100% 96% Study itself
Ferraris 199285 72% 96% Study itself
Johnston 201152 100% 94% Sciaretta 198642
Kurien 201186 80–90% ∼100% Merrick 1985,39 Sciaretta 198642
Merrick 198539 97% 80–99% Study itself
Pattni 200913 80–90% 70–100% Not reported
Sciaretta 198642 100% 94% Study itself
Wedlake 20096 89% 100% Sciaretta 198642
DISCUSSION
100thus not considered relevant. However, trial of treatment could also not be completely excluded as an
option. Thus, in this report, for both populations we presented two sets of results: one where trial of
treatment is not considered as a comparator and one where it is. In the trial of treatment strategy, patients
first receive a BAS and when patients do not respond they receive regular treatment for either IBS-D or
chronic diarrhoea in Crohn’s.
For each population, three models were combined:
1. a short-term decision tree that models the diagnostic pathway and initial response to treatment
(first 6 months)
2. a long-term Markov model that estimates the life time costs and effects for patients initially
receiving BAS
3. a long-term Markov model that estimates the life time costs and effects for patients initially receiving
regular treatment (IBS-D treatment in the first population and Crohn’s treatment in the
second population).
In the decision tree the 6-month number of responders and the expected costs were calculated for each
comparator while for the Markov models lifetime expected QALYs and expected costs per patient were
calculated for each comparator.
Where possible, input for the model was based on our SeHCAT systematic review, other published
literature and UK databases. When such evidence was not available, expert opinion was used.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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probabilistic sensitivity analyses and scenario analyses.
Incremental cost-effectiveness ratios were estimated as additional cost per additional responder in the
short term (first 6 months) and per additional QALY in the long term (lifetime).
When trial of treatment is not considered as a comparator, the evaluation for the IBS-D population
showed, for the short term, that the optimal choice depends on the willingness to pay for an additional
responder. For lower values (base case £2400, scenarios between £1800 and £4600) the choice will be no
SeHCAT in all scenarios; for higher values either SeHCAT 10% or SeHCAT 15% becomes cost-effective.
For the lifetime perspective, we did not define a base case, as we had no information of any kind to
inform the transition probabilities between the health states diarrhoea and no diarrhoea and vice versa.
Thus, only scenario analysis was performed. The various scenarios showed widely differing results.
Depending on the scenario, in the threshold range of £20,000–30,000 per QALY gained, we found as
optimal choice either no SeHCAT, SeHCAT 5% or SeHCAT 15%; only SeHCAT 10% never had the highest
probability of being cost-effective.
When trial of treatment is considered a comparator, the analysis showed for the IBS-D population that for
the short term, trial of treatment is the optimal choice across a range of scenarios. In the base-case
scenario, trial of treatment dominated all other strategies and had a 95% probability of being the most
cost-effective option. In the various scenarios, trial of treatment was dominant compared with all
strategies. For all scenarios trial of treatment had the highest probability of being cost-effective; this
probability was for most scenarios around 90%, decreasing for some scenarios to 50%.
For the lifetime perspective, for all but two scenarios, trial of treatment was the strategy with the highest
probability of being cost-effective for thresholds above £5000 to £15,000, with no SeHCAT the most
favourable strategy for lower threshold ICERs. In the two scenarios where the transition probability from
diarrhoea to no diarrhoea in the BAM model was 5% per cycle while all others were 0, we observed that
for thresholds higher than £15,000 SeHCAT 15% had the highest probability of being cost-effective.
For the Crohn’s population, the short-term evaluation without trial of treatment as comparator showed for
the short term that the optimal choice depends on the willingness to pay for an additional responder. For
lower values (base case £2300, scenarios between £1500 and £4000) the choice will be no SeHCAT in all
scenarios, for higher values SeHCAT 10% becomes cost-effective.
For the long term, the various scenarios show widely differing results. Depending on the scenario, in the
threshold range of £20,000–30,000 per QALY gained, we found as optimal choice either no SeHCAT
or SeHCAT 15% while some scenarios found that all three strategies had the same probability of
being cost-effective.
When trial of treatment is considered a comparator, the analysis showed for the Crohn’s population that
for the short term, trial of treatment dominated all other strategies (in terms of number of responders) and
had an almost 100% probability of being the most cost-effective option. In the various scenarios, trial of
treatment was dominant compared with all strategies. For all scenarios trial of treatment had the highest
probability of being cost-effective; for most scenarios this probability was around 90%.
For the lifetime perspective in Crohn’s with trial of treatment, again the various scenarios show widely
differing results. Depending on the scenario, in the threshold range of £20,000–30,000 per QALY gained,
we found as optimal choice either trial of treatment, no SeHCAT or SeHCAT 15%.
In conclusion, the various analyses have shown that for both populations considerable decision uncertainty
exists, and that no firm conclusions can be formulated as to which strategy is optimal.101
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102Strengths and limitations of assessment
Clinical effectiveness
A main strength for this assessment is the fact that the SeHCAT test has been long established; it has been
used for over 25 years in clinical practice. The adverse events profile of the test seems favourable.
Unfortunately, there are no published data to support this statement.
Extensive literature searches were conducted in an attempt to maximise retrieval of relevant studies. These
included electronic searches of a variety of bibliographic databases, as well as screening of clinical trials
registers and conference abstracts to identify unpublished studies. Because of the known difficulties in
identifying test accuracy studies using study design-related search terms,87 no study design filters were
used in order to maximise sensitivity at the expense of reduced specificity. Thus, large numbers of citations
were identified and screened, many of which did not meet the inclusion criteria of the review.
The possibility of publication bias remains a potential problem for all systematic reviews. Considerations
may differ for systematic reviews of test accuracy studies. It is relatively simple to define a positive result for
studies of treatment, e.g. a significant difference between the treatment and control groups that favours
treatment. This is not the case for test accuracy studies, which measure agreement between index test and
reference standard. It would seem likely that studies finding greater agreement (high estimates of
sensitivity and specificity) will be published more often. In addition, test accuracy data are often collected
as part of routine clinical practice, or by retrospective review of records; test accuracy studies are not
subject to the formal registration procedures applied to RCTs and are therefore more easily discarded
when results appear unfavourable. The extent to which publication bias occurs in studies of test accuracy
remains unclear; however, simulation studies have indicated that the effect of publication bias on meta-
analytic estimates of test accuracy is minimal.88 Formal assessment of publication bias in systematic reviews
of test accuracy studies remains problematic and reliability is limited.88 We did not undertake a statistical
assessment of publication bias in this review. However, our search strategy included a variety of routes to
identify unpublished studies and resulted in the inclusion of a number of conference abstracts.
Clear inclusion criteria were specified in the protocol for this review and the one protocol modification that
occurred during the assessment has been documented in the methods section (see Chapter 3, Assessment
of clinical effectiveness, Methods) of this report. The eligibility of studies for inclusion is therefore
transparent. In addition, we have provided specific reasons for excluding all of the studies considered
potentially relevant at initial citation screening (see Appendix 5). The review process followed
recommended methods to minimise the potential for error and/or bias;14 studies were independently
screened for inclusion by two reviewers and data extraction and quality assessment were done by one
reviewer and checked by a second (RR and SD). Any disagreements were resolved by consensus. The only
French-language study was extracted by one reviewer and checked by a second (Shona Lang and RR).
Three studies included in the review were test accuracy studies. The methodological quality of these
studies was assessed using a modification of the QUADAS-2 tool.25 The QUADAS tool has been
recommended for assessing the methodological quality of test accuracy studies,14,17 and has been widely
adopted by researchers and key organisations such as the Cochrane Collaboration, NICE in the UK, and
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) in Germany. It has been
mentioned in more than 200 abstracts on the DARE database and has been cited more than 500 times.
The revised version of QUADAS (QUADAS-2) has recently been published.25 QUADAS-2 more closely
resembles the approach and structure of the Cochrane risk of bias tool. It is structured into four key
domains covering participant selection, index test, reference standard, and the flow of patients through
the study (including timing of tests). Each domain is rated for risk of bias (low, high or unclear) and the
tool provides signalling questions, in each domain, to help reviewers in reaching a judgement. The
participant selection, index test and reference standard domain are also, separately, rated for concerns
regarding the applicability of the study to the review question (low, high or unclear). However, the
QUADAS-2 tool does not currently include domains specific to the assessment of studies comparingNIHR Journals Library www.journalslibrary.nihr.ac.uk
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modified version of the QUADAS-2 tool, which includes an additional domain for the comparator test and
additional signalling questions in the ‘flow and timing’ domain. It should be noted, however, that these
components of the tool were not developed using the same rigorous evidence-based approach as the core
QUADAS-2 tool. The inclusion criteria for this review were considered to largely match the review question
and questions of applicability were, therefore, only relevant to the ‘patient selection’ domain. The review-
specific guidance used in our QUADAS-2 assessment is reported in Appendix 2. The results of the risk of
bias assessment are reported, in full, for all included studies (see Appendix 3) and in summary in the
results section (see Chapter 3, Assessment of clinical effectiveness, Results). However, the usefulness of
this assessment was limited by poor reporting of primary study methods, particularly with respect to how
the index and comparator tests and the reference standard were applied.
The main limitations for this assessment are the lack of data, differences between studies included in the
review, and the generally poor quality of included papers. As reported in Chapter 3 (see Assessment of
clinical effectiveness, Results), most studies did not report information on the probability of a response to
treatment with BAS for people with a negative SeHCAT test. Therefore, information on the accuracy of the
SeHCAT test to predict a treatment response is largely missing. In addition, there were considerable
differences between studies; the principal diagnosis, treatment dose, the definition of response, follow-up
period and SeHCAT administration were different between trials (see Appendix 4 for details).
Three studies were included for the assessment of the accuracy of a SeHCAT test to predict a response to
treatment. All three studies were published between 1985 and 1987; two were Italian studies and one
was a UK study. It is unclear whether or not there was any overlap in study populations included in the
two Italian studies, which were performed by the same group.Cost-effectiveness
Searching the literature, no economic evaluation studies were found regarding the use of SeHCAT-testing
in chronic diarrhoea patients. This report therefore presents, as far as we are aware, the first full economic
evaluation study, both in (a) patients presenting with chronic diarrhoea with unknown cause and
symptoms suggestive of functional disease (IBS-D) and (b) people with Crohn’s disease and chronic
diarrhoea with unknown cause (i.e. without resection of the terminal ileum) assessing the short- and
long-term consequences both in costs and effects of using SeHCAT. For this purpose, for each of these
patient populations, a linked evidence approach was used in modelling cost and consequences, combining
outcomes of the diagnostic test and the related changes in treatment decisions and final health outcomes.
A clear distinction was made between the initial diagnostic phase (treatment responder vs. non-responder
at 6 months) and the long-term projection of this intermediate outcome of the diagnostic phase into final
health outcomes (lifetime costs and consequences, the latter presented in QALYs).
The available evidence regarding the cut-off values defining a positive and negative SeHCAT test shows
that various cut-off values are used, which influences test-accuracy estimates expressed in BAS treatment
response. In our approach we assessed the impact of different cut-off values explicitly by making a
distinction between SeHCAT test strategies based on three levels: 5%; 10% and 15%. Furthermore,
current clinical practice shows that no-SeHCAT testing implies different clinical approaches. Two major
approaches were explicitly modelled: first, IBS-D treatment in all patients involved, and secondly, the trial
of treatment approach, in which all patients initially receive BAS and within the first period of 6 months
(the time horizon of the diagnostic decision tree) non-responders will switch from BAS to IBS-D treatment.
Our methods made it possible to analyse and present the cost-effectiveness of all competing five
strategies simultaneously.
We included the impact of using SeHCAT in terms of BAS-treatment response as reported in peer
reviewed papers and selected for this purpose only those papers that fulfilled our quality criteria as
presented in Chapter 3. In all models presented (both the decision trees that represented the diagnostic
phase and the Markov models represented the subsequent life-years of patients) we have used evidence to103
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104inform parameters that was UK relevant and as up to date and high quality as possible. Where evidence
was not available through published studies or databases, we used the most likely and plausible values
and ranges as reported by clinical experts. However, given the time constraints, no formal expert
solicitation process could be conducted and instead a questionnaire was sent out. The seven experts who
filled out the questionnaire showed a wide variation in their responses, highlighting the uncertainty about
important input parameters.
The remaining lack of evidence of certain parameters was handled by performing extensive uncertainty
analyses, both using probabilistic sensitivity analyses and running a wide range of scenario analyses. For
the latter, because the plausibility of one of the scenarios was not larger over any other, we did not judge
about the likelihood of any of them. Additionally, given the discussion on the acceptability of trial of
treatment with BAS as a comparator, we also ran all analyses once with trial of treatment as comparator
and once without.
One of the main limitations of the study is that the studies used to estimate the probability of a positive
SeHCAT test and the probability of a BAS response were based on other populations than the ones
defined in this evaluation. Most, if not all, IBS-D studies included patients in whom various tests had been
performed and where no organic cause of the diarrhoea could be found. This is in contrast with the
population defined here, which is patients with symptoms suggestive of functional disease in whom only
basic blood tests have been performed. It is not unlikely that in our population the prevalence of BAM is
lower than that observed in the published studies.
For the Crohn’s population, we combined the estimates from Tunney et al.32 and Smith et al.3 The Tunney
paper does not provide much detail on the population of surgically naïve Crohn’s patients, so it is unclear
whether or not this group would be representative of the population under investigation here. The study
by Smith was specifically in patients who were in clinical remission, thus excluding patients having a
relapse. It is unclear how this would impact the results.
Another limitation concerns the modelling of the IBS-D population. It is assumed in the model that patients
not responding to IBS-D treatment will only use loperamide for some symptomatic relief. It is, however,
not unlikely that in our IBS-D population (i.e. patients in whom no diagnostic testing other than initial
blood work has been performed) some non-responders will be referred for diagnostic testing to check for
organic causes of the chronic diarrhoea. However, the discussion among the experts during the scoping
meeting suggested that SeHCAT testing would not make subsequent tests for organic disease redundant
in which case these costs would be the same in all strategies.
We also did not incorporate patients switching from treatment with cholestyramine to colesevelam
because of non-response or intolerability, as no data on response rates for colesevelam were available.
Including that option would most likely lead to a higher response rate, a smaller percentage of patients
moving from the ‘no diarrhoea’ health state to the ‘diarrhoea’ health state over time (due to increased
persistence) and to higher treatment costs since colesevelam is more expensive than cholestyramine.
However, the most important limitation is the lack of data on various important parameters, and thus the
necessity to rely on expert opinion for the short term and to rely on scenario analysis for the long term.Uncertainties
Clinical effectiveness
The main uncertainties regarding clinical effectiveness are both the accuracy of the SeHCAT test in
predicting either BAM or response to treatment and the effectiveness of BAS for the treatment of chronic
diarrhoea caused by BAM.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61For the assessment of the accuracy of the SeHCAT test in predicting BAM there was no evidence, mainly
because there is not an appropriate reference standard for this assessment. For the assessment of the
accuracy of the SeHCAT test in predicting a response to treatment, we found three studies. However, the
studies had small numbers of patients with unknown cause chronic diarrhoea, they used different cut-offs
for the assessment of BAM and between-study heterogeneity was considerable. One study was included
for the assessment of the clinical effectiveness of BAS for the treatment of chronic diarrhoea caused by
BAM. This study looked at colesevelam versus placebo and included 24 patients: 12 in each arm. All other
included studies used cholestyramine.
We found no data on the accuracy of the SeHCAT test in predicting either BAM or response to treatment,
or the clinical effectiveness of BAS for the treatment of chronic diarrhoea caused by BAM in patients with
Crohn’s disease.Cost-effectiveness
The main uncertainties in the cost-effectiveness analyses are caused by lack of essential data. Several
assumptions had to be made to make it possible to perform the cost-effectiveness analyses.
The lack of evidence of the accuracy of SeHCAT based on a reference test meant that in the diagnostic
decision trees the conventional way of modelling test accuracy using sensitivity and specificity of testing
was not feasible. Therefore, it remained impossible to indicate FP and FN probabilities of testing. The
accuracy of SeHCAT testing was necessarily based on test result in combination with response to BAS
treatment. Logically, this response after testing is an unknown function of actual test accuracy and BAS
efficacy. In other words, patients responding to BAS may be TP patients with a true response but may also
be FP patients with a placebo response.
The limited number of papers was heterogeneous regarding cut-off value of SeHCAT test results. Given
the variety of cut-off values between 8% and 12% and the small number of studies, these studies were
considered one group. Of course it is not possible to make a distinction between these grouped cut-off
values. The 5% and 15% cut-off values based date are more homogenous in this respect.
The parameter value for BAS treatment response given a positive SeHCAT test was derived from the
literature. However, for the SeHCAT-negative patients the model assumed IBS-D treatment and for this
specific response parameter only a subjective assumption could be made with what was only indirectly
related expert opinion: the expert opinion on IBS-D treatment response without testing (52%) was
increased by 10 percentage points for this purpose. This was motivated by the idea that a positive SeHCAT
test would have selected potential IBS-D non-responders to be treated by BAS.
Important uncertainties exist about the trial of treatment strategy. No data were available to inform the
response rate to BAS, and so we made assumptions based on the total number of BAS responders in the
SeHCAT 15% strategy. One question is to what extent it is reasonable to choose this strategy rather than
SeHCAT 10% to base the response rate on, as resorption values between 10% and 15% are often seen
as subnormal. However, we found in our model that the combination of first a positive SeHCAT test and
then a positive response to BAS occurs almost as often in the SeHCAT 10% strategy as in the SeHCAT
15% strategy. Thus, this choice does not influence the results. Other issues regarding the trial of treatment
strategy relate to the placebo response that may be expected in the true IBS-D patients receiving BAS. It is
a well-known fact that patients with IBS-D tend to show high placebo responses to treatment.68 One of
the clinical experts pointed out that long-term inappropriate treatment with BAS may have implications for
instance absorption of other drugs and vitamins. Ideally, such long-term consequences would need to be
included when modelling the trial of treatment strategy. Additionally, long-term transitions between
‘diarrhoea’ and ‘no diarrhoea’ may not be the same for BAS patients having a positive SeHCAT result and
patients responding to a trial of treatment, as patients without a positive diagnosis may be less inclined to
accept the side effects of BAS.105
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106In the long-term Markov model, the state of having diarrhoea was valued by cost and utilities irrespective
of the cause of the symptom, being either BAM or IBS-D. It remains to be seen whether or not this is fact.
For the increase in utility when patients become responders (i.e. are in the ‘no diarrhoea’ health state) we
made two assumptions; one where this increase is the same for BAM and IBS-D patients and one where
the increase in BAM patients is only 75% of the increase seen for IBS-D patients. This latter scenario
reflects the idea that BAS is usually not well tolerated by patients with side effects leading to a smaller
utility gain. To what extent this assumption of 75% is realistic is unknown.
The lifetime transition probabilities between the Markov states diarrhoea and non-diarrhoea could not be
based on reliable evidence. For this reason, several equally plausible scenarios were used. Furthermore, it
turned out to be impossible to include a health state constipation in the long-term Markov model because
data on this issue were lacking and the impact on the results was estimated to be negligible.
In the protocol of the study, it was suggested that in patients who tested positive for BAM despite in fact
not having BAM (FPs) an important question would be whether or not (some of) these patients will be
detected at some point as having IBS-D. Likewise, patients who tested negative for BAM despite in fact
having BAM (FNs) are assumed to receive treatment for IBS-D. Again, an important question is whether or
not (some of) these patients will be detected at some point as having BAM. Experts indicated that in the
latter situation, patients most likely would not be diagnosed as BAM with some delay. For the first
situation the lack of essential data made it impossible to incorporate the impact of a possible delay in
efficacious treatment in the cost-effectiveness analyses.
As stated, for the Crohn’s disease population no evidence regarding essential parameters could be found
to be used in the model calculations. This raises the question if modelling should have even been
attempted. However, as the NICE diagnostic assessments may also be used to formulate which, if any,
additional research is required, it was felt useful to make all the uncertainties for the Crohn’s population
explicit. Thus, for various parameters the assumption was made that the data defined for the population of
patients presenting with chronic diarrhoea with unknown cause and symptoms suggestive of functional
disease were considered to be generalisable to the Crohn’s population. Expert inputs did not state to
do otherwise.
The cost-effectiveness analyses are based on adult patient data only. Whether or not the findings hold for
children and adolescents is unknown.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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or response to treatment, and the clinical effectiveness of BAS for the treatment of chronic diarrhoea
caused by BAM, are uncertain. Additionally, the results of our economic evaluation showed that for both
populations studied, the lifetime perspective gave different results for different scenarios meaning that all
strategies may potentially be the most cost-effective. Therefore, the implications for service provision of
SeHCAT are equally uncertain. The main reason for this uncertainty is the lack of good-quality evidence.Suggested research prioritiesStandardisation of the definition of a positive SeHCAT test should be the first step in assessing the
usefulness of this test. As there is no reference standard for the diagnosis of BAM and SeHCAT testing
provides a continuous measure of metabolic function, DTA studies are not the most appropriate study
design. However, in studies where all patients are tested with SeHCAT and all patients are treated with
BAS (see Chapter 4, Results, Accuracy of selenium-75-homocholic acid taurine for the assessment of
responses to treatment in people with chronic diarrhoea), response to treatment can provide a surrogate
reference standard; further DTA studies of this type may provide information on the ability of SeHCAT to
predict response to BAS. A potentially more informative option would be multivariate regression modelling
of treatment response (dependent variable), with SeHCAT result and other candidate clinical predictors as
covariates. Such a study design could also inform the definition of a positive SeHCAT result.
The limited evidence identified means that the effectiveness of BAS, both in unselected patients with
chronic diarrhoea and where treatment decisions are based on SeHCAT test results, remains uncertain.
Two possible randomised controlled designs are, therefore, potentially useful:
1. Patients with chronic diarrhoea receive SeHCAT testing and all patients are then randomised to
treatment with BAS or placebo. This study design can provide information on the effectiveness of BAS
in all patients with relevant symptoms. If the analysis is then stratified by test result, information can be
obtained on any difference in effectiveness between SeHCAT positive and SeHCAT-negative patients, or
variation in the effectiveness of BAS with levels of SeHCAT absorption.
2. Patients with chronic diarrhoea receive SeHCAT testing and only patients with a positive SeHCAT test
are randomised to treatment with BAS or placebo. This study design can provide information on the
effectiveness of BAS in SeHCAT-positive patients. This design might be considered more ethical if it is
believed that current evidence is sufficient to indicate no, or minimal, effectiveness of BAS in SeHCAT-
negative patients.
The inclusion criteria for such a trial are important to make sure that patients are not unnecessarily
subjected to BAS treatment and, at the same time, that all patients suitable for a SeHCAT test are
included. Treatment strategies should be clearly described in the study protocol. Long-term follow-up is
needed to fully assess the effectiveness of BAS in all relevant patient groups. Outcomes should include all
relevant bowel function and transit outcomes, as well as quality of life and adverse events of testing and
treatment. Additionally, such a trial would enable the collection of resource use data related to the chronic
diarrhoea problems.107
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CONCLUSIONS
108Moreover, the large variation in outcomes between the scenarios considered for the Markov models make
it clear that long-term data is important for patients with IBS-D, patients identified as having BAM and
Crohn’s patients with chronic diarrhoea. These data do not necessarily need to come from a RCT; it might
be possible to set up a retrospective study using existing databases, patient records, etc. to find relevant
long-term data. If those sources of information do not provide enough information, prospective
observational studies could collect data on treatment and treatment switches and resource use.
It was also shown in the various scenarios that the assumption about utility values for BAM health states
have an important impact on the results. For reliable utility estimates for the various health states, a
cross-sectional study in the relevant patient populations would be a relatively easy way to inform these
important parameters.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Search 1: scoping search
(SeHCAT or Stool B Assay) + bile acid malabsorption
Scoping search to identify background literature on this topic prior to NICE scoping meeting.EMBASE (OvidSP): 1980 to week 40 2011
Searched 11 October 2011.
1. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).mp. (150)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75).mp. (711)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid).mp. (18)
4. (selenium adj3 "75").mp. (480)
5. or/1-4 (1095)
6. ((Stool$ or f?ecal or f?eces) adj3 (bile salt$ or bile acid$ or BA) adj3 (assay$ or measure$ or test$ or
analy$ or check$ or assess$)).mp. (111)
7. ((stool$ or f?ecal or f?eces) adj3 (mass spectro$ or mass spectrum analy$ or gas chromatog$ or flame
ioni?ation or mass fragmentography or GC or Gas-Liquid chromatography or GLC)).mp. (952)
8. or/6-7 (1047)
9. 5 or 8 (2139)
10. (BAM or I-BAM or IBAM or PBAM).mp. (1937)
11. primary bile acid diarrh?ea$.mp. (4)
12. chronic diarrhea/ (2468)
13. ((chronic or watery or recur$ or persist$ or protracted) adj2 diarrh?e$).mp. (11,457)
14. malabsorption.mp. (15,720)
15. ((bile or biliary) adj3 (acid$ or salt$)).mp. (31,082)
16. bile acid/ (17,139)
17. or/10-16 (58,203)
18. 9 and 17 (439)
19. limit 18 to embase (326)MEDLINE (OvidSP): 1948 to week 4 September 2011
Searched 11 October 2011.
1. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).ti,ab,ot,hw. (2)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75).ti,ab,ot,hw. (220)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid).ti,ab,ot,hw. (314)
4. (selenium adj3 "75").ti,ab,ot,hw. (143)
5. or/1-4 (582)
6. ((Stool$ or f?ecal or f?eces) adj3 (bile salt$ or bile acid$ or BA) adj3 (assay$ or measure$ or test$ or
analy$ or check$ or assess$)).ti,ab,ot,hw. (100)
7. ((stool$ or f?ecal or f?eces) adj3 (mass spectro$ or mass spectrum analy$ or gas chromatog$ or flame
ioni?ation or mass fragmentography or GC or Gas-Liquid chromatography or GLC)).ti,ab,ot,hw. (128)
8. or/6-7 (223)117
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1189. 5 or 8 (803)
10. (BAM or I-BAM or IBAM or PBAM).mp. (1664)
11. primary bile acid diarrh?ea$.mp. (3)
12. diarrhea/ (35,419)
13. ((chronic or watery or recur$ or persist$ or protracted) adj2 diarrh?e$).mp. (6619)
14. "Bile Acids and Salts"/ (18,279)
15. malabsorption.mp. (13,123)
16. ((bile or biliary) adj3 (acid$ or salt$)).mp. (28,188)
17. or/10-16 (79,009)
18. 9 and 17 (256)MEDLINE In-Process & Other Non-Indexed Citations (OvidSP):
up to 10 October 2011
MEDLINE Daily Update (OvidSP): up to 10 October 2011
Searched 11 October 2011.
1. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).ti,ab,ot,hw. (1)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75).ti,ab,ot,hw. (7)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid).ti,ab,ot,hw. (1)
4. (selenium adj3 "75").ti,ab,ot,hw. (3)
5. or/1-4 (9)
6. ((Stool$ or f?ecal or f?eces) adj3 (bile salt$ or bile acid$ or BA) adj3 (assay$ or measure$ or test$ or
analy$ or check$ or assess$)).ti,ab,ot,hw. (2)
7. ((stool$ or f?ecal or f?eces) adj3 (mass spectro$ or mass spectrum analy$ or gas chromatog$ or flame
ioni?ation or mass fragmentography or GC or Gas-Liquid chromatography or GLC)).ti,ab,ot,hw. (6)
8. or/6-7 (8)
9. 5 or 8 (17)
10. (BAM or I-BAM or IBAM or PBAM).mp. (209)
11. primary bile acid diarrh?ea$.mp. (1)
12. diarrhea/ (32)
13. ((chronic or watery or recur$ or persist$ or protracted) adj2 diarrh?e$).mp. (206)
14. "Bile Acids and Salts"/ (9)
15. malabsorption.mp. (197)
16. ((bile or biliary) adj3 (acid$ or salt$)).mp. (568)
17. or/10-16 (1181)
18. 9 and 17 (7)Cochrane Central Register of Controlled Trials (CENTRAL)
(Wiley Online Library): Issue 4: 2011
Searched 12 October 2011.
#1 tauroselcholic or selenohomocholyltaurine or 75018-71-2 3
#2 SeHCAT or Se-HCAT or 75SeHCAT or Se-75 7
#3 23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or selenium
radioisotopes or tauroselenocholic acid 6
#4 selenium near "75" 13
#5 (#1 OR #2 OR #3 OR #4) 26NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61#6 (Stool* or faecal or fecal or feces or faeces) near (bile salt* or bile acid* or BA) near (assay* or
measure* or test* or analy* or check* or assess*) 43
#7 (Stool* or faecal or fecal or feces or faeces) near (mass spectro* or mass spectrum analy* or gas
chromatog* or flame ionization or flame ionisation or mass fragmentography or GC or Gas-Liquid
chromatography or GLC) 27
#8 (#6 OR #7) 67
#9 (#5 OR #8) 93
#10 BAM or I-BAM or IBAM or PBAM 43
#11 primary near bile acid near (diarrhoe* or diarrhe*) 1
#12 (chronic or watery or recur* or persist* or protracted) near (diarrhoe* or diarrhe*) 548
#13 malabsorption 463
#14 (bile or biliary) near (acid* or salt*) 1242
#15 Medical subject heading (MeSH) descriptor Bile Acids and Salts explode all trees 806
#16 MeSH descriptor Diarrhea, this term only 1856
#17 (#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16) 4048
#18 (#9 AND #17) 56
The CENTRAL search retrieved 53 records.Search 2.5: clinical effectiveness searches(SeHCAT or bile acid sequestrant/aluminium hydroxide) + bile
acid malabsorption
The searches detailed below are the final iteration of a series of strategies and supersede strategies 2 to
2.4 illustrated in Figure 3 (see Chapter 3). The earlier iterations of these strategies are not included below;
for further information please contact the authors. All results were collated and deduplicated in the
Clinical Effectiveness EndNote Library. Original searches undertaken between 9 and 11 January 2012
retrieved 4763 records. Update searches undertaken between 17 and 20 April 2012 found an additional
78 records (after deduplication), but no new includes.
EMBASE search: Facet 1 combined terms for SeHCAT (lines #1–5) and Bile Acid Sequestrants (lines #6–12)
using OR in line #13 (n = 33005). Facet 2 for Bile Acid Malabsorption (lines #14–20) was then combined
with facet 1 using AND in line #21 (n = 3190). Line #21 was limited to remove animal studies. The final set
was then limited to EMBASE records only in line #33 (n = 2359). For the full strategy please see below.EMBASE (OvidSP): 1980 to week 15 2012
Searched 18 April 2012.
1. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).mp. (155)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75).mp. (781)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid or 75Se-homotaurocholate).mp. (22)
4. (selenium adj3 "75").mp. (494)
5. or/1-4 (1172)
6. bile acid sequestrant/ (671)
7. ((bile adj3 (acid or salt) adj3 sequestra$) or BAS).ti,ab,ot,hw,rn. (14,757)
8. Colestipol/ or (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-epichlorohydrin-
copolymer or diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or epichlorohydrin-
copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a or u-26597-a or
u-26597a or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6).ti,ab,ot,hw,rn. (2514)119
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1209. Colestyramine/ or (colestyramine or chol-less or choles or cholesthexal or cholestyramin or
cholestyramine or cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or
colestyramin or cuemid or lipocol-merz or lismol or locholest or prevalite or quantalan or questran or
resincoles-tiramina or resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6 or
58391-37-0).ti,ab,ot,hw,rn. (9165)
10. Colesevelam/ or (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or
gt-31-104hb or gt31-104 or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or
182815-44-7).ti,ab,ot,hw,rn. (744)
11. aluminum hydroxide/ or (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or
algeldraat or algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu
cap or alu-cap or alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina
trihydrate or aluminium hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum
hydrate or aluminum hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or
amphogel or amphojel or amphotabs or antiphos or bayerite or chefarox or collumina or collumol
or colodral or colugel or creamalin or cremorin or diplogel or f 1000 or f1000 or fluagel or gastracol
or gastrosetarderm or gelumina or hoemigel or hycolal or hydracoll or hydrated alumina or hydrolum
or hydronal or hydroxal or lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p or vanogel
or 21645-51-2 or brasivil or rocgel or alugel or hydrated alumina or basalgel or dialume or nephrox).ti,
ab,ot,hw,rn. (7652)
12. or/6-11 (31,903)
13. 5 or 12 (33,005)
14. (BAM or I-BAM or IBAM or PBAM or BSM).mp. (2760)
15. primary bile acid diarrh?ea$.mp. (5)
16. chronic diarrhea/ or bile acid/ or bile salt/ (23,708)
17. ((chronic or watery or recur$ or persist$ or protract$ or continual$ or continuous$ or sustain$ or
constant$ or relentless$ or unrelent$ or functional or aggressive) adj2 (diarrh?e$ or diarrea$)).mp.
(15,363)
18. (malabsorb$ or mal-absorb$ or malabsorp$ or mal-absorp$).mp. (17,122)
19. ((bile or biliary) adj3 (acid$ or salt$)).mp. (32,898)
20. or/14-19 (65,965)
21. 13 and 20 (3190)
22. animal/ (1,767,504)
23. animal experiment/ (1,500,644)
24. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep
or ovine or monkey or monkeys).mp. (505,4056)
25. or/22-24 (5,054,056)
26. exp human/ (13,75,388)
27. human experiment/ (299,549)
28. or/26-27 (13,376,780)
29. 25 not (25 and 28) (4,017,276)
30. 21 not 29 (2684)
31. limit 30 to embase (2359)MEDLINE (OvidSP): 1946 to week 1 April 2012
Searched 18 April 2012.
1. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).ti,ab,ot,hw,rn. (3)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75).ti,ab,ot,hw,rn. (277)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid or 75Se-homotaurocholate).ti,ab,ot,hw,rn. (321)
4. (selenium adj3 "75").ti,ab,ot,hw. (145)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 615. or/1-4 (641)
6. ((bile adj3 (acid or salt) adj3 sequestra$) or BAS).ti,ab,ot,hw,rn. (2637)
7. Colestipol/ or (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-
epichlorohydrin-copolymer or diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or
epichlorohydrin-copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a or
u-26597-a or u-26597a or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6).
ti,ab,ot,hw,rn. (504)
8. Cholestyramine Resin/ or (colestyramine$ or chol-less or choles or cholesthexal or cholestyramin or
cholestyramine$ or cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or
colestyramin or cuemid$ or lipocol-merz or lismol or locholest or prevalite or quantalan or questran$
or resincoles-tiramina or resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6
or 58391-37-0 or mk 135 or mk135).ti,ab,ot,hw,rn. (3239)
9. (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or gt31-104 or
gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7).ti,ab,ot,hw,rn. (155)
10. Aluminum Hydroxide/ or (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or
algeldraat or algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu
cap or alu-cap or alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina
trihydrate or aluminium hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum
hydrate or aluminum hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or
amphogel or amphojel or amphotabs or antiphos or bayerite or chefarox or collumina or collumol
or colodral or colugel or creamalin or cremorin or diplogel or f 1000 or f1000 or fluagel or
gastracol or gastrosetarderm or gelumina or hoemigel or hycolal or hydracoll or hydrated alumina or
hydrolum or hydronal or hydroxal or lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p
or vanogel).ti,ab,ot,hw,rn. (4378)
11. or/6-10 (10,414)
12. 5 or 11 (11,017)
13. (BAM or I-BAM or IBAM or PBAM or BSM).ti,ab,ot,hw. (2205)
14. primary bile acid diarrh?ea$.ti,ab,ot,hw. (4)
15. diarrhea/ (35,612)
16. ((chronic or watery or recur$ or persist$ or protracted or continual$ or continuous$ or sustain$ or
constant$ or relentless$ or unrelent$ or functional or aggressive) adj2 (diarrh?e$ or diarrea$)).ti,ab,ot,
hw. (6803)
17. "Bile Acids and Salts"/ (18,212)
18. (malabsorb$ or mal-absorb$ or malabsorp$ or mal-absorp$).ti,ab,ot,hw. (13,540)
19. ((bile or biliary) adj3 (acid$ or salt$)).ti,ab,ot,hw. (28,118)
20. or/13-19 (80,116)
21. 12 and 20 (1769)
22. animals/ not (animals/ and humans/) (3,607,371)
23. 21 not 22 (1312)MEDLINE In-Process & Other Non-Indexed Citations (OvidSP):
up to 17 April 2012
MEDLINE Daily Update (OvidSP): up to 17 April 2012
Searched 18 April 2012.
1. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).ti,ab,ot,hw,rn. (0)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75).ti,ab,ot,hw,rn. (6)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid or 75Se-homotaurocholate).ti,ab,ot,hw,rn. (0)
4. (selenium adj3 "75").ti,ab,ot,hw. (1)
5. or/1-4 (7)121
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1226. ((bile adj3 (acid or salt) adj3 sequestra$) or BAS).ti,ab,ot,hw,rn. (172)
7. Colestipol/ or (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-
epichlorohydrin-copolymer or diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or
epichlorohydrin-copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a or
u-26597-a or u-26597a or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6).ti,ab,ot,hw,rn. (2)
8. Cholestyramine Resin/ or (colestyramine$ or chol-less or choles or cholesthexal or cholestyramin or
cholestyramine$ or cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or
colestyramin or cuemid$ or lipocol-merz or lismol or locholest or prevalite or quantalan or questran$
or resincoles-tiramina or resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6
or 58391-37-0 or mk 135 or mk135).ti,ab,ot,hw,rn. (28)
9. (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or gt31-104 or
gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7).ti,ab,ot,hw,rn. (18)
10. Aluminum Hydroxide/ or (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or
algeldraat or algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu
cap or alu-cap or alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina
trihydrate or aluminium hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum
hydrate or aluminum hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or
amphogel or amphojel or amphotabs or antiphos or bayerite or chefarox or collumina or collumol
or colodral or colugel or creamalin or cremorin or diplogel or f 1000 or f1000 or fluagel or gastracol
or gastrosetarderm or gelumina or hoemigel or hycolal or hydracoll or hydrated alumina or hydrolum
or hydronal or hydroxal or lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p or vanogel).
ti,ab,ot,hw,rn. (152)
11. or/6-10 (357)
12. 5 or 11 (363)
13. (BAM or I-BAM or IBAM or PBAM or BSM).ti,ab,ot,hw. (261)
14. primary bile acid diarrh?ea$.ti,ab,ot,hw. (0)
15. diarrhea/ (24)
16. ((chronic or watery or recur$ or persist$ or protracted or continual$ or continuous$ or sustain$ or
constant$ or relentless$ or unrelent$ or functional or aggressive) adj2 (diarrh?e$ or diarrea$)).ti,ab,ot,
hw. (222)
17. "Bile Acids and Salts"/ (12)
18. (malabsorb$ or mal-absorb$ or malabsorp$ or mal-absorp$).ti,ab,ot,hw. (254)
19. ((bile or biliary) adj3 (acid$ or salt$)).ti,ab,ot,hw. (627)
20. or/13-19 (1367)
21. 12 and 20 (50)
22. animals/ not (animals/ and humans/) (3162)
23. 21 not 22 (49)Cochrane Central Register of Controlled Trials (CENTRAL)
(Wiley Online Library): Issue 4: 2012
Cochrane Database of Systematic Reviews (CDSR) (Wiley Online Library):
Issue 3: 2012
Searched 18 April 2012.
#1 tauroselcholic or selenohomocholyltaurine or 75018-71-2 3
#2 SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75 10
#3 23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or selenium
radioisotopes or tauroselenocholic acid or 75Se-homotaurocholate 7
#4 selenium near "75" 16
#5 (#1 OR #2 OR #3 OR #4) 33NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61#6 ((bile near (acid or salt) near sequestra*) or BAS) 342
#7 MeSH descriptor Colestipol, this term only 90
#8 (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-epichlorohydrin-copolymer or
diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or epichlorohydrin-copolymer-with-
diethylenetriamine or flavored-colestid or lestid or u-26,597a or u-26597-a or u-26597a or u-26,597a or
25085-17-0 or 37296-80-3 or 50925-79-6) 190
#9 MeSH descriptor Cholestyramine Resin, this term only 250
#10 (colestyramine or chol-less or choles or cholesthexal or cholestyramin or cholestyramine or cholybar or
cholytar or colestepril or colestiramina or colestran or colestrol or colestyramin or cuemid or lipocol-merz or
lismol or locholest or prevalite or quantalan or questran or resincoles-tiramina or resincolestiramina or
vasosan-p-granulat or vasosan-s-granulat or 11041-12-6 or 58391-37-0) 462
#11 (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or gt31-104
or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7) 49
#12 MeSH descriptor Aluminum Hydroxide, this term only 350
#13 (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or algeldraat or algeldrate or
algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu cap or alu-cap or alu-tab or
alucol or aludrox or alugelibys or alumigel or alumina gel or alumina trihydrate or aluminium hydroxide or
aluminium hydroxide or aluminoid or aluminox or aluminum hydrate or aluminum hydroxide gel or
aluminum oxide trihydrate or aluminum trihydrate or alutab or amphogel or amphojel or amphotabs or
antiphos or bayerite or chefarox or collumina or collumol or colodral or colugel or creamalin or cremorin or
diplogel or f 1000 or f1000 or fluagel or gastracol or gastrosetarderm or gelumina or hoemigel or hycolal
or hydracoll or hydrated alumina or hydrolum or hydronal or hydroxal or lactalumina or neutroxide or
palliacol or pepsamar or ulcerin-p or vanogel or 21645-51-2 or brasivil or rocgel or alugel or hydrated
alumina or basalgel or dialume or nephrox) 3393
#14 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13) 4263
#15 (#5 OR #14) 4287
#16 primary near bile acid near (diarrhoe* or diarrhe* or diarrea*) 1
#17 (chronic or watery or recur* or persist* or protract* or continual* or continuous* or sustain* or
constant* or relentless* or unrelent* or functional or aggressive) near (diarrhoe* or diarrhe* or diarrea*) 653
#18 (malabsorb* or mal-absorb* or malabsorp* or mal-absorp*) 577
#19 BAM or I-BAM or IBAM or PBAM or BSM 71
#20 (bile or biliary) near (acid* or salt*) 1269
#21 MeSH descriptor Bile Acids and Salts explode all trees 813
#22 MeSH descriptor Diarrhea, this term only 1907
#23 (#16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22) 4306
#24 (#15 AND #23) 305
The CENTRAL search retrieved 168 records.
The CDSR search retrieved 130 records.Database of Abstracts of Reviews of Effects (DARE) (internet):
up to 19 April 2012
Health Technology Assessment Database (HTA) (internet): up to 19 April 2012
www.york.ac.uk/inst/crd/
Searched 19 April 2012.
1. ((tauroselcholic or selenohomocholyltaurine or 75018-71-2)) 0
2. ((SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75)) 0123
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1243. ((23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid opr 75Se-homotaurocholate)) 0
4. ((selenium near "75")) 1
5. #1 OR #2 OR #3 OR #4 1
6. (((bile near (acid or salt) near sequestra*) or BAS)) 18
7. MeSH DESCRIPTOR Colestipol 3
8. ((Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-epichlorohydrin-copolymer or
diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or epichlorohydrin-copolymer-with-
diethylenetriamine or flavored-colestid or lestid or u-26,597a or u-26597-a or u-26597a or u-26,597a
or 25085-17-0 or 37296-80-3 or 50925-79-6) ) 21
9. ((colestyramine or chol-less or choles or cholesthexal or cholestyramin or cholestyramine or cholybar or
cholytar or colestepril or colestiramina or colestran or colestrol or colestyramin or cuemid or lipocol-
merz or lismol or locholest or prevalite or quantalan or questran or resincoles-tiramina or
resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6 or 58391-37-0)) 32
10. ((Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or gt31-104
or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7)) 3
11. MeSH DESCRIPTOR Aluminum Hydroxide 2
12. ((aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or algeldraat or algeldrate or
algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu cap or alu-cap or alu-tab or
alucol or aludrox or alugelibys or alumigel or alumina gel or alumina trihydrate or aluminium
hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum hydrate or aluminum
hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or amphogel or amphojel
or amphotabs or antiphos or bayerite or chefarox or collumina or collumol or colodral or colugel or
creamalin or cremorin or diplogel or f1000 or fluagel or gastracol or gastrosetarderm or gelumina or
hoemigel or hycolal or hydracoll or hydrated alumina or hydrolum or hydronal or hydroxal or
lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p or vanogel or 21645-51-2 or brasivil or
rocgel or alugel or hydrated alumina or basalgel or dialume or nephrox)) 7
13. #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 65
14. ((primary near bile acid near (diarrhoe* or diarrhe* or diarrea*))) 0
15. ((chronic or watery or recur* or persist* or protract* or continual* or continuous* or sustain* or
constant* or relentless* or unrelent* or functional or aggressive) near (diarrhoe* or diarrhe* or
diarrea*))) 55
16. ((malabsorb* or mal-absorb* or malabsorp* or mal-absorp*)) 28
17. ((BAM or I-BAM or IBAM or PBAM or BSM)) 3
18. ((bile or biliary) near (acid* or salt*)) 26
19. MeSH DESCRIPTOR Diarrhea EXPLODE ALL TREES 130
20. #14 OR #15 OR #16 OR #17 OR #18 OR #19 221
21. #5 OR #13 66
22. #20 AND #21 11
23. #22 IN DARE 9
24. #22 IN HTA 0
The DARE search retrieved nine records.
The HTA search retrieved no records.Science Citation Index (SCI) (Web of Knowledge): 1970 to 18 April 2012
Searched 19 April 2012.
Databases=SCI-EXPANDED Timespan=All Years
Lemmatization=OnNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61#21 892 #19 not #20
#20 3,083,864 TS=(cat or cats or dog or dogs or animal or animals or rat or rats or hamster or hamster or
feline or ovine or canine or bovine or sheep or mice)
#19 1,350 #12 and #18
#18 50,168 #13 or #14 or #15 or #16 or #17
#17 35,208 TS= ((bile or biliary) SAME (acid* or salt*))
#16 8,288 TS= (malabsorb* or mal-absorb* or malabsorp* or mal-absorp*)
#15 3,716 TS= ((chronic or watery or recur* or persist* or protracted or continual* or continuous* or
sustain* or constant* or relentless* or unrelent* or functional or aggressive) SAME (diarrh?e* or diarrea*))
#14 23 TS= primary bile acid diarrh?ea*
#13 3,908 TS= (BAM or I-BAM or IBAM or PBAM or BSM)
#12 26,883 #5 or #11
#11 24,843 #6 or #7 or #8 or #9 or #10
#10 18,785 TS= (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or algeldraat or
algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu cap or alu-cap or
alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina trihydrate or aluminium
hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum hydrate or aluminum hydroxide
gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or amphogel or amphojel or amphotabs
or antiphos or bayerite or chefarox or collumina or collumol or colodral or colugel or creamalin or cremorin
or diplogel or f 1000 or f1000 or fluagel or gastracol or gastrosetarderm or gelumina or hoemigel or
hycolal or hydracoll or hydrated alumina or hydrolum or hydronal or hydroxal or lactalumina or neutroxide
or palliacol or pepsamar or ulcerin-p or vanogel)
#9 227 TS= (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or
gt31-104 or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7)
#8 2,201 TS= (colestyramine* or chol-less or choles or cholesthexal or cholestyramin or cholestyramine* or
cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or colestyramin or cuemid* or
lipocol-merz or lismol or locholest or prevalite or quantalan or questran* or resincoles-tiramina or
resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6 or 58391-37-0 or mk 135
or mk135)
#7 653 TS= (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-epichlorohydrin-
copolymer or epichlorohydrin-copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a
or u-26597-a or u-26597a or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6)
#6 3,444 TS= ((bile SAME (acid or salt) SAME sequestra*) or BAS)
#5 2,084 #1 or #2 or #3 or #4
#4 1,208 TS= (selenium SAME "75")
#3 48 TS= (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or selenium
radioisotopes or tauroselenocholic acid or 75Se-homotaurocholate)
#2 1,161 TS= (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75)
#1 2 TS=(tauroselcholic or selenohomocholyltaurine or 75018-71-2)125
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
APPENDIX 1
126NIHR Health Technology Assessment (HTA) (internet): up to 19 April 2012
http://www.journalslibrary.nihr.ac.uk
Searched 19 April 2012.
Browsed by relevant terms, found three references.Search 3: scoping search alternative tests
Scoping search to identify background literature on this topic prior to NICE scoping meeting.Cochrane Database of Systematic Reviews (CDSR) (Wiley Online Library):
Issue 10: 2011
Searched 27 October 2011
#1 (barium follow-through or barium follow through):ti,ab,kw 23
#2 (barium enema or lower gastrointestinal series or barium-examination):ti,ab,kw 257
#3 MeSH descriptor Barium Sulfate explode all trees 253
#4 (Barium-Sulfate or Barium Sulfate or alubar or anatrast or artificial-barite or artificial-heavy-spar or
astrabaryt or bakontal or bar-test or baridol or bariform or barite or barium- compound-bas-16 or barium-
sulfate-suspension or baro-cat or barolac or baropaque or barosperse or barotrast or barytcontrast or bear-
e-yum-gi or blanc-fixe or citobaryum or colloidal-barium-sulfate or e-z-cat or e-z-em or e- z-em or eneset-2
or entero-h or esophotrast or ez-hd or ezem or falibaryt or fotogel or gelobarin or hd-85 or intestibar or
kinetrast or microbar or microfanox-enema or micropaque or microtrast or mixobar or neobar or notopacol
or nov-umbrose or oratrast or polibar or prontobario or pulvobarin or raybar or rayso or shadoform or
skiabaryt or skiabaryum or steripaque* or stomagnost or synthetic-barytes or tixobar or tonojug or
tonopaque or unibaryt):ti,ab,kw 314
#5 MeSH descriptor Sigmoidoscopy, this term only 269
#6 Sigmoidoscopy:ti,ab,kw 433
#7 MeSH descriptor Colonoscopy explode all trees 1194
#8 (Colonoscopy or colonscopy or coloscopy or fiber-colonoscopy):ti,ab,kw 1425
#9 99mTc-HMPAO:ti,ab,kw 39
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9) 2102
The CDSR search retrieved 19 records.Database of Abstracts of Reviews of Effects (DARE) (CRD):
up to 27 October 2011
www.york.ac.uk/inst/crd/
Searched 29 October 2011.
1. ((barium follow-through or barium follow through)) 3
2. ((barium enema or lower gastrointestinal series or barium-examination)) 51
3. MeSH DESCRIPTOR Sigmoidoscopy WITH QUALIFIER undefined 39
4. (Sigmoidoscopy) 120
5. MeSH DESCRIPTOR Colonoscopy EXPLODE ALL TREES WITH QUALIFIER undefined 148
6. (Colonoscopy or colonscopy or coloscopy or fiber-colonoscopy) 303
7. (99mTc-HMPAO) 1
8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 337
9. (#8) IN DARE FROM 2006 TO 2011 66
The DARE search retrieved 66 records.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Search 4: trials searches
SeHCAT or bile acid sequestrant
Original searches undertaken between 9 and 16 January 2012 retrieved 379 records. Update searches
undertaken between 17 and 20 April 2012 found an additional 4 records (after deduplication), but no
new includes.Clinicaltrials.gov (internet)
http://clinicaltrials.gov/ct2/search/advanced
Searched 19 April 2012.
Advanced search option – search terms box:Search terms Results
SeHCAT OR Se-HCAT OR 75SeHCAT OR Se-75 OR 75-SeHCAT OR SE75 0
tauroselcholic OR selenohomocholyltaurine OR selenium homocholic acid taurine OR tauroselenocholic acid OR
75Se-homotaurocholate
0
(Colestipol OR cholestabyl OR cholestipol OR colestid OR flavored-colestid OR lestid OR u-26,597a OR u-26597-a
OR u-26597a OR u-26,597a OR 25085-17-0 OR 37296-80-3 OR 50925-79-6)
4
(colestyramine OR chol-less OR choles OR cholesthexal OR cholestyramin OR cholestyramine OR cholybar OR
cholytar OR colestepril OR colestiramina OR colestran OR colestrol OR colestyramin OR cuemid OR lipocol-merz
OR questran)
14
(Colesevelam OR cholestagel OR gt-31-104 OR gt-31-104hb OR gt-31-104 OR gt-31-104hb OR gt31-104 OR
gt31-104hb OR gt31-104 OR gt31-104hb OR welchol OR 182815-43-6 OR 182815-44-7)
35
aluminum hydroxide OR Ageldrate OR al u creme OR alcid OR aldrox OR algeldraat OR algeldrate OR algelox
OR alhydrogel OR alkagel OR alocol OR alokreem OR alterna gel OR alu cap OR hycolal OR hydracoll OR
hydrated alumina OR hydrolum OR hydronal OR hydroxal OR lactalumina OR neutroxide
123
TOTAL 176127
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128mRCT – metaRegister of Current Controlled Trials (internet)
www.controlled-trials.com/
Searched 19 April 2012.
Advanced search option – search terms box:Search terms Results
SeHCAT OR Se-HCAT 1
75SeHCAT OR Se-75 0
75-SeHCAT OR SE75 0
tauroselcholic OR selenohomocholyltaurine OR 75Se-homotaurocholate 0
selenium homocholic acid taurine 0
tauroselenocholic acid 0
(Colestipol OR cholestabyl OR cholestipol OR colestid OR flavored-colestid OR lestid ) AND (diarrhea* OR
diarrhoea* OR diarrea* OR bile acid* OR bile salt* OR BAM)
14
(colestyramine OR cholesthexal OR cholestyramin OR cholestyramine OR cholybar OR colestepril OR
colestiramina OR colestran OR colestrol OR colestyramin OR cuemid OR questran) AND (diarrhea* OR
diarrhoea* OR diarrea* OR bile acid* OR bile salt* OR BAM)
36
(Colesevelam OR cholestagel OR gt-31-104 OR gt-31-104hb OR welchol OR 182815-43-6 OR 182815-44-7)
AND (diarrhea* OR diarrhoea* OR diarrea* OR bile acid* OR bile salt* OR BAM)
22
(aluminum hydroxide OR Ageldrate OR al u creme OR alcid OR aldrox OR algeldraat OR algeldrate OR alu cap
OR hycolal OR hydracoll OR hydrated alumina)AND (diarrhea* OR diarrhoea* OR diarrea* OR bile acid* OR bile
salt* OR BAM)
1
TOTAL 74WHO International Clinical Trials Registry Platform (ICTRP) (internet)www.who.int/ictrp/en/
Searched 20 April 2012.
Advanced search option – search terms box:Search terms Results
SeHCAT OR Se-HCAT OR 75SeHCAT OR Se-75 OR 75-SeHCAT OR SE75 0
tauroselcholic OR selenohomocholyltaurine OR selenium homocholic acid taurine OR tauroselenocholic acid OR
75Se-homotaurocholate
0
(Colestipol OR cholestabyl OR cholestipol OR colestid OR flavored-colestid OR lestid OR u-26,597a OR u-26597-a
OR u-26597a OR u-26,597a OR 25085-17-0 OR 37296-80-3 OR 50925-79-6)
4
(colestyramine OR chol-less OR choles OR cholesthexal OR cholestyramin OR cholestyramine OR cholybar OR
cholytar OR colestepril OR colestiramina OR colestran OR colestrol OR colestyramin OR cuemid OR lipocol-merz
OR questran)
3/13
(Colesevelam OR cholestagel OR gt-31-104 OR gt-31-104hb OR gt-31-104 OR gt-31-104hb OR gt31-104 OR
gt31-104hb OR gt31-104 OR gt31-104hb OR welchol OR 182815-43-6 OR 182815-44-7)
3/47
aluminum hydroxide OR Ageldrate OR al u creme OR alcid OR aldrox OR algeldraat OR algeldrate OR algelox
OR alhydrogel OR alkagel OR alocol OR alokreem OR alterna gel OR alu cap OR hycolal OR hydracoll OR
hydrated alumina OR hydrolum OR hydronal OR hydroxal OR lactalumina OR neutroxide
7/56
TOTAL 120
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61EU Clinical Trials Registry (EU CTR) (internet)www.clinicaltrialsregister.eu/ctr-search/
Searched 20 April 2012.
Advanced search option – search terms box:Search terms Results
SeHCAT OR Se-HCAT OR 75SeHCAT OR Se-75 OR 75-SeHCAT OR SE75 2
tauroselcholic OR selenohomocholyltaurine OR selenium homocholic acid taurine OR
tauroselenocholic acid OR 75Se-homotaurocholate
0
(Colestipol OR cholestabyl OR cholestipol OR colestid OR flavored-colestid OR lestid OR u-26,597a
OR u-26597-a OR u-26597a OR u-26,597a OR 25085-17-0 OR 37296-80-3 OR 50925-79-6)
0
(colestyramine OR chol-less OR choles OR cholesthexal OR cholestyramin OR cholestyramine OR
cholybar OR cholytar OR colestepril OR colestiramina OR colestran OR colestrol OR colestyramin OR
cuemid OR lipocol-merz OR questran)
27
(Colesevelam OR cholestagel OR gt-31-104 OR gt-31-104hb OR gt-31-104 OR gt-31-104hb
OR gt31-104 OR gt31-104hb OR gt31-104 OR gt31-104hb OR welchol OR 182815-43-6
OR 182815-44-7)
3
aluminum hydroxide OR Ageldrate OR al u creme OR alcid OR aldrox OR algeldraat OR algeldrate
OR algelox OR alhydrogel OR alkagel OR alocol OR alokreem OR alterna gel OR alu cap OR hycolal
OR hydracoll OR hydrated alumina OR hydrolum OR hydronal OR hydroxal OR lactalumina
OR neutroxide
0
TOTAL 32Search 5: conference abstract searchesOnline Learning in Gastroenterology (OLGa) (internet)
http://olga.uegf.org/portal/documents-explore.html#solr0
Searched 10 February 2012.
Documents search:Keyword Results
"SeHCAT" 5
"Se-HCAT" 5 (duplicates)
"75SeHCAT" 0
"75-SeHCAT" 0
TOTAL 5OLGa contains the following conferences:
l Advances in Clinical Oesophageal Investigation Conference (ASCONA ESSENTIALS 2011)
l Eighth Summer School of Gastroenterology (ASNEMGE-SS-PRAGUE2011)
l GASTRO2009
l 18th United European Gastroenterology Week (UEGW2010)
l 19th United European Gastroenterology Week (UEGW2011).129
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130British Society of Gastroenterology (BSG) Annual Meetings (internet)
www.bsg.org.uk/education/meeting/index.html
Searched 10 February 2012.Terms 2011 2010 2009 2008
SeHCAT 3 3 1 1
Se-HCAT 0 0 0 0
75SeHCAT 0 0 0 0
75-SeHCAT 0 0 0 0
Total 8Conference Proceedings Citation Index: Science (CPCI-S) (Web of Knowledge):
1990 to 18 April 2012
Searched 19 April 2012.
#14 12 #12 or #13
#13 11 TS=(SeHCAT or Se-HCAT or 75SeHCAT or 75-SeHCAT)
#12 11 #5 and #11
#11 4,584 #6 or #7 or #8 or #9 or #10
#10 2,975 TS= ((bile or biliary) SAME (acid* or salt*))
#9 564 TS= (malabsorb* or mal-absorb* or malabsorp* or mal-absorp*)
#8 243 TS= ((chronic or watery or recur* or persist* or protracted or continual* or continuous* or sustain*
or constant* or relentless* or unrelent* or functional or aggressive) SAME (diarrh?e* or diarrea*))
#7 1 TS= primary bile acid diarrh?ea*
#6 894 TS= (BAM or I-BAM or IBAM or PBAM or BSM)
#5 190 #1 or #2 or #3 or #4
#4 122 TS= (selenium SAME "75")
#3 5 TS= (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or selenium
radioisotopes or tauroselenocholic acid or 75Se-homotaurocholate)
#2 106 TS= (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75)
#1 0 TS=(tauroselcholic or selenohomocholyltaurine or 75018-71-2)Cost-effectiveness search strategies
Search A: scoping search
Bile acid malabsorption + (prevalence/incidence) + other conditions
Scoping search to identify background literature on this topic prior to NICE Scoping meeting.EMBASE (OvidSP): 1980 to week 43 2011
Searched 1 November 2011.
1. chronic diarrhea/ (2481)
2. ((chronic or watery or recur$ or persist$ or protract$ or continual$ or continuous$ or sustain$ or
constant$ or relentless$ or unrelent$) adj2 diarrh?e$).mp. (14,305)
3. or/1-2 (14,305)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 614. (Irritable bowel syndrome or IBS or spastic colon).mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name,
keyword] (10,347)
5. inflammatory bowel disease/ (35,062)
6. (inflammat$ adj3 (bowel disease$ or intestinal or intestine)).mp. (33,511)
7. (inflammatory bowel disease or inflammatory enteropathy or granulomatous enteritis or acute
hemorrhagic necrotizing enteritis or IBD).mp. (28,794)
8. or/5-7 (50,644)
9. Crohn disease/ (43,017)
10. ((cleron or Crohn’s or Crohns) adj3 disease).mp. (31,200)
11. morbus crohn.mp. (1119)
12. ((regional or regionalis) adj3 (enteritis or enterocolitis)).mp. (893)
13. or/9-12 (47,518)
14. ulcerative colitis/ (36,695)
15. ((colitis or colorectitis or proctocolitis) adj3 (ulcerative or ulcerosa or mucosal or ulcerous)).mp. (40249)
16. or/14-15 (40,249)
17. Incidence/ (172,688)
18. Prevalence/ (266,293)
19. exp morbidity/ (154,454)
20. (morbidit$ or frequency or frequencies or occurrence$ or incidence$ or prevalence$ or number$ or
times or rate or rates or episode$ or recurren$ or reoccur$ or re-occur$ or distributed or distribution$).
mp. (5,600,176)
21. or/17-20 (5,600,176)
22. (BAM or I-BAM or IBAM or PBAM).mp. (1948)
23. primary bile acid diarrh?ea$.mp. (4)
24. (malabsorb$ or mal-absorb$ or malabsorp$ or mal-absorp$).mp. (16,265)
25. ((bile or biliary) adj3 (acid$ or salt$)).mp. (31,172)
26. bile acid/ (17,182)
27. or/25-26 (31,172)
28. 24 and 27 (960)
29. 22 or 23 or 28 (2870)
30. 3 or 4 or 8 or 13 or 16 (121,285)
31. 21 and 29 and 30 (98)
32. limit 31 to embase (87)Search B: searches to inform model
Irritable bowel syndrome + cost/quality of life
The health economists requested a search to identify literature on health-related quality of life and
cost-effectiveness for IBS. These searches were conducted to inform the model and were not intended
to be exhaustive.NHS Economic Evaluation Database (NHS EED) (CRD) (internet):
up to 18 November 2011
www.york.ac.uk/inst/crd
Searched: 18 November 2011.
1. MeSH DESCRIPTOR irritable bowel syndrome EXPLODE ALL TREES IN NHSEED 5
2. ((Irritable bowel syndrome* or IBS or IBS-D) ) IN NHSEED 21
3. (((spastic or irritable or spasm or unstable) NEAR colon)) IN NHSEED 0131
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1324. ((Colitis or colitides) NEAR (spastic or mucous or mucomembraneous or mucomembranous)) IN NHSEED 0
5. (colonospasm) IN NHSEED 0
6. #1 OR #2 OR #3 OR #4 OR #5 21
NHS EED search retrieved 21 records.MEDLINE (OvidSP): 1948 to week 2 November 2011
Searched 21 November 2011.
1. Irritable bowel syndrome/ (3197)
2. (Irritable bowel syndrome$ or IBS or IBS-D).ti,ab,ot,hw. (7638)
3. ((spastic or irritable or spasm or unstable) adj2 colon).ti,ab,ot,hw. (493)
4. ((Colitis or colitides) adj2 (spastic or mucous or mucomembraneous or mucomembranous)).ti,ab,ot,hw. (30)
5. colonospasm.ti,ab,ot,hw. (0)
6. or/1-5 (8061)
7. economics/ (26,484)
8. exp "costs and cost analysis"/ (161,477)
9. economics, dental/ (1888)
10. exp "economics, hospital"/ (17,725)
11. economics, medical/ (8761)
12. economics, nursing/ (3855)
13. economics, pharmaceutical/ (2303)
14. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (351,771)
15. (expenditure$ not energy).ti,ab. (14,848)
16. (value adj1 money).ti,ab. (20)
17. budget$.ti,ab. (14,945)
18. or/7-17 (467,125)
19. ((energy or oxygen) adj cost).ti,ab. (2391)
20. (metabolic adj cost).ti,ab. (629)
21. ((energy or oxygen) adj expenditure).ti,ab. (13,784)
22. or/19-21 (16,171)
23. 18 not 22 (463,461)
24. letter.pt. (732,976)
25. editorial.pt. (288,333)
26. historical article.pt. (284,321)
27. or/24-26 (1,292,390)
28. 23 not 27 (438,432)
29. (sf36 or sf 36 or short form 36 or shortform 36).ti,ab. (11,834)
30. (sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirty six or short
form thirtysix or short form thirty six).ti,ab. (1)
31. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab. (879)
32. (euroqol or euro qol or eq5d or eq 5d).ti,ab. (2414)
33. (hql or hrql or hqol or h qol or hrqol or hr qol).ti,ab. (7060)
34. (hye or hyes).ti,ab. (50)
35. health$ year$ equivalent$.ti,ab. (36)
36. (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3).ti,ab. (677)
37. (quality of well being or quality of wellbeing or qwb).ti,ab. (306)
38. (Disability adjusted life year$ or Disability-adjusted life year$ or health adjusted life year$ or health-
adjusted life year$ or years of healthy life or healthy years equivalent or years of potential life lost or
years of health life lost or quality adjusted life year$).ti,ab. (5185)
39. (QALY$ or HRQOL or HRQL or DALY$ or HALY$ or YHL or HYES or YPLL or YHLL).ti,ab. (11,277)
40. (Irritable Bowel Syndrome adj Quality Of Life).ti,ab,ot,hw. (26)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 6141. (Quality of Life Questionnaire for Functional Digestive Disorders or Gastrointestinal Symptom Rating
Scale).ti,ab,ot,hw. (165)
42. (FDDQL or GSRS-self or GSRS or IBS-36 or IBS-QOL).ti,ab,ot,hw. (245)
43. or/29-42 (26,151)
44. 28 or 43 (457,578)
45. animals/ not (animals/ and humans/) (3,623,263)
46. 44 not 45 (431,745)
47. 6 and 46 (475)
48. (2000$ or 2001$ or 2002$ or 2003$ or 2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or
2010$ or 2011$).ed. (8,439,370)
49. 47 and 48 (410)Economics filter
Centre for Reviews and Dissemination. NHS EED Economics Filter: Medline (Ovid) monthly search. York:
Centre for Reviews and Dissemination; 2010 (cited 28 September 2010). URL: www.york.ac.uk/inst/crd/
intertasc/nhs_eed_strategies.html.Patient-Reported Outcome and Quality of Life Instruments
Database (PROQOLID)
www.proqolid.org
Searched 21 November 2011.
Browsed for relevant QoL instruments to inform MEDLINE search.Search C: guidelines
(IBS or Crohn’s or BAM or chronic diarrhoea or SeHCAT)International Guidelines Library (GIN) (internet): up to 28 November 2011
www.g-i-n.net
Searched 28 November 2011.Terms searched Hits
Free-text: Irritable bowel syndrome* or IBS or IBS-D or spastic colon 7
Free-text: BAM or I-BAM or IBAM or PBAM or Bile acid malabsorption 0
Bile and acid* 0
Free-text: SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75 0
Free-text: Crohn* disease 10
Free-text: chronic diarrhea* or chronic diarrhoea* or functional diarrhea* or functional diarrhoea* 0
Free-text: diarrhea* or diarrhoea* 14
Total (prior to deduplication) 31Update search undertaken 1 May 2012; no new relevant references were retrieved.133
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134National Guidelines Clearinghouse (internet): up to 28 November 2011
www.guideline.gov
Searched 28 November 2011.
Advanced search:Terms searched Hits
Irritable bowel syndrome* or IBS or IBS-D or spastic colon 23
BAM or I-BAM or IBAM or PBAM or Bile acid malabsorption 2
SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75 0
Crohn* disease 48
“chronic diarrhea” or “chronic diarrhoea” or “functional diarrhea” or “functional diarrhoea*” 11
Total (prior to deduplication) 84Update search undertaken 1 May 2012, no new relevant references were retrieved.National Institute for Health and Clinical Excellence (NICE) Guidance (internet):
up to 2012/05/01
http://guidance.nice.org.uk/
Searched 1 May 2012.
Advanced search:Terms searched Hits
Irritable bowel syndrome OR IBS OR IBS-D 13/52
BAM OR I-BAM OR IBAM OR PBAM OR Bile acid malabsorption 1
SeHCAT OR Se-HCAT OR 75SeHCAT OR Se-75 OR 75-SeHCAT OR SE75 1
Crohn disease OR crohns disease OR crohn’s disease 26/69
chronic diarrhea OR chronic diarrhoea OR functional diarrhea OR functional diarrhoea 12/55
Total 53/178Original search undertaken 28 November 2011 retrieved 31/146 results. An issue with the search interface
resulted in only being able to search for single terms, at the time of the update search (see above) this had
been rectified. An additional 22 references were retrieved, but no new includes were identified.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Turning Research into Practice (TRIP database) (internet): up to 2011/12/08
http://www.tripdatabase.com/
Searched 9 December 2011.
Limited to guidelines only.Terms searched Hits
“Irritable bowel syndrome” or “Irritable bowel syndromes” or IBS or IBS-D or “spastic colon” 74
BAM or I-BAM or IBAM or PBAM or “Bile acid malabsorption” 7
SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75 4
Crohns disease OR Crohn disease 94
"chronic diarrhea" or "chronic diarrhoea" or "functional diarrhea" or "functional diarrhoea" 29
Total (prior to deduplication) 208Update search undertaken 1.5.12, Total 0/212 no new relevant references were retrieved.Health Technology Assessment Database (HTA) (internet):
up to 28 November 2011
www.york.ac.uk/inst/crd
Searched 28 November 2011.
1. MeSH DESCRIPTOR Irritable bowel syndrome IN HTA 2
2. ((Irritable bowel syndrome* or IBS or IBS-D or spastic colon)) IN HTA 12
3. (BAM or I-BAM or IBAM or PBAM ) IN HTA 0
4. ((Bile near acid*) OR (Biliary near acid*) OR (Bile near salt*) OR (Biliary near salt*)) IN HTA 3
5. MeSH DESCRIPTOR Crohn disease IN HTA 25
6. ((Crohn* near disease)) IN HTA 43
7. (((chronic near diarrhoea*) or (chronic near diarrhea*))) IN HTA 2
8. MeSH DESCRIPTOR diarrhea IN HTA 8
9. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75) IN HTA 0
10. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 64
Update search undertaken 2 May 2012; no new relevant references were retrieved.
HTA search retrieved 64 records.NIHR Health Technology Assessment (HTA) (internet): up to 9 December 2011
www.hta.ac.uk
Searched 9 December 2011.
Browsed by relevant terms found three references.
Update search undertaken 2 May 2012; no new relevant references were retrieved.135
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136Search D: cost-effectiveness(SeHCAT or bile acid sequestrant/aluminium hydroxide or bile acid
malabsorption) + cost
MEDLINE search: Facet 1 combined terms for SeHCAT (lines #1–5) and Bile Acid Sequestrants (lines #6–11)
and BAM (lines #12–19) using OR in line #20 (n = 13,148). Facet 2 contained an economics filter and was
limited to remove animal studies (lines #21–44). Facet 2 was then combined with facet 1 using AND in line
#45 (n = 209). For the full strategy please see below.MEDLINE (OvidSP): 1946 to week 1 January 2012
Searched 16 January 2012.
1. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).ti,ab,ot,hw,rn. (2)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75).ti,ab,ot,hw,rn. (273)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid).ti,ab,ot,hw,rn. (317)
4. (selenium adj3 "75").ti,ab,ot,hw. (144)
5. or/1-4 (636)
6. ((bile adj3 acid adj3 sequestra$) or BAS).ti,ab,ot,hw,rn. (2524)
7. Colestipol/ or (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-epichlorohydrin-
copolymer or diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or epichlorohydrin-
copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a or u-26597-a or u-26597a
or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6).ti,ab,ot,hw,rn. (503)
8. Cholestyramine Resin/ or (colestyramine$ or chol-less or choles or cholesthexal or cholestyramin or
cholestyramine$ or cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or
colestyramin or cuemid$ or lipocol-merz or lismol or locholest or prevalite or quantalan or questran$
or resincoles-tiramina or resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6
or 58391-37-0 or mk 135 or mk135).ti,ab,ot,hw,rn. (3217)
9. (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or gt31-104 or
gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7).ti,ab,ot,hw,rn. (152)
10. Aluminum Hydroxide/ or (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or
algeldraat or algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu
cap or alu-cap or alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina
trihydrate or aluminium hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum
hydrate or aluminum hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or
amphogel or amphojel or amphotabs or antiphos or bayerite or chefarox or collumina or collumol
or colodral or colugel or creamalin or cremorin or diplogel or f 1000 or f1000 or fluagel or gastracol
or gastrosetarderm or gelumina or hoemigel or hycolal or hydracoll or hydrated alumina or hydrolum
or hydronal or hydroxal or lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p or vanogel).
ti,ab,ot,hw,rn. (4308)
11. or/6-10 (10226)
12. (BAM or I-BAM or IBAM or PBAM).ti,ab,ot,hw. (1659)
13. primary bile acid diarrh?ea$.ti,ab,ot,hw. (3)
14. "Bile Acids and Salts"/ (17,977)
15. ((bile or biliary) adj3 (acid$ or salt$)).ti,ab,ot,hw. (27,677)
16. 14 or 15 (27,677)
17. (malabsorb$ or mal-absorb$ or malabsorp$ or mal-absorp$).ti,ab,ot,hw. (13,415)
18. 16 and 17 (852)
19. 12 or 13 or 18 (2487)
20. 5 or 11 or 19 (13,148)
21. economics/ (26,137)
22. exp "costs and cost analysis"/ (160,072)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 6123. economics, dental/ (1833)
24. exp "economics, hospital"/ (17,561)
25. economics, medical/ (8422)
26. economics, nursing/ (3852)
27. economics, pharmaceutical/ (2278)
28. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (347,246)
29. (expenditure$ not energy).ti,ab. (14,604)
30. (value adj1 money).ti,ab. (17)
31. budget$.ti,ab. (14,875)
32. or/21-31 (461,486)
33. ((energy or oxygen) adj cost).ti,ab. (2356)
34. (metabolic adj cost).ti,ab. (618)
35. ((energy or oxygen) adj expenditure).ti,ab. (13,458)
36. or/33-35 (15,805)
37. 32 not 36 (457,877)
38. letter.pt. (727,126)
39. editorial.pt. (286,075)
40. historical article.pt. (278,564)
41. or/38-40 (1,278,705)
42. 37 not 41 (433,012)
43. animals/ not (animals/ and humans/) (3,550,250)
44. 42 not 43 (407,938)
45. 20 and 44 (209)Economics filter
Centre for Reviews and Dissemination. NHS EED Economics Filter: Medline (Ovid) monthly search. York:
Centre for Reviews and Dissemination; 2010 (cited 28.9.10). URL: www.york.ac.uk/inst/crd/intertasc/
nhs_eed_strategies.html.MEDLINE In-Process & Other Non-Indexed Citations (OvidSP):
up to 13 January 2012
MEDLINE Daily Update (OvidSP): up to 13 January 2012
Searched 16 January 2012.
1. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).ti,ab,ot,hw,rn. (1)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75).ti,ab,ot,hw,rn. (5)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid).ti,ab,ot,hw,rn. (0)
4. (selenium adj3 "75").ti,ab,ot,hw. (2)
5. or/1-4 (6)
6. ((bile adj3 acid adj3 sequestra$) or BAS).ti,ab,ot,hw,rn. (154)
7. Colestipol/ or (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-
epichlorohydrin-copolymer or diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or
epichlorohydrin-copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a or
u-26597-a or u-26597a or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6).ti,ab,ot,hw,rn. (3)
8. Cholestyramine Resin/ or (colestyramine$ or chol-less or choles or cholesthexal or cholestyramin or
cholestyramine$ or cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or
colestyramin or cuemid$ or lipocol-merz or lismol or locholest or prevalite or quantalan or questran$
or resincoles-tiramina or resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6
or 58391-37-0 or mk 135 or mk135).ti,ab,ot,hw,rn. (28)137
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1389. (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or gt31-104
or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7).
ti,ab,ot,hw,rn. (17)
10. Aluminum Hydroxide/ or (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or
algeldraat or algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu
cap or alu-cap or alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina
trihydrate or aluminium hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum
hydrate or aluminum hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or
amphogel or amphojel or amphotabs or antiphos or bayerite or chefarox or collumina or collumol
or colodral or colugel or creamalin or cremorin or diplogel or f 1000 or f1000 or fluagel or gastracol
or gastrosetarderm or gelumina or hoemigel or hycolal or hydracoll or hydrated alumina or hydrolum
or hydronal or hydroxal or lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p or vanogel).
ti,ab,ot,hw,rn. (146)
11. or/6-10 (332)
12. (BAM or I-BAM or IBAM or PBAM).ti,ab,ot,hw. (204)
13. primary bile acid diarrh?ea$.ti,ab,ot,hw. (1)
14. "Bile Acids and Salts"/ (7)
15. ((bile or biliary) adj3 (acid$ or salt$)).ti,ab,ot,hw. (601)
16. 14 or 15 (601)
17. (malabsorb$ or mal-absorb$ or malabsorp$ or mal-absorp$).ti,ab,ot,hw. (247)
18. 16 and 17 (8)
19. 12 or 13 or 18 (211)
20. 5 or 11 or 19 (542)
21. economics/ (0)
22. exp "costs and cost analysis"/ (134)
23. economics, dental/ (0)
24. exp "economics, hospital"/ (13)
25. economics, medical/ (0)
26. economics, nursing/ (1)
27. economics, pharmaceutical/ (1)
28. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (26398)
29. (expenditure$ not energy).ti,ab. (746)
30. (value adj1 money).ti,ab. (3)
31. budget$.ti,ab. (1394)
32. or/21-31 (27873)
33. ((energy or oxygen) adj cost).ti,ab. (146)
34. (metabolic adj cost).ti,ab. (40)
35. ((energy or oxygen) adj expenditure).ti,ab. (614)
36. or/33-35 (783)
37. 32 not 36 (27,665)
38. letter.pt. (17,895)
39. editorial.pt. (11,256)
40. historical article.pt. (107)
41. or/38-40 (29,247)
42. 37 not 41 (27,328)
43. animals/ not (animals/ and humans/) (1960)
44. 42 not 43 (27,296)
45. 20 and 44 (17)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Economics filter
Centre for Reviews and Dissemination. NHS EED Economics Filter: Medline (Ovid) monthly search. York:
Centre for Reviews and Dissemination; 2010 (cited 28 September 2010). URL: www.york.ac.uk/inst/crd/
intertasc/nhs_eed_strategies.html.EMBASE (OvidSP): 1980 to week 2 2012
Searched 16 January 2012.
1. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).mp. (154)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75).mp. (769)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid).mp. (19)
4. (selenium adj3 "75").mp. (485)
5. or/1-4 (1154)
6. bile acid sequestrant/ (651)
7. ((bile adj3 acid adj3 sequestra$) or BAS).ti,ab,ot,hw,rn. (16,068)
8. Colestipol/ or (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-
epichlorohydrin-copolymer or diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or
epichlorohydrin-copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a or
u-26597-a or u-26597a or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6).
ti,ab,ot,hw,rn. (2501)
9. Colestyramine/ or (colestyramine or chol-less or choles or cholesthexal or cholestyramin or
cholestyramine or cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or
colestyramin or cuemid or lipocol-merz or lismol or locholest or prevalite or quantalan or questran or
resincoles-tiramina or resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6 or
58391-37-0).ti,ab,ot,hw,rn. (9054)
10. Colesevelam/ or (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-
104hb or gt31-104 or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-
44-7).ti,ab,ot,hw,rn. (715)
11. aluminum hydroxide/ or (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or
algeldraat or algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu
cap or alu-cap or alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina
trihydrate or aluminium hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum
hydrate or aluminum hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or
amphogel or amphojel or amphotabs or antiphos or bayerite or chefarox or collumina or collumol
or colodral or colugel or creamalin or cremorin or diplogel or f 1000 or f1000 or fluagel or gastracol
or gastrosetarderm or gelumina or hoemigel or hycolal or hydracoll or hydrated alumina or hydrolum
or hydronal or hydroxal or lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p or vanogel
or 21645-51-2 or brasivil or rocgel or alugel or hydrated alumina or basalgel or dialume or nephrox).
ti,ab,ot,hw,rn. (7448)
12. or/6-11 (32,909)
13. 5 or 12 (33,993)
14. (BAM or I-BAM or IBAM or PBAM).mp. (1964)
15. primary bile acid diarrh?ea$.mp. (5)
16. (malabsorb$ or mal-absorb$ or malabsorp$ or mal-absorp$).mp. (16,434)
17. ((bile or biliary) adj3 (acid$ or salt$)).mp. (31,558)
18. bile acid/ or bile salt/ (20,540)
19. or/17-18 (31,558)
20. 16 and 19 (968)
21. 14 or 15 or 20 (2893)
22. 5 or 12 or 21 (36,610)
23. health-economics/ (30,837)139
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14024. exp economic-evaluation/ (176,160)
25. exp health-care-cost/ (168,886)
26. exp pharmacoeconomics/ (142,771)
27. or/23-26 (402,578)
28. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (460,397)
29. (expenditure$ not energy).ti,ab. (18,296)
30. (value adj2 money).ti,ab. (1018)
31. budget$.ti,ab. (19,324)
32. or/28-31 (479,792)
33. 27 or 32 (716,473)
34. letter.pt. (752,514)
35. editorial.pt. (389,343)
36. note.pt. (462,400)
37. or/34-36 (1,604,257)
38. 33 not 37 (642,745)
39. (metabolic adj cost).ti,ab. (679)
40. ((energy or oxygen) adj cost).ti,ab. (2622)
41. ((energy or oxygen) adj expenditure).ti,ab. (15,921)
42. or/39-41 (18,536)
43. 38 not 42 (638,607)
44. exp animal/ (1,665,824)
45. exp animal-experiment/ (1,486,602)
46. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep
or ovine or monkey or monkeys).mp. (4,860,767)
47. or/44-46 (4,861,129)
48. exp human/ (12,846,204)
49. exp human-experiment/ (296,685)
50. or/48-49 (12,847,588)
51. 47 not (47 and 50) (3,891,410)
52. 43 not 51 (610,079)
53. 22 and 52 (1164)
54. limit 53 to embase (1102)Economics filter
Centre for Reviews and Dissemination. NHS EED Economics Filter: Embase (Ovid) weekly search. York:
Centre for Reviews and Dissemination; 2010 (cited 17 March 2011). URL: www.york.ac.uk/inst/crd/
intertasc/nhs_eed_strategies.html.NHS Economic Evaluation Database (NHS EED) (CRD) (internet):
up to 16 January 2012
www.york.ac.uk/inst/crd
Searched 16 January 2012.
1. ((tauroselcholic or selenohomocholyltaurine or 75018-71-2)) 0
2. ((SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75)) 0
3. ((23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid)) 0
4. ((selenium near "75")) 1
5. #1 or #2 or #3 or #4 1NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 616. (((bile near acid near sequestra*) or BAS) ) 18
7. MeSH DESCRIPTOR Colestipol EXPLODE ALL TREES 3
8. ((Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-epichlorohydrin-copolymer or
diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or epichlorohydrin-copolymer-with-
diethylenetriamine or flavored-colestid or lestid or u-26,597a or u-26597-a or u-26597a or u-26,597a
or 25085-17-0 or 37296-80-3 or 50925-79-6)) 21
9. ((colestyramine or chol-less or choles or cholesthexal or cholestyramin or cholestyramine or cholybar or
cholytar or colestepril or colestiramina or colestran or colestrol or colestyramin or cuemid or lipocol-
merz or lismol or locholest or prevalite or quantalan or questran or resincoles-tiramina or
resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6 or 58391-37-0)) 32
10. ((Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or gt31-104
or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7)) 3
11. MeSH DESCRIPTOR Aluminum Hydroxide EXPLODE ALL TREES 2
12. ((aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or algeldraat or algeldrate or
algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu cap or alu-cap or alu-tab or
alucol or aludrox or alugelibys or alumigel or alumina gel or alumina trihydrate or aluminium
hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum hydrate or aluminum
hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or amphogel or amphojel
or amphotabs or antiphos or bayerite or chefarox or collumina or collumol or colodral or colugel or
creamalin or cremorin or diplogel or f1000 or fluagel or gastracol or gastrosetarderm or gelumina or
hoemigel or hycolal or hydracoll or hydrated alumina or hydrolum or hydronal or hydroxal or
lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p or vanogel or 21645-51-2 or brasivil or
rocgel or alugel or hydrated alumina or basalgel or dialume or nephrox)) 7
13. #6 or #7 or #8 or #9 or #10 or #11 or #12 65
14. (primary near bile acid near (diarrhoe* or diarrhe* or diarrea*)) 0
15. (BAM or I-BAM or IBAM or PBAM)) 0
16. ((bile or biliary) near (acid* or salt*)) 26
17. ((malabsorb* or mal-absorb* or malabsorp* or mal-absorp*)) 28
18. #14 or #15 or #16 or #17 54
19. #5 or #13 or #18 111
20. #19 and NHS EED 19
NHS EED search retrieved 19 records.Health Economics Evaluation Database (HEED) (internet): up to 6 March 2012
http://onlinelibrary.wiley.com/book/10.1002/9780470510933
Searched 6 March 2012.
Compound search, (all data), unable to limit by date:
tauroselcholic OR selenohomocholyltaurine OR 75018-71-2
OR
SeHCAT OR Se-HCAT OR 75SeHCAT OR Se-75 OR 75-SeHCAT OR SE75
OR
23-seleno-25-homo-tauro-cholic acid OR selenium homocholic acid taurine OR 23-selena-25-
homocholyltaurine OR 23-selena-25-homotaurocholate OR 23- selena-25-homotaurocholic-acid OR
selenium radioisotopes OR tauroselenocholic acid OR 75Se-homotaurocholate
OR
bile acid sequestrant OR bile acid sequestrants OR BAS
OR141
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142Colestipol OR cholestabyl OR cholestipol OR colestid OR flavored-colestid OR lestid OR u-26,597a OR
u-26597-a OR u-26597a OR u-26,597a OR 25085-17-0 OR 37296-80-3 OR 50925-79-6
OR
colestyramine OR chol-less OR choles OR cholesthexal OR cholestyramin OR cholestyramine OR cholybar
OR cholytar OR colestepril OR colestiramina OR colestran OR colestrol OR colestyramin OR cuemid OR
lipocol-merz OR questran
OR
Colesevelam OR cholestagel OR gt-31-104 OR gt-31-104hb OR gt-31-104 OR gt-31-104hb OR gt31-104
OR gt31-104hb OR gt31-104 OR gt31-104hb OR welchol OR 182815-43-6 OR 182815-44-7
OR
aluminum hydroxide OR Ageldrate OR alcid OR aldrox OR algeldraat OR algeldrate OR algelox OR
alhydrogel OR alkagel OR alocol OR alokreem OR alterna gel OR alu cap OR hycolal OR hydracoll OR
hydrated alumina OR hydrolum OR hydronal OR hydroxal OR lactalumina OR neutroxide
OR
BAM OR I-BAM OR IBAM OR PBAM OR BSM
OR
Bile acid OR bile salt OR Bile acids OR bile salts
Heed search retrieved 85 records.Science Citation Index (Web of Science): 1970 to 12 January 2012
Searched 17 January 2012.
Databases=SCI-EXPANDED Timespan=All Years
Lemmatization=On
#31 65 #19 and #30
#30 617,715 #24 not #29
#29 2,436,639 #25 or #26 or #27 or #28
#28 2,376,074 TS=(cat or cats or dog or dogs or animal or animals or rat or rats or hamster or hamster or
feline or ovine or canine or bovine or sheep)
#27 22,447 TS=((energy or oxygen) SAME expenditure)
#26 6,234 TS=(metabolic SAME cost)
#25 44,234 TS=((energy or oxygen) SAME cost)
#24 691,819 #20 or #21 or #22 or #23
#23 44,677 TS=(budget*)
#22 798 TS=(value NEAR/1 money)
#21 13,786 TS=(expenditure* not energy)
#20 648,500 TS=(economic* or cost or costs or costly or costing or price or prices or pricing or
pharmacoeconomic*)
#19 5,706 #5 or #17 or #18
#18 99 #11 and #17
#17 3,756 #12 or #13 or #16
#16 684 #14 and #15
#15 34,726 TS= ((bile or biliary) SAME (acid* or salt*))
#14 8,188 TS= (malabsorb* or mal-absorb* or malabsorp* or mal-absorp*)
#13 23 TS= primary bile acid diarrh?ea*
#12 3,094 TS= (BAM or I-BAM or IBAM or PBAM)
#11 24,351 #6 or #7 or #8 or #9 or #10NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61#10 18,388 TS= (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or algeldraat or
algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu cap or alu-cap or
alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina trihydrate or aluminium
hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum hydrate or aluminum hydroxide
gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or amphogel or amphojel or amphotabs
or antiphos or bayerite or chefarox or collumina or collumol or colodral or colugel or creamalin or cremorin
or diplogel or f 1000 or f1000 or fluagel or gastracol or gastrosetarderm or gelumina or hoemigel or
hycolal or hydracoll or hydrated alumina or hydrolum or hydronal or hydroxal or lactalumina or neutroxide
or palliacol or pepsamar or ulcerin-p or vanogel)
#9 215 TS= (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or
gt31-104 or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7)
#8 2,190 TS= (colestyramine* or chol-less or choles or cholesthexal or cholestyramin or cholestyramine* or
cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or colestyramin or cuemid* or
lipocol-merz or lismol or locholest or prevalite or quantalan or questran* or resincoles-tiramina or
resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6 or 58391-37-0 or mk 135 or
mk135)
#7 652 TS= (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-epichlorohydrin-
copolymer or epichlorohydrin-copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a
or u-26597-a or u-26597a or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6)
#6 3,356 TS= ((bile SAME acid SAME sequestra*) or BAS)
#5 2,055 #1 or #2 or #3 or #4
#4 1,185 TS= (selenium SAME "75")
#3 47 TS= (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or selenium
radioisotopes or tauroselenocholic acid)
#2 1,156 TS= (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75)
#1 2 TS=(tauroselcholic or selenohomocholyltaurine or 75018-71-2)EconLit (EBSCOhost) 1886 to 3 February 2012
Searched 3 February 2012.
Search modes – Boolean/Phrase:
S17 S5 or S11 or S16 (22)
S16 S12 or S13 or S14 or S1 (19)
S15 TX(malabsorb* or mal-absorb* or malabsorp* or mal-absorp*) (0)
S14 (bile N4 acid*) or (biliary N4 acid*) or (bile N4 salt*) (0)
S13 TX(BAM or I-BAM or IBAM or PBAM) (19)
S12 TX(primary N4 bile acid N4 diarrhoe*) or (primary N4 bile acid N4 diarrhe*) or
(primary N4 bile acid N4 diarrea*) (0)
S11 S6 or S7 or S8 or S9 or S10 (3)
S10 TX(“aluminum hydroxide” or Ageldrate or “al u crème” or alcid or aldrox or algeldraat or algeldrate
or algelox or alhydrogel or alkagel or alocol or alokreem or “alterna gel” or “alu cap” or alu-cap or alu-tab
or alucol or aludrox or alugelibys or alumigel or “alumina gel” or “alumina trihydrate” or “aluminium
hydroxide” or aluminoid or aluminox or “aluminum hydrate” or “aluminum hydroxide gel” or “aluminum
oxide trihydrate” or “aluminum trihydrate” or alutab or amphogel or amphojel or amphotabs or antiphos
or bayerite or chefarox or collumina or collumol or colodral or colugel or creamalin or cremorin or diplogel143
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144or f1000 or fluagel or gastracol or gastrosetarderm or gelumina or hoemigel or hycolal or hydracoll or
hydrated alumina or hydrolum or hydronal or hydroxal or lactalumina or neutroxide or palliacol or
pepsamar or ulcerin-p or vanogel or 21645-51-2 or brasivil or rocgel or alugel or hydrated alumina or
basalgel or dialume or nephrox) (0)
S9 TX(colestyramine or chol-less or choles or cholesthexal or cholestyramin or cholestyramine or cholybar
or cholytar or colestepril or colestiramina or colestran or colestrol or colestyramin or cuemid or lipocol-merz
or lismol or locholest or prevalite or quantalan or questran or resincoles-tiramina or resincolestiramina or
vasosan-p-granulat or vasosan-s-granulat or 11041-12-6 or 58391-37-0) (3)
S8 TX(Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or gt31-104
or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7) (0)
S7 TX(Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-epichlorohydrin-copolymer
or diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or epichlorohydrin-copolymer-with-
diethylenetriamine or flavored-colestid or lestid or u-26,597a or u-26597-a or u-26597a or u-26,597a or
25085-17-0 or 37296-80-3 or 50925-79-6)(0)
S6 TX(bile N4 acid N4 sequestra*) (0)
S5 S1 or S2 or S3 or S4 (0)
S4 TX(selenium N4 "75") (0)
S3 TX(23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or selenium
radioisotopes or tauroselenocholic acid or 75Se-homotaurocholate ) (0)
S2 TX(SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75) (0)
S1 TX(tauroselcholic or selenohomocholyltaurine or 75018-71-2) (0)Subset search of clinical effectiveness EndNote Library
Searched 31 January 2012.
An EndNote Library containing 4010 references, identified by the search undertaken for the evidence of
effectiveness review, was searched to identify potentially relevant cost/economic studies. After
deduplication 121 records were identified.
The following terms were entered line by line (_indicates a space):
#1 _cost_ (46)
#2 _costs_ (39)
#3 _cost-_ (0)
#4 _costly (8)
#5 _costing (0)
#6 _econom (40)
#7 _budget (2)
#8 _price (6)
#9 _pricing (2)
#10 _expenditure (27)
#11 value for money. (0)
Total of 121 references were retrieved and scanned for relevance.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Crohn’s + cost/quality of life
The health economists requested a search to identify literature on health-related quality of life and
cost-effectiveness for Crohn’s disease. These searches were conducted to inform the model and were
not intended to be exhaustive.NHS Economic Evaluation Database (NHS EED) (CRD) (internet):
up to 6 January 2012
www.york.ac.uk/inst/crd
Searched 6 January 2012.
1. MeSH DESCRIPTOR crohn disease EXPLODE ALL TREES IN NHSEED 22
2. (((cleron or Crohn*) NEAR disease)) IN NHSEED 40
3. (morbus crohn) IN NHSEED 0
4. (((regional or regionalis or granulomatous) NEAR (enteritis or enterocolitis))) IN NHSEED 0
5. (Ileocolitis) IN NHSEED 0
6. ((ileitis NEAR (terminal or regional))) IN NHSEED 0
7. (colitis granulomatous) IN NHSEED 0
8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 40
NHS EED search retrieved 40 records.MEDLINE (OvidSP): 1946 to week 3 January 2012
Searched 27 January 2012.
1. Crohn Disease/ (26,810)
2. ((cleron or Crohn$) adj3 disease).ti,ab,ot,hw. (32,722)
3. morbus crohn.ti,ab,ot,hw. (769)
4. ((regional or regionalis or granulomatous) adj3 (enteritis or enterocolitis)).ti,ab,ot,hw. (997)
5. Ileocolitis.ti,ab,ot,hw. (344)
6. (ileitis adj3 (terminal or regional)).ti,ab,ot,hw. (536)
7. colitis granulomatous.ti,ab,ot,hw. (6)
8. or/1-7 (33,051)
9. economics/ (26,139)
10. exp "costs and cost analysis"/ (160,362)
11. economics, dental/ (1833)
12. exp "economics, hospital"/ (17,587)
13. economics, medical/ (8423)
14. economics, nursing/ (3853)
15. economics, pharmaceutical/ (2280)
16. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (348,214)
17. (expenditure$ not energy).ti,ab. (14,640)
18. (value adj1 money).ti,ab. (17)
19. budget$.ti,ab. (14,893)
20. or/9-19 (462,563)
21. ((energy or oxygen) adj cost).ti,ab. (2360)
22. (metabolic adj cost).ti,ab. (623)145
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14623. ((energy or oxygen) adj expenditure).ti,ab. (13491)
24. or/21-23 (15,846)
25. 20 not 24 (45,8945)
26. letter.pt. (728,276)
27. editorial.pt. (286,848)
28. historical article.pt. (278,816)
29. or/26-28 (1,280,851)
30. 25 not 29 (434,045)
31. (sf36 or sf 36 or short form 36 or shortform 36).ti,ab. (11,765)
32. (sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirty six or short
form thirtysix or short form thirty six).ti,ab. (1)
33. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab. (868)
34. (euroqol or euro qol or eq5d or eq 5d).ti,ab. (2454)
35. (hql or hrql or hqol or h qol or hrqol or hr qol).ti,ab. (6944)
36. (hye or hyes).ti,ab. (50)
37. health$ year$ equivalent$.ti,ab. (36)
38. (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3).ti,ab. (668)
39. (quality of well being or quality of wellbeing or qwb).ti,ab. (303)
40. (Disability adjusted life year$ or Disability-adjusted life year$ or health adjusted life year$ or health-
adjusted life year$ or years of healthy life or healthy years equivalent or years of potential life lost or
years of health life lost or quality adjusted life year$).ti,ab. (5122)
41. (QALY$ or HRQOL or HRQL or DALY$ or HALY$ or YHL or HYES or YPLL or YHLL).ti,ab. (11,115)
42. (Crohn$ adj3 Quality Of Life).ti,ab,ot,hw. (24)
43. (Gastrointestinal Quality of Life index or Digestive Health Status Instrument).ti,ab,ot,hw. (194)
44. (GIQLI or DHSI).ti,ab,ot,hw. (165)
45. or/31-44 (25,863)
46. 30 or 45 (453,004)
47. animals/ not (animals/ and humans/) (3,554,274)
48. 46 not 47 (427,393)
49. 8 and 48 (587)
50. (2000$ or 2001$ or 2002$ or 2003$ or 2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or
2010$ or 2011$ or 2012$).ed. (8,244,633)
51. 49 and 50 (472)Economics filter:
Centre for Reviews and Dissemination. NHS EED Economics Filter: Medline (Ovid) monthly search. York:
Centre for Reviews and Dissemination; 2010 (cited 28 September 2010). URL: http://www.york.ac.uk/inst/
crd/intertasc/nhs_eed_strategies.html.Patient-Reported Outcome and Quality of Life Instruments
Database (PROQOLID)
www.proqolid.org
Searched 27 January 2012.
Browsed for relevant quality of life instruments to inform MEDLINE search.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Search F: utilities
Cost-Effectiveness Analysis Registry (CEA) (internet): up to 6 February 2012
https://research.tufts-nemc.org/cear4/Home.aspx
Searched 6 February 2012.Terms searched Utility weights
#1 Irritable bowel syndrome 13
#2 IBS 64
#3 BAM 0
#4 Bile acid malabsorption 0
#5 Crohn 69
#6 diarrhea 29
#7 diarrhoea 18
Total 193147
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DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Appendix 2 Quality assessment checklistsAppendix 2a: Study specific guide to completion of QUADAS-2The version of QUADAS-2 used in this assesses only applicability for the ‘patient selection’ domain, as it
was considered that the inclusion criteria matched the review question for the ‘index test’ and ‘reference
standard’ domains. All risk of bias domains are included.
Before starting the risk of bias assessment, we considered the relevance of each signalling question to our
review, as well as the potential need for additional questions. Further criteria were then defined, as
needed, to ensure consistent application of signalling questions and to help in the judgement of the risk of
bias. Many signalling questions were not further specified and the answer was judged to be ‘yes’ if it was
clearly reported in the study. If the answer to a signalling question was not clearly reported the question
was judged as ‘unclear’ unless specified differently. ‘No’ was answered if it was clear from the reporting
that an aspect was not fulfilled. Details of the assessment criteria used are reported below.Domain 1: patient selection
Risk of bias
Question 1: Was a consecutive or random sample of patients enrolled?
l ‘Yes’→ low risk of bias.
l ‘Unclear’→ unclear risk of bias.
l ‘No’→ high risk of bias.
Question 2: Was a case–control design avoided?
l ‘Yes’→ low risk of bias.
l ‘Unclear’→ unclear risk of bias.
l ‘No’→ high risk of bias.
Question 3: Did the study avoid inappropriate exclusions?
l ‘Yes’ or < 10% of patients excluded→ low risk of bias.
l ‘Unclear’→ unclear risk of bias.
l ‘No’ or≥ 10% of patients excluded→ high risk of bias.Concerns regarding applicabilityl If≥ 90% of included patients were people with chronic diarrhoea with unknown cause and symptoms
suggestive of functional disease→ low concern.
l If≥ 90% of included patients were people with Crohn’s disease and chronic diarrhoea with unknown
cause (before resection of terminal ileum)→ low concern.
l If≤ 90% included patients were people with chronic diarrhoea with unknown cause or people with
Crohn’s disease with chronic diarrhoea with known cause or with unknown cause after resection of
terminal ileum→ high concern.149
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150Domain 2: index test
Risk of bias
Question 1: Were the index test results interpreted without knowledge of the results of the
reference standard?
Question 2: Did the study pre-specify the threshold for a positive result?
The same criteria applied to each of the two signalling questions:
l ‘Yes’→ low risk of bias.
l ‘Unclear’→ unclear risk of bias.
l ‘No’→ high risk of bias.Domain 3: reference standard
Risk of bias
Question 1: Is the reference standard likely to correctly classify the target condition?
l ‘Yes’ if≥ 90% of test results were confirmed using the reference standard (response to treatment,
where response is defined as no symptoms of diarrhoea)→ low risk of bias.
l ‘Unclear’→ unclear risk of bias.
l ‘No’ if < 90% of test results were confirmed using the reference standard (response to treatment,
where response is defined as no symptoms of diarrhoea)→ high risk of bias.
Question 2: Were the reference standard results interpreted without knowledge of the results of the
index test?
l ‘Yes’→ low risk of bias.
l ‘Unclear’→ unclear risk of bias.
l ‘No’ → high risk of bias.Domain 4: flow and timing
Question 1: Was response to treatment assessed over an adequate period?
Follow-up had to be≥ 6 months in order to be judged as ‘adequate’.
l ‘No’ but for < 10% of patients or ‘Yes’→ low risk of bias.
l The answer was judged to be ‘unclear’ if the follow-up period was not reported or if it was unclear
what proportion of patients had an inadequate follow-up→ unclear risk of bias.
l ‘No’ for ≥ 10% of patients→ high risk of bias.
Question 2: Did all patients receive a reference standard?
l ‘No’ but for < 10% of patients or ‘Yes’→ low risk of bias.
l ‘Unclear’→ unclear risk of bias.
l ‘No’ for ≥ 10% of patients→ high risk of bias.
Question 3: Were all patients included in the analysis?
l ‘No’ but for < 10% of patients or ‘Yes’→ low risk of bias.
l ‘Unclear’→ unclear risk of bias.
l ‘No’ for ≥ 10% of patients→ high risk of bias.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61The following criteria were used to reach a per-domain judgement of risk of bias:
l If at least one of the signalling questions of a domain had an answer associated with a high risk of bias
the domain was judged to have a high risk of bias.
l If the answer to any of the signalling questions was ‘unclear’ and the answers to the remaining
questions were ‘yes’, the risk of bias was judged to be unclear.
l The answer to all the signalling questions had to be ‘yes’ in order for the domain to be judged as
having a low risk of bias.Appendix 2b: Checklists for the methodological quality
assessment of included effectiveness studies
A. Case–control studiesl Is the case definition explicit?
l Has the disease state of the cases been reliably assessed and validated?
l Were the controls randomly selected from the source of population of the cases?
l Were interventions and other exposures assessed in the same way for cases and controls?
l How was the response rate defined?
l Were the non-response rates and reasons for non-response the same in both groups?
l Is it possible that overmatching has occurred in that cases and controls were matched on factors
related to exposure?
l Was an appropriate statistical analysis used (matched or unmatched)?B. Cohort studiesl Is there sufficient description of the groups and the distribution of prognostic factors?
l Are the groups assembled at a similar point in their disease progression?
l Is the intervention/treatment reliably ascertained?
l Were the groups comparable on all important confounding factors?
l Was there adequate adjustment for the effects of these confounding variables?
l Was a dose–response relationship between intervention and outcome demonstrated?
l Was outcome assessment blind to exposure status?
l Was follow-up long enough for the outcomes to occur?
l What proportion of the cohort was followed-up?
l Were drop-out rates and reasons for drop-out similar across intervention and unexposed groups?C. Other observational studiesl Does the study have a retrospective ‘R’ or prospective ‘P’ study design? (R/P/Unclear)
l Has a clear definition of diarrhoea in the presenting population been given or a validated tool for
assessing chronic diarrhoea been used? (Y/N)
l Does the population include people with known causes of chronic diarrhoea? (Y/N/Unclear)
l Has an adequate description of the SeHCAT test procedures been provided? (Y/N)
l Are the cut-off values used for establishing severity of BAM clearly reported? (Y/N)
l Are the reasons for treating people clearly described (e.g. ‘all with a positive test’)? (Y/N)
l Are data provided for people with a negative SeHCAT test (> 15%)? (Y-all/Y-some/N)
l Is the treatment clearly described, including dose and duration of treatment and follow-up? (Y/N)
l Has an objective measure of response to treatment been provided? (Y/N)151
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DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Appendix 3 Quality assessment: QUADAS-2
resultsCompleted QUADAS-2 assessments for all included studies.
Study ID: Merrick 198539
Domain 1: patient selection
A. Risk of biasDescribe methods of patient selection: prospective study but not clear if a consecutive or random
sample of patients was enrolled. Three patients not treated but < 10%. The study included four groups
of patients:
1. healthy controls
2. small bowel resection
3. diarrhoea after vagotomy
4. chronic diarrhoea due to IBS, coeliac disease, small bowel ischaemia and ‘other’
Data were extracted for the IBS subgroup of group four only©
H
p
ad
PaWas a consecutive or random sample of patients enrolled?
Was a case–control design avoided?Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by t
ealth. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
rovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial rep
dressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University
rk, Southampton SO16 7NS, UK.Unclear
YesDid the study avoid inappropriate exclusions? YesCould the selection of patients have introduced bias? RISK: UNCLEARB. Concerns regarding applicabilityDescribe included patients (prior testing, presentation, intended use of index test and setting):
chronic diarrhoea of non-inflammatory origin: namely, IBS in 43Is there concern that the included patients do not match the
review question?CONCERN: LOW153
he Secretary of State for
professional journals
roduction should be
of Southampton Science
APPENDIX 3
154Domain 2: index test
A. Risk of biasNDescribe how the index test was conducted and interpreted: the process of conducting and
interpreting the index test was described (a tracer dose of less than 100 µg SeHCAT was administered
labelled with 40 kBq (1 µCi) selenium-75. Seven days later the patients reattended and a further whole-
body count was obtained. On each occasion the count rate from the patient was compared with that in
a standard. The percentage of the initial activity retained at 7 days was calculated for both 58Co and 75Se
by comparison with the initial value and the standards. In normal subjects the retention of 75SeHCAT at
7 days is > 15%, while in subjects with ileal disease it is < 8%)
Retention was categorised as follows:
< 8% = BAM positive
> 15%= BAM negative
8 to 15%= equivocal
Data were extracted using two 7-day retention cut-offs for BAM positive of 8% and 15%, i.e. grouping
the patients with an ‘equivocal’ test results with either test negative or test positiveWere the index test results interpreted without knowledge of the results of the
reference standard?
If a threshold was used, was it prespecified?IHR Journals Library www.journalslibrary.nihr.ac.ukYes
YesCould the conduct or interpretation of the index test have
introduced bias?RISK: LOWDomain 3: reference standard
A. Risk of biasDescribe the reference standard and how it was conducted and interpreted: treatment: simple
conservative treatment (cholestyramine) in test-positive and ‘equivocal’ patients. Three patients were not
treated but < 10%. Test-negative patients were followed-up for 12–24 months. The interpretation of
reference standard result was response to treatment, which was not influenced by index testIs the reference standard likely to correctly classify the target condition? YesWere the reference standard results interpreted without knowledge of the results of
the index test?UnclearCould methods used to conduct or interpret the reference standard have
introduced bias?RISK: UNCLEAR
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Domain 4: flow and timing
A. Risk of bias©
H
p
ad
PaDescribe any patients who did not receive the index test or reference standard or who were
excluded from the 2 × 2 table(s): three patients were not treated but < 10%
Describe the time interval and any interventions between index, comparator(s) and reference
standard: follow up of at least 12 months, and in some up to 24 monthsWas response to treatment assessed over an adequate period?Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secre
ealth. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professio
rovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproductio
dressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Sout
rk, Southampton SO16 7NS, UK.YesDid all patients receive a reference standard? NoWere all patients included in the analysis? YesCould the patient flow have introduced bias? RISK: HIGH155
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156Study ID: Sciaretta 198642
Domain 1: patient selection
A. Risk of biasDescribe methods of patient selection: prospective study but not clear if a consecutive or random
sample of patients was enrolled. The study included four groups of patients:
(a) healthy controls
(b) patients with resected pathological distal ileum
(c) patients with intestinal pathology, but normal distal ileum
(d) patients with diarrhoea, but no evidence of intestinal pathology
Data were extracted for group D onlyNWas a consecutive or random sample of patients enrolled?IHR Journals Library www.journalslibrary.nihr.ac.ukUnclearWas a case–control design avoided? YesDid the study avoid inappropriate exclusions? YesCould the selection of patients have introduced bias? RISK: UNCLEARB. Concerns regarding applicabilityDescribe included patients (prior testing, presentation, intended use of index test and setting):
of 13 patients from group D, three patients had cholecystomy with onset of diarrhoea in 2. Thus, < 90%
people were with unknown cause of diarrhoeaIs there concern that the included patients do not match the
review question?CONCERN: HIGHDomain 2: index test
A. Risk of biasDescribe how the index test was conducted and interpreted: the test was described, 370 kBq
(10 µCi) of 75SeHCAT (provided by Amersham Radiochemical Centre) in capsule form,
containing < 100 µg of active ingredient absorbed on inert carrier, was orally administered following the
technique of Thaysen et al.89
The threshold was specified as 3-day retention (see figure 2 in paper); cut-off: 34% (data obtained from
the activity vs. time curve), which is according to the authors equivalent to a 7-day retention cut-off of 5%Were the index test results interpreted without knowledge of the results of the
reference standard? YesIf a threshold was used, was it pre-specified? NoCould the conduct or interpretation of the index test have
introduced bias?RISK: HIGH
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Domain 3: reference standard
A. Risk of bias©
H
p
ad
PaDescribe the reference standard and how it was conducted and interpreted: treatment given was
cholestyramine. All 13 patients were treatedIs the reference standard likely to correctly classify the target condition?Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by t
ealth. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
rovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial rep
dressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University
rk, Southampton SO16 7NS, UK.YesWere the reference standard results interpreted without knowledge of the
results of the index test? UnclearCould methods used to conduct or interpret the reference standard
have introduced bias?RISK: UNCLEARDomain 4: flow and timing
A. Risk of biasDescribe any patients who did not receive the index test, comparator(s) and/or reference
standard or who were excluded from the 2 × 2 table(s): all 13 treated
Describe the time interval and any interventions between index, comparator(s) and reference
standard: follow-up not reportedWas response to treatment assessed over an adequate period? UnclearDid all patients receive a reference standard? YesWere all patients included in the analysis? YesCould the patient flow have introduced bias? RISK: UNCLEAR157
he Secretary of State for
professional journals
roduction should be
of Southampton Science
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158Study ID: Sciaretta 198743
Domain 1: patient selection
A. Risk of biasNDescribe methods of patient selection: not clear if the study was prospective or retrospective
The study included healthy volunteers and patients with IBS or cholecystectomy. Data were only extracted
for IBS/cholecystectomy patients
There may be some overlap in populations in the two Sciaretta papersWas a consecutive or random sample of patients enrolled?
Was a case–control design avoided?IHR Journals Library www.journalslibrary.nihr.ac.ukUnclear
YesDid the study avoid inappropriate exclusions? YesCould the selection of patients have introduced bias? RISK: UNCLEARB. Concerns regarding applicabilityDescribe included patients (prior testing, presentation, intended use of index test and setting):
8/46 (> 10%) patients had cholecystectomyIs there concern that the included patients do not match the
review question?CONCERN: HIGHDomain 2: index test
A. Risk of biasDescribe how the index test was conducted and interpreted: the index test was described
(the 75SeHCAT test was carried out in all patients using the method we described elsewhere)
The threshold was specified: 7-day retention; cut-off: ≤ 8%Were the index test results interpreted without knowledge of the results of the
reference standard?YesIf a threshold was used, was it prespecified? YesCould the conduct or interpretation of the index test have introduced bias? RISK: LOW
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Domain 3: reference standard
A. Risk of bias©
H
p
ad
PaDescribe the reference standard and how it was conducted and interpreted: treatment given was
2–8 g cholestyramine, twice daily for at least 10 days. When cholestyramine was not effective in relieving
symptoms, therapy was discontinued. Where cholestyramine was effective, therapy was stopped for 7
days and started again if symptoms returned. A positive test was defined as symptom resolution on
treatment and return of symptoms when treatment was discontinued
Stool frequency was taken as the average number of bowel actions per day over a 1-week period, and
was recorded before and after cholestyramine administration
All patients received trial of treatmentIs the reference standard likely to correctly classify the target condition?Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secre
ealth. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professio
rovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproductio
dressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of South
rk, Southampton SO16 7NS, UK.YesWere the reference standard results interpreted without knowledge of the results
of the index test? UnclearCould methods used to conduct or interpret the reference standard
have introduced bias?RISK: LOWDomain 4: flow and timing
A. Risk of biasDescribe any patients who did not receive the index test, comparator(s) and/or reference
standard or who were excluded from the 2 × 2 table(s): all patients were treated
Describe the time interval and any interventions between index, comparator(s) and reference
standard: follow-up not reported, but the trial of treatment includes a description of withdrawal of
treatment to test for reappearance of symptoms in responsive patientsWas response to treatment assessed over an adequate period? YesDid all patients receive a reference standard? YesWere all patients included in the analysis? YesCould the patient flow have introduced bias? RISK: LOW159
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Details of the methods and interpretation of the index test (assessed technology) and reference standardused in included studies.161
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The following is a list of studies excluded at the full-paper screening stage of the review, along with thereasons for their exclusion (n = 141), along with the studies that could not be found (n = 3).
The reasons for study exclusion are coded as follows:
Population – the study did not consider the relevant populations for this assessment: people presenting
with chronic diarrhoea with unknown cause and symptoms suggestive of functional disease or people with
Crohn’s disease and chronic diarrhoea with unknown cause (i.e. before resection of the terminal ileum).
Index test –the study did not assess the effectiveness of SeHCAT.
Reference standard – for test accuracy studies, the study did not use an acceptable reference standard.
Outcomes – the study did not report any of the outcomes specified in Chapter 3, OR, for DTA studies,
insufficient data were reported to allow the construction of 2 × 2 contingency tables (numbers of TP, FN,
FP and TN test results).
Study design – the study design was not one of those specified in Chapter 3, Inclusion and exclusion
criteria, OR the study included < 10 participants in the relevant patient groups.
Duplicate – the study was a duplicate publication.
Authors contacted – the study did not report sufficient information for inclusion assessment and authors
were contacted for additional information, but no response was received.
1. Allan JG, Russell RI. Proceedings: double-blind controlled trial of cholestyramine in the treatment of
post-vagotomy diarrhoea. Gut 1975;16:830. Population.
2. Allan JG, Russell RI. Cholestyramine in treatment of postvagotomy diarrhoea: double-blind controlled
trial. Br Med J 1977;1:674–6. Population.
3. Bajor A, Kilander A, Fae A, Galman C, Jonsson O, Ohman L, et al. Normal or increased bile acid uptake
in isolated mucosa from patients with bile acid malabsorption. [Erratum appears in Eur J Gastroenterol
Hepatol 2007;19:185]. Eur J Gastroenterol Hepatol 2006;18:397–403. Outcomes.
4. Bajor A, Rudling M, Ung KA, Wallin J, Simren M. Effects of the bile acid load to the intestine on IBS
symptoms. Paper presented at 2010 Joint International Neurogastroenterology and Motility Meeting,
26–29 August 2010, Boston, MA. Neurogastroenterol Motil 2010;22:7. Study design.
5. Bajor A, Rudling M, Ung KA, Wallin J, Simren M. Impact of bile acids on IBS symptoms and the effects
of resin treatment. Paper presented at Digestive Disease Week (DDW) 2011, 7–10 May 2011, Chicago,
IL. Gastroenterology 2011;140(Suppl. 1):S3. Study design.
6. Bajor A, Wallin J, Strid H, Abrahamsson H, Ung K-A, Simren M. Overweight, high age and the presence
of loose and frequent stools are suggestive of bile acid malabsorption in patients with the irritable
bowel syndrome (IBS). [AGA Institute Abstracts: W1201]. Gastroenterology 2007;32:A682. Outcomes.
7. Balzer K, Breuer N, Quebe-Fehling E. [Postprandial serum bile acid level and 75SeHCAT retention
in diagnosis of bile acid malabsorption syndrome. a comparative study.] Med Klin
1993;88(Suppl. 1):23–8. Population.185
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9. Balzer K, Goebell H. Bile-acid loss syndrome: an often overlooked diagnosis: experiences with the
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test (SeHCAT test) in diagnosis of diarrhoea.] Med Klin 1995;90:27–32. Study design.
11. Benson GM, Hickey DMB. Bile acid sequestrants. Expert Opin Investig Drugs 1994;3:493–500.
Study design.
12. Brown SR, Baraza W. Chromoscopy versus conventional endoscopy for the detection of polyps in the
colon and rectum. Cochrane Database Syst Rev 2010;10:CD006439. Study design.
13. Bruck R, Chamovitz DL, Federico C, Bar-Meir S. Does the 75SeHCAT test diagnose bile acid
malabsorption? J Clin Gastroenterol 1991;13:115–16. Study design.
14. Brydon G, Culbert P, Lacucci M, Ghosh S. An evaluation of the clinical use of serum 7 alpha
hydroxycholestenone as a test of bile acid malabsorption [M1071]. Paper presented at
Digestive Disease Week (DDW) 2010, 1–6 May 2010, New Orleans, LA. Gastroenterology
2010;138(5 Suppl. 1):S325. Index test.
15. Brydon WG, Culbert P, Kingstone K, Jarvie A, Iacucci M, Tenhage M, et al. An evaluation of the use of
serum 7-alpha-hydroxycholestenone as a diagnostic test of bile acid malabsorption causing watery
diarrhea. Can J Gastroenterol 2011;25:319–23. Outcomes.
16. Brydon WG, Nyhlin H, Eastwood MA, Merrick MV. Serum 7 alpha-hydroxy-4-cholesten-3-one and
selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced
diarrhoea. Eur J Gastroenterol Hepatol 1996;8:117–23. Outcomes.
17. Camilleri M, Nadeau A, Tremaine WJ, Lamsam J, Burton D, Odunsi S, et al. Measurement of serum
7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in
health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass
spectrometry. Neurogastroenterol Motil 2009;21:734–e43. Index test.
18. Campbell S, Chandra N, Lisa G, Anthony M. Serum 7alpha - Hydroxycholestenone in patients with
idiopathic bile salt malabsorption: a detailed comparison with conventional SeHCAT testing.
Gastroenterology 2006;130:A319. Outcomes.
19. Capron JP, Dupas JL, Boulard A. [Effect of cholestyramine in the treatment of diarrhea resistant to
common drugs.] Med Chir Dig 1977;6:165–6. Study design.
20. Caspary WF. [Diagnosis of bile acid malabsorption: evaluation of the new 75SeHCAT-test.] Inn Med
1986;13:248–51. Study design.
21. Centi-Colella A, Di Rocco E, Liberatore MF. Retention of 75Se-homotaurocholic acid measured by a
low-background whole-body counter. J Nucl Med Allied Sci 1983;27:309–12. Population.
22. Chaparro M, Gisbert JP, del Campo L, Cantero J, Mate J. Accuracy of computed tomographic
colonography for the detection of polyps and colorectal tumors: a systematic review and
meta-analysis. Digestion 2009;80:1–17. Study design.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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enterohepatic bile-salt circulation: a preliminary-study in normal subjects: Paper presented at
Winter Meeting of the Surgical Research Society, 6–7 January 1983, Cambridge, UK. Br J Surg
1983;70:306. Population.
24. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia
in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006;2:CD000279.
Study design.
25. Dalhez H, Van Den Berg JWO, Van Blankenstein M, Meerwaldt JH. New method for the
determination of bile acid turnover using 75-Se-homocholic acid taurine. Eur J Nucl Med
1982;7:269–71. Population.
26. Danielsson A, Nyhlin H, Suhr O. [SeHCAT–a gamma-radiating bile acid isotope for the diagnosis of
dysfunction of the terminal ileum.] Lakartidningen 1987;84:1266–70. Study design.
27. D’Arienzo A, Maurelli L, Di Siervi P, Panarese A, Giannattasio F, Scuotto A, et al. [The 75-seleno-
homocholic acid-taurine test (SeHCAT): a useful method for detecting the idiopathic malabsorption of
bile salts in chronic functional diarrhea]. Clin Ter 1989;130:11–16. Study design.
28. Darienzo A, Scuotto A, Maurelli L, Disiervi P, Squame G, Mazzacca G. Comparison between SeHCAT
and fecal recovery of C-14 after oral-administration of cholylglycine-C-14 in the diagnosis of bile-salt
malabsorption-syndrome. Ital J Gastroenterol 1986;18:50. Outcomes.
29. Davidson MH. A systematic review of bile acid sequestrant therapy in children with familial
hypercholesterolemia. J Clin Lipidol 2011;5:76–81. Population.
30. De Lima Ramos PA, Martin-Comin J, Xiol X, Roca M, Castell M, Cervantes X, et al. [Diarrhoeic
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measurement.] Rev Esp Med Nucl 1996;15:21–5. Population.
31. Del Vecchio Blanco G, Pallone F. [Malabsorbtion syndrome and chronic diarrhoea.] Giornale Italiano di
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32. Dionisio PM, Gurudu SR, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, et al. Capsule endoscopy
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Crohn’s disease: a meta-analysis. Am J Gastroenterol 2010;105:1240–8. Study design.
33. Dumaswala R, Heubi JE. Differential effect of cholestyramine (CHOL) on ileal and hepatic bile-acid (BA)
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34. Duncombe VM, Bolin TD, Davis AE. Double-blind trial of cholestyramine in post-vagotomy diarrhoea.
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Hepatol 1992;4:317–21. Outcomes.
36. Fagan EA, Chadwick VS, McLean Baird I. SeHCAT absorption: a simple test of ileal dysfunction.
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British Society of Gastroenterology guidelines for the investigation of chronic diarrhoea [report].
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5. Zaniboni MG, Fagioli G, Lambertini A, Romeo N, Vicini G. [Use of the 75-SeHCAT (23-seleno-25-
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© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.

DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Appendix 7 National Institute for Health and Care
Excellence guidance relevant to the treatment of
chronic diarrhoeaNone.
Other relevant guidelines:l National Institute for Health and Care Excellence. Irritable bowel syndrome in adults: diagnosis and
management of irritable bowel syndrome in primary care. February 2008. URL: http://guidance.nice.
org.uk/CG61
l Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of
inflammatory bowel disease in adults. Gut 2011;60:571–607.199
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Systematic Reviews and Meta-Analyses checklistSection/topic # Checklist item Reported on page #
Title
Title 1 Identify the report as a systematic review, meta-analysis,
or both
Front page
Abstract
Structured
summary
2 Provide a structured summary including, as applicable:
background; objectives; data sources; study eligibility criteria,
participants, and interventions; study appraisal and synthesis
methods; results; limitations; conclusions and implications of
key findings; systematic review registration number
Scientific summary,
pp. xiii–xviii
Introduction
Rationale 3 Describe the rationale for the review in the context of what is
already known
Chapter 1, pp. 1–5
Objectives 4 Provide an explicit statement of questions being addressed with
reference to participants, interventions, comparisons,
outcomes, and study design (PICOS)
Chapter 2, p. 7
Methods
Protocol and
registration
5 Indicate if a review protocol exists, if and where it can be
accessed (e.g. Web address), and, if available, provide
registration information including registration number
PROSPERO
CRD42012001911; www.
crd.york.ac.uk/prospero
Eligibility
criteria
6 Specify study characteristics (e.g. PICOS, length of follow-up)
and report characteristics (e.g. years considered, language,
publication status) used as criteria for eligibility, giving rationale
Chapter 3, pp. 9–10
Information
sources
7 Describe all information sources (e.g. databases with dates of
coverage, contact with study authors to identify additional
studies) in the search and date last searched
Chapter 3, pp. 10–12,
Figure 3
Search 8 Present full electronic search strategy for at least one database,
including any limits used, such that it could be repeated
Appendix 1
Study selection 9 State the process for selecting studies (i.e. screening, eligibility,
included in systematic review, and, if applicable, included in
the meta-analysis)
Chapter 3, p. 11
Data collection
process
10 Describe method of data extraction from reports (e.g. piloted
forms, independently, in duplicate) and any processes for
obtaining and confirming data from investigators
Chapter 3, p. 11
Data items 11 List and define all variables for which data were sought (e.g.
PICOS, funding sources) and any assumptions and
simplifications made
Chapter 3, p. 9–10
Risk of bias in
individual
studies
12 Describe methods used for assessing risk of bias of individual
studies (including specification of whether this was done at the
study or outcome level), and how this information is to be used
in any data synthesis
Chapter 3, pp. 11–14
Summary
measures
13 State the principal summary measures (e.g. risk ratio, difference
in means)
Chapter 3, pp. 13–15
Synthesis of
results
14 Describe the methods of handling data and combining results
of studies, if done, including measures of consistency (e.g. I2)
for each meta-analysis
Chapter 3, pp. 13–15
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Section/topic # Checklist item Reported on page #
Risk of bias
across studies
15 Specify any assessment of risk of bias that may affect the
cumulative evidence (e.g. publication bias, selective reporting
within studies)
NA
Additional
analyses
16 Describe methods of additional analyses (e.g. sensitivity or
subgroup analyses, meta-regression), if done, indicating which
were pre-specified
NA
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and
included in the review, with reasons for exclusions at each
stage, ideally with a flow diagram
Chapter 3, pp. 15–16,
Figure 4, Appendix 5 and 6
Study
characteristics
18 For each study, present characteristics for which data were
extracted (e.g. study size, PICOS, follow-up period) and provide
the citations
Chapter 3, pp. 17–32,
Tables 2 and 6, Appendix 4
Risk of bias
within studies
19 Present data on risk of bias of each study and, if available, any
outcome level assessment (see item 12)
Chapter 3, pp. 26–28,
Table 3, Appendix 2 and 3
Chapter 3, pp. 30–33,
Tables 5 and 7
Chapter 3, pp. 40–41,
Table 12
Results of
individual
studies
20 For all outcomes considered (benefits or harms), present, for
each study: (a) simple summary data for each intervention
group (b) effect estimates and confidence intervals, ideally with
a forest plot
Chapter 3, p. 26
Chapter 3, pp. 26–28,
Table 4
Chapter 3, p. 28
Chapter 3, pp. 28–40,
Tables 6, 8 and 9
Chapter 3, pp. 40–41,
Table 13
Synthesis of
results
21 Present results of each meta-analysis done, including
confidence intervals and measures of consistency
Chapter 3, pp. 41–43
Risk of bias
across studies
22 Present results of any assessment of risk of bias across studies
(see Item 15)
NA
Additional
analysis
23 Give results of additional analyses, if done (e.g. sensitivity or
subgroup analyses, meta-regression [see Item 16])
NA
Discussion
Summary of
evidence
24 Summarize the main findings including the strength of
evidence for each main outcome; consider their relevance to
key groups (e.g. healthcare providers, users, and policy makers)
Chapter 5, pp. 99–101
Limitations 25 Discuss limitations at study and outcome level (e.g. risk of bias),
and at review-level (e.g. incomplete retrieval of identified
research, reporting bias)
Chapter 5, pp.102–103
Chapter 5, p.104–106
Conclusions 26 Provide a general interpretation of the results in the context of
other evidence, and implications for future research
Chapter 6, pp.107–108
Funding
Funding 27 Describe sources of funding for the systematic review and
other support (e.g. supply of data); role of funders for the
systematic review
p. xviii
NA, not applicable.
APPENDIX 8
202
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Appendix 9 Questionnaire203
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
APPENDIX 9
204NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61205
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
APPENDIX 9
206NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61207
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
APPENDIX 9
208NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61209
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
APPENDIX 9
210NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61211
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
APPENDIX 9
212NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Appendix 10 Details on estimation medication
costs for IBS-D and diarrhoea in Crohn’s patients
without ileal resection213
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TA
B
LE
71
R
es
p
o
n
se
s
o
f
ex
p
er
ts
to
q
u
es
ti
o
n
o
f
w
h
ic
h
d
ru
g
s
ar
e
g
iv
en
to
p
at
ie
n
ts
d
ia
g
n
o
se
d
as
IB
S-
D
Ex
p
er
t
D
ru
g
Pe
r
ce
n
t
o
f
p
at
ie
n
ts
(l
o
w
es
t–
h
ig
h
es
t)
D
o
sa
g
e/
fr
eq
u
en
cy
To
ta
l
d
o
sa
g
e
p
er
d
ay
(e
xp
er
t)
D
o
sa
g
e
p
er
d
ay
(m
o
d
el
)
Pr
ic
e
p
er
u
n
it
(£
)
C
o
st
s
p
er
d
ay
(£
)
W
ei
g
h
te
d
co
st
p
er
d
ay
(l
o
w
es
t–
h
ig
h
es
t)
(£
)
A
Lo
pe
ra
m
id
e
0.
2
(0
.1
–
0.
25
)
2–
4
m
g
t.
i.d
.
6–
12
m
g
9
m
g
0.
03
pe
r
2
m
g
0.
13
5
0.
03
(0
.0
1–
0.
03
)
A
Q
ue
st
ra
n®
(B
ris
to
l-M
ye
rs
Sq
ui
bb
)
0.
55
(0
.4
–
0.
8)
4–
8
g
O
D
–
t.i
.d
.
4–
24
m
g
14
m
g
0.
21
pe
r
4
m
g
0.
73
5
0.
40
(0
.3
–
0.
6)
A
A
nt
id
ep
re
ss
an
t
(a
ss
um
e
TC
A
)
0.
2
(0
.1
5–
0.
25
Lo
w
es
t
re
co
m
m
en
de
d
do
se
0.
06
0.
01
(0
.0
1–
0.
02
)
A
To
ta
l
0.
45
(0
.3
2–
0.
64
)
B
Lo
pe
ra
m
id
e
0.
9
(0
.6
–
1)
2–
16
m
g
2–
16
m
g
9
m
g
0.
03
pe
r
2
m
g
0.
13
5
0.
12
(0
.0
8–
0.
14
)
B
C
od
ei
ne
ph
os
ph
at
e
0.
25
(0
.0
5–
0.
4)
30
–
60
m
g
30
–
60
m
g
45
m
g
0.
04
pe
r
15
m
g
0.
12
0.
03
(0
.0
1–
0.
05
)
B
C
ol
es
tr
yr
am
in
e
0.
1
(0
–
0.
4)
2–
12
g
2–
12
g
7
m
g
0.
21
pe
r
4
m
g
0.
36
8
0.
04
(0
–
0.
15
)
B
A
m
itr
ip
ty
lin
e
0.
05
(0
–
0.
5)
10
–
30
m
g
10
–
30
m
g
20
m
g
0.
03
pe
r
10
m
g
0.
06
0.
00
(0
–
0.
01
)
B
To
ta
l
0.
19
(0
.0
9–
0.
34
)
C
Lo
pe
ra
m
id
e
0.
9
(0
.8
–
1)
2
m
g
A
s
ne
ed
ed
(a
ss
um
e
2/
3
of
th
e
tim
e)
66
.7
%
×
2
m
g
0.
03
pe
r
2
m
g
0.
02
0
0.
02
(0
.0
2–
0.
02
)
C
C
od
ei
ne
ph
os
ph
at
e
0.
3
(0
–
0.
4)
30
–
60
m
g
A
s
ne
ed
ed
(a
ss
um
e
2/
3
of
th
e
tim
e)
66
.7
%
×
45
m
g
0.
04
pe
r
15
m
g
0.
08
0
0.
02
(0
–
0.
03
)
C
C
ho
le
st
yr
am
in
e
0.
3
(0
–
0.
5)
4
m
g
q.
i.d
.
A
s
ne
ed
ed
(a
ss
um
e
2/
3
of
th
e
tim
e)
66
.7
%
×
16
m
g
0.
21
pe
r
4
m
g
0.
56
0
0.
17
(0
–
0.
3)
C
M
eb
ev
er
in
e
0.
3
(0
–
0.
5)
10
0
m
g
t.
i.d
.
A
s
ne
ed
ed
(a
ss
um
e
2/
3
of
th
e
tim
e)
66
.7
%
×
30
0
m
g
0.
03
7
pe
r
10
0
m
g
0.
07
4
0.
02
(0
–
0.
04
)
C
To
ta
l
0.
23
(0
.0
2–
0.
37
)
D
O
pi
at
e
(a
ss
um
e
lo
pe
ra
m
id
e)
0.
75
(0
.7
–
0.
9)
A
ss
um
e
av
er
ag
e
A
an
d
B
9
m
g
0.
03
pe
r
2
m
g
0.
13
5
0.
10
(0
.0
9–
0.
12
)
APPENDIX 10
214
NIHR Journals Library www.journalslibrary.nihr.ac.uk
p
er
t
D
ru
g
Pe
r
ce
n
t
o
f
p
at
ie
n
ts
(l
o
w
es
t–
h
ig
h
es
t)
D
o
sa
g
e/
fr
eq
u
en
cy
To
ta
ld
o
sa
g
e
p
er
d
ay
(e
xp
er
t)
D
o
sa
g
e
p
er
d
ay
(m
o
d
el
)
Pr
ic
e
p
er
u
n
it
(£
)
C
o
st
s
p
er
d
ay
(£
)
W
ei
g
h
te
d
co
st
p
er
d
ay
(l
o
w
es
t–
h
ig
h
es
t)
(£
)
C
ho
le
st
yr
am
in
e
0.
15
(0
–
0.
3)
A
ss
um
e
av
er
ag
e
A
an
d
B
12
m
g
0.
21
pe
r
4
m
g
0.
63
0.
09
(0
–
0.
19
)
To
ta
l
0.
20
(0
.0
9–
0.
31
)
A
nt
is
pa
sm
od
ic
(a
ss
um
e
m
eb
ev
er
in
e)
0.
8
(0
.6
–
0.
9)
A
ss
um
e
10
0
m
g
t.
i.d
.
30
0
m
g
30
0
m
g
0.
03
7
pe
r
10
0
m
g
0.
11
1
0.
09
(0
.0
7–
0.
1)
SS
RI
0.
1
(0
.0
5–
0.
2)
O
nc
e
pe
r
da
y
A
ss
um
e
sa
m
e
as
B
0.
03
pe
r
10
m
g
0.
06
0.
01
(0
–
0.
01
)
TC
A
0.
2
(0
.1
–
0.
4)
Ev
er
y
ni
gh
t
A
ss
um
e
sa
m
e
as
A
0.
03
pe
r
10
m
g
0.
06
0.
01
(0
.0
1–
0.
02
)
A
nt
i-d
ia
rr
ho
ea
l
(a
ss
um
e
lo
pe
ra
m
id
e)
0.
15
(0
.1
–
0.
2)
A
s
ne
ed
ed
(a
ve
ra
ge
on
e
pe
r
da
y)
2
m
g
0.
03
pe
r
2
m
g
0.
03
0.
00
(0
–
0.
01
)
To
ta
l
0.
11
(0
.0
8–
0.
14
)
Lo
pe
ra
m
id
e
0.
75
(0
.5
–
0.
9)
1–
8
m
g
1–
8
m
g
4.
5
m
g
0.
03
pe
r
2
m
g
0.
06
8
0.
05
(0
.0
3–
0.
06
)
C
od
ei
ne
ph
os
ph
at
e
0.
25
(0
.1
–
0.
4)
30
–
12
0
m
g
30
–
12
0
m
g
75
m
g
0.
04
pe
r
15
m
g
0.
2
0.
05
(0
.0
2–
0.
08
)
TC
A
0.
5
(0
.2
5–
0.
75
)
A
ss
um
e
sa
m
e
as
A
0.
03
pe
r
10
m
g
0.
06
0.
03
(0
.0
2–
0.
05
)
Q
ue
st
ra
n
®
0.
25
(0
.2
5–
0.
75
)
1–
2
sa
ch
et
s
2
×
pe
r
da
y
8–
16
m
g
12
m
g
0.
21
pe
r
4
m
g
0.
63
0.
16
(0
.0
6–
0.
25
)
To
ta
l
0.
29
(0
.1
3–
0.
44
)
Lo
pe
ra
m
id
e
1
(0
.7
5–
1)
2–
8
m
g
2–
8
m
g
5
m
g
0.
03
pe
r
2
m
g
0.
07
5
0.
08
(0
.0
6–
0.
08
)
To
ta
l
0.
08
(0
.0
6–
0.
08
)
,
on
ce
a
da
y;
q.
i.d
.,
qu
at
er
in
di
e
(f
ou
r
tim
es
a
da
y)
;
t.
i.d
.,
te
r
in
di
e
(t
hr
ee
tim
es
a
da
y)
.
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Ex D D E E E E E F F F F F G G O
D
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.215
TA
B
LE
72
R
es
p
o
n
se
s
o
f
ex
p
er
ts
to
q
u
es
ti
o
n
o
f
w
h
ic
h
d
ru
g
s
ar
e
g
iv
en
to
p
at
ie
n
ts
w
it
h
C
ro
h
n
’s
w
it
h
o
u
t
ile
al
re
se
ct
io
n
w
it
h
ch
ro
n
ic
d
ia
rr
h
o
ea
Ex
p
er
t
D
ru
g
Pe
r
ce
n
t
o
f
p
at
ie
n
ts
(l
o
w
es
t–
h
ig
h
es
t)
D
o
sa
g
e/
fr
eq
u
en
cy
To
ta
ld
o
sa
g
e
p
er
d
ay
(e
xp
er
t)
D
o
sa
g
e
p
er
d
ay
(m
o
d
el
)
Pr
ic
e
p
er
u
n
it
(£
)
C
o
st
s
p
er
d
ay
(£
)
W
ei
g
h
te
d
co
st
p
er
d
ay
(l
o
w
es
t–
h
ig
h
es
t)
(£
)
Q
Lo
pe
ra
m
id
e
0.
8
(0
.5
–
1)
2–
16
m
g
9
m
g
0.
03
pe
r
2
m
g
0.
13
5
0.
11
(0
.0
7–
0.
14
)
Q
C
od
ei
ne
0.
2
(0
–
0.
5)
30
–
12
0
m
g
75
m
g
0.
04
pe
r
15
m
g
0.
2
0.
04
(0
–
0.
1)
Q
C
or
tic
os
te
ro
id
s
0.
7
(0
.5
–
1)
40
m
g
pr
ed
ni
so
lo
ne
/
9
m
g
bu
de
so
ni
de
40
m
g
pr
ed
ni
so
lo
ne
/
9
m
g
bu
de
so
ni
de
Pr
ed
ni
so
lo
ne
:
0.
04
pe
r
5
m
g;
bu
de
so
ni
de
:
0.
75
pe
r
3
m
g
1.
28
5
(a
ss
um
e
av
er
ag
e
pr
ed
ni
so
lo
ne
an
d
bu
de
so
ni
de
)
0.
90
(0
.6
4–
1.
29
)
Q
A
nt
i-T
N
F-
α
ad
al
im
um
ab
0.
1
(0
–
0.
3)
16
0–
40
m
g
A
ss
um
e
16
0
m
g
on
ce
pl
us
40
m
g
at
w
ee
ks
2,
4,
6
35
2.
14
pe
r
40
m
g
13
.6
9
1.
37
(0
–
4.
11
)
Q
To
ta
l
2.
42
(0
.7
1–
5.
63
)
R
Pe
nt
as
a®
(F
er
rin
g)
0.
6
(0
.4
–
0.
7)
4
g
pe
r
da
y
4
g
2.
4
pe
r
4
m
g
2.
4
1.
44
(0
.9
6–
1.
68
)
R
A
za
th
io
pr
in
e
0.
5
(0
.2
–
0.
7)
2
m
g/
kg
pe
r
da
y
15
6
m
g
(a
ss
um
e
av
er
ag
e
w
ei
gh
t
78
)
0.
08
pe
r
50
m
g
0.
24
96
0.
12
(0
.0
5–
0.
17
)
R
C
or
tic
os
te
ro
id
s
0.
8
(0
.6
–
1)
40
m
g
pr
ed
ni
so
lo
ne
/
9
m
g
bu
de
so
ni
de
40
m
g
pr
ed
ni
so
lo
ne
/
9
m
g
bu
de
so
ni
de
Pr
ed
ni
so
lo
ne
:
0.
04
pe
r
5
m
g;
bu
de
so
ni
de
:
0.
75
pe
r
3
m
g
1.
28
5
(a
ss
um
e
av
er
ag
e
pr
ed
ni
so
lo
ne
an
d
bu
de
so
ni
de
)
1.
03
(0
.7
7–
1.
29
)
R
A
nt
i-T
N
F-
α
ad
al
im
um
ab
0.
1
(0
–
0.
15
)
16
0–
40
m
g
A
ss
um
e
16
0
m
g
on
ce
pl
us
40
m
g
at
w
ee
ks
2,
4,
6
35
2.
14
pe
r
40
m
g
13
.6
9
1.
37
(0
–
2.
05
)
R
BA
S
0.
2
(0
.0
5–
0.
4)
2–
8
g
O
D
–
t.
i.d
.
2–
24
m
g
13
m
g
0.
21
pe
r
4
m
g
0.
68
25
0.
14
(0
.0
3–
0.
28
)
R
A
nt
ib
io
tic
s
(s
m
al
lb
ow
el
ov
er
gr
ow
th
)
0.
2
(0
.0
5–
0.
3)
N
ot
in
cl
ud
ed
as
it
w
ou
ld
be
a
sh
or
t
co
ur
se
,
co
st
s
ne
gl
ig
ib
le
R
To
ta
l
4.
10
(1
.8
2–
5.
47
)
APPENDIX 10
216
NIHR Journals Library www.journalslibrary.nihr.ac.uk
p
er
t
D
ru
g
Pe
r
ce
n
t
o
f
p
at
ie
n
ts
(l
o
w
es
t–
h
ig
h
es
t)
D
o
sa
g
e/
fr
eq
u
en
cy
To
ta
ld
o
sa
g
e
p
er
d
ay
(e
xp
er
t)
D
o
sa
g
e
p
er
d
ay
(m
o
d
el
)
Pr
ic
e
p
er
u
n
it
(£
)
C
o
st
s
p
er
d
ay
(£
)
W
ei
g
h
te
d
co
st
p
er
d
ay
(l
o
w
es
t–
h
ig
h
es
t)
(£
)
C
od
ei
ne
0.
5
(0
.4
–
0.
8)
30
–
12
0
m
g
75
m
g
0.
04
pe
r
15
m
g
0.
2
0.
10
(0
.0
8–
0.
16
)
Lo
pe
ra
m
id
e
0.
5
(0
.4
–
0.
8)
2–
8
m
g
5
m
g
0.
03
pe
r
2
m
g
0.
07
5
0.
04
(0
.0
3–
0.
06
)
To
ta
l
0.
14
(0
.1
1–
0.
22
)
BA
S
0.
8
(0
.7
–
0.
9)
2–
8
g
O
D
–
t.
i.d
.
2–
24
m
g
13
m
g
0.
21
pe
r
4
m
g
0.
68
25
0.
55
(0
.4
8–
0.
62
)
Lo
pe
ra
m
id
e
0.
3
(0
.2
5–
0.
35
)
2–
4
m
g
O
D
–
t.
i.d
.
2–
12
m
g
7
m
g
0.
03
pe
r
2
m
g
0.
10
5
0.
03
(0
.0
3–
0.
04
)
To
ta
l
0.
58
(0
.5
1–
0.
66
)
C
od
ei
ne
0.
5
(0
.4
–
0.
8)
30
–
12
0
m
g
75
m
g
0.
04
pe
r
15
m
g
0.
2
0.
10
(0
.0
8–
0.
16
)
Lo
pe
ra
m
id
e
0.
8
(0
.5
–
1)
2–
4
m
g
O
D
–
t.
i.d
.
2–
12
m
g
7
m
g
0.
03
pe
r
2
m
g
0.
10
5
0.
08
(0
.0
5–
0.
12
)
C
or
tic
os
te
ro
id
s
0.
8
(0
.6
–
1)
40
m
g
pr
ed
ni
so
lo
ne
/
9
m
g
bu
de
so
ni
de
40
m
g
pr
ed
ni
so
lo
ne
/
9
m
g
bu
de
so
ni
de
Pr
ed
ni
so
lo
ne
:
0.
04
pe
r
5
m
g;
bu
de
so
ni
de
:
0.
75
pe
r
3
m
g
1.
28
5
(a
ss
um
e
av
er
ag
e
pr
ed
ni
so
lo
ne
an
d
bu
de
so
ni
de
)
1.
03
(0
.7
7–
1.
29
)
BA
S
0.
8
(0
.7
–
0.
9)
2–
8G
O
D
–
t.
i.d
.
2–
24
m
g
13
m
g
0.
21
pe
r
4
m
g
0.
68
25
0.
55
(0
.4
8–
0.
62
)
To
ta
l
1.
76
(1
.3
8–
2.
17
)
,
on
ce
a
da
y;
t.
i.d
.,
te
r
in
di
e
(t
hr
ee
tim
es
a
da
y)
.
Th
is
ex
pe
rt
lis
te
d
on
ly
dr
ug
na
m
es
.
Th
e
pe
rc
en
ta
ge
of
pa
tie
nt
s
us
in
g
it
w
as
th
e
hi
gh
es
t
re
po
rt
ed
by
ot
he
r
ex
pe
rt
s;
do
sa
ge
w
as
al
so
ta
ke
n
fr
om
th
e
ot
he
r
ex
pe
rt
s.
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Ex S S S T T T U
a
U
a
U
a
U
a
U O
D
a
217
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.

DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Appendix 11 Final protocolDIAGNOSTIC ASSESSMENT REPORT COMMISSIONED BY THE NIHR
HTA PROGRAMME ON BEHALF OF THE NATIONAL INSTITUTE FOR
HEALTH AND CLINICAL EXCELLENCE – PROTOCOL1 Title of projectA systematic review and economic evaluation of SeHCAT (Tauroselcholic [75Selenium] acid) for the
investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss.2 Name of External Assessment Group (EAG) and project leadKleijnen Systematic Reviews Ltd.
Project lead:
Rob Riemsma
Kleijnen Systematic Reviews Ltd
Unit 6, Escrick Business Park
Riccall Road
Escrick
York YO19 6FD
Tel: 01904 727986
Email: rob@systematic-reviews.com
Second contact:
Jos Kleijnen
Kleijnen Systematic Reviews Ltd
Unit 6, Escrick Business Park
Riccall Road
Escrick
York YO19 6FD
Tel: 01904 727981
Email: jos@systematic-reviews.com
Health economics lead:
Maiwenn Al
Institute for Medical Technology Assessment (iMTA)
Erasmus University
P.O. Box 1738
3000 DR Rotterdam
The Netherlands
Tel: +31-10-4088565
Email: al@bmg.eur.nl219
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
APPENDIX 11
2203 Plain English SummaryBile acids are produced in the liver, secreted into the biliary system, stored in the gall-bladder and are released
after meals. They are important for the digestion and absorption of fats in the small intestine. Usually over
95% of the bile acids are absorbed in the terminal ileum and are taken up by the liver and resecreted. When
larger amounts of bile acids enter the large intestine, they stimulate water secretion and intestinal motility in
the colon, which causes symptoms of chronic diarrhoea. This is called bile acid malabsorption (BAM).
A SeHCAT scan is a diagnostic procedure, which looks at the function of the bowel. It involves swallowing
a capsule containing a very slightly radioactive tracer and imaging with a special camera shortly after
swallowing the capsule and after a week. This then shows which percentage of bile acid was absorbed,
and thus whether the patient has BAM.
The purpose of this project is to assess the benefits, risks and cost-effectiveness of [75Se] tauroselcholic acid
(SeHCAT), a bile acid analogue which is used as a test for investigating bile acid malabsorption (BAM) and the
measurement of bile acid pool loss in patients with chronic diarrhoea referred to a GI clinic for investigation
and diagnosis of BAM. Patients with Crohn’s disease with chronic diarrhoea will be assessed separately.4 Decision problem
4.1 Objectives
The objective of this project is to evaluate the clinical and cost effectiveness of [75Se] tauroselcholic acid
(SeHCAT), a bile acid analogue which is used as a test for investigating bile acid malabsorption (BAM) and the
measurement of bile acid pool loss in patients referred to a GI clinic for investigation and diagnosis of BAM.
This can be translated in the following research questions. For people with chronic diarrhoea with unknown
cause and in people with Crohn’s disease and chronic diarrhoea with unknown cause (i.e. before resection):
1. What are the effects of SeHCAT compared to no SeHCAT in terms of chronic diarrhoea, other health
outcomes and costs?
2. What are the effects of bile acid sequestrants (BAS) compared to no BAS in people with a positive or
negative SeHCAT test?
3. Does a positive or negative SeHCAT test predict improvement in terms of chronic diarrhoea, other
health outcomes and costs?4.2. Intervention technologies
For questions 1 and 3, SeHCAT is the intervention.
SeHCAT (GE Healthcare) is a radiopharmaceutical that is licensed for use in the investigation of bile acid
malabsorption (BAM) and measurement of bile acid pool loss. It may also be used in assessing ileal
function, in the investigation of Inflammatory Bowel Disease (IBD) and chronic diarrhoea and in the study
of enterohepatic circulation.
SeHCAT product information lists its applications as:
Tauroselcholic acid is a bile acid analogue which shows identical physiological behaviour with naturally
occurring bile acid conjugates. Following oral administration in normal subjects, approximately 95% of
the labelled bile acid is absorbed, mainly by the terminal ileum during each enterohepatic cycle. The
distribution of activity is almost entirely confined to the lumen of the biliary ducts, gut and liver. Whole
body retention data from normal subjects showed 97 to 100% of [75Se]tauroselcholic was excreted with a
biological half-life of 2.6 days and that, in most cases, a small component of about 3% was eliminated
with a mean half time of 62 days.1NIHR Journals Library www.journalslibrary.nihr.ac.uk
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sequestrants available: colestyramine, colestipol, and colesevelam. Where evidence is available, the
effectiveness of fat restrictions and other dietary modifications will also be assessed.4.3. Population
The populations for this evaluation are:
1. People presenting with chronic diarrhoea with unknown cause;
2. People with Crohn’s disease and chronic diarrhoea with unknown cause (i.e. before resection of the
terminal ileum).4.4. Relevant comparators
There is no direct comparator for this diagnostic test. Current diagnostic options include analysis of a
patient’s history, investigations to exclude ‘red flag’ symptoms and a variety of other diagnostic tests such
as blood tests and lactose tolerance tests. Trial of treatment and measurement of faecal bile acids are
two methods used, with mixed results, to diagnose BAM. They are however, not widely used in
current practice.Basic investigations
FBC, LFT, Ca, B12,
folate, Fe status,
thyroid function,
coeliac serology
History suggestive of
organic diarrhoea
Abnormal basic
investigations
History or findings
suggestive of
malabsorption
History or findings
suggestive of
colonic or terminal
ileal disease
‘Difficult diarrhoea’
Suspicion of laxative
abuse
Persistent symptoms
with negative
investigations
High volume diarrhoea
Consider inpatient
assessment
24 – 72 stool weights
Stool osmolality/
osmotic gap
Laxative screen
Flexible simoidoscopy
if < 45
Complement with
barium enema if > 45
Colonoscopy preferred
if > 45
B1: SeHCAT
A: SeHCAT
Pancreatic
CT pancreas
Faecal elastase or
chymotrypsin
Pancreolauryl test
Small bowel
D2 biopsy
Barium followthrough
Enteropathy
Review histology?
Enteroscopy
Bacterial overgrowth
Glucose hydrogen
breath test
Jejeunal aspirate and
culture
Further structural
tests ERCP or
MRCP
Terminal diseases
excluded?
Barium follow through
99m Tc-HMPAO
C: 75SeHCAT
Gut hormones
Serum gestrin, VIP
Urinary 5-HIAA
Symptoms suggestive
 of functional disease
Age < 45 + normal
basic investigations =
irritable bowel
syndrome
B2: SeHCAT
FIGURE 1 BSG diagnostic algorithm for chronic diarrhoea.2
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222The current BSG guideline for chronic diarrhoea places SeHCAT at the end of the diagnostic algorithm
(position C in Figure 1). Possible alternatives are:
1. SeHCAT as part of the basic investigations for all patients presenting with chronic diarrhoea (position A
in Figure 1);
2. SeHCAT for all patients presenting with chronic diarrhoea and symptoms suggestive of functional
disease (i.e. age < 45 and normal basic investigations) (position B1 in Figure 1); and also for patients
with a history of findings suggestive of colonic or terminal ileal disease (position B2 in Figure 1).
SeHCAT as part of the basic investigations (position A in Figure 1), means that all patients presenting with
chronic diarrhoea will be tested with SeHCAT. However, during the scoping workshop clinical experts
advised that a positive SeHCAT test at this stage does not rule out the possibility of organic disease. As no
subsequent tests for organic disease are made redundant, it is unlikely that SeHCAT in position A will be
more cost-effective than in position B1. Therefore, this protocol will focus on position B1.
The same applies to SeHCAT in position B2. A positive SeHCAT test in position B2 will most likely not stop
clinicians from doing subsequent tests (e.g. simoisdoscopy, barium enema or colonoscopy). Therefore,
position B2 will be treated the same as position C in this report.
This leaves two possible populations for investigation:
1. People presenting with chronic diarrhoea with unknown cause and symptoms suggestive of
functional disease;
2. People with Crohn’s disease and chronic diarrhoea with unknown cause (i.e. before resection of the
terminal ileum)
For both populations, the intervention will be SeHCAT followed by the appropriate treatment (see figures
2 and 3); and the comparator will be appropriate treatment without SeHCAT.5. Report methods for assessing clinical effectivenessA systematic review will be conducted to summarise the evidence on the clinical effectiveness of SeHCAT
for the assessment of bile acid malabsorption (BAM) and the measurement of bile acid pool loss.
Systematic review methods will follow the principles outlined in the Centre for Reviews and Dissemination
(CRD) guidance for undertaking reviews in health care3 and NICE Diagnostic Assessment Programme
interim methods statement.45.1. Inclusion and exclusion criteria
Participants
Study populations eligible for inclusion will be:
All patients (including children) referred to a GI clinic for investigation and diagnosis of BAM which is a
common underlying cause of chronic diarrhoea and the measurement of bile acid pool loss.5,6
As explained above, this report will focus on two specific populations:
1. People presenting with chronic diarrhoea with unknown cause and symptoms suggestive of
functional disease;
2. People with Crohn’s disease and chronic diarrhoea with unknown cause (i.e. before resection of the
terminal ileum).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Relevant settings are primary or secondary care.Interventions (index test(s))
For population 1 the intervention is SeHCAT as the first test in people with symptoms suggestive of
functional disease (position B1 in Figure 1).
For population 2 the intervention is SeHCAT.Comparators
In the economic model the comparator will be no SeHCAT test (the current situation).Outcomes
The following outcomes will be considered:
l Effect of testing on treatment plan (e.g. surgical or medical management), where information on the
appropriateness of the final treatment plan is also reported
l Effect of testing on clinical outcome, (e.g. morbidity and adverse events)
l Prognosis- the ability of test result to predict clinical outcome (e.g. response to treatment).
For included studies reporting any of the above outcome measures, the following outcomes will also be
considered if reported:
l Acceptability of tests to patients or surrogate measures of acceptability (e.g. waiting time and
associated anxiety).
l Adverse events associated with testing (e.g. pain/discomfort experienced during the procedure and
waiting times before results).Study design
The following types of studies will be included:
l Randomised or non-randomised controlled trials, where participants are assigned to the intervention or
comparator tests, for treatment planning, and outcomes are compared at follow-up.
l Observational studies which report the results of multi-variable regression modelling with clinical
outcome as the dependent variable and index test result as an independent variable. Included studies
should control adequately for potential confounders (e.g. age, gender, disease, etc.).
The following study/publication types will be excluded:
l Pre-clinical and animal.
l Reviews, editorials, and opinion pieces.
l Case reports.
l Studies reporting only technical aspects of the test, or image quality.
l Studies with < 10 participants.5.2. Search strategy
Search strategies will be based on target condition and intervention, as recommended in the Centre for
Reviews and Dissemination (CRD) guidance for undertaking reviews in health care and the Cochrane
Handbook for Diagnostic Test Accuracy Reviews.7–9
Additional supplementary searches will be carried out as necessary. Searches for studies for cost and
quality of life will also be included, see Section 6 for further detail.223
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224The following databases will be searched for relevant studies from inception to the present:
l MEDLINE (OvidSP)
l MEDLINE In-Process Citations and Daily Update (OvidSP)
l EMBASE (OvidSP)
l Cochrane Database of Systematic Reviews (CDSR) (internet)
l Cochrane Central Register of Controlled Trials (CENTRAL) (internet)
l Database of Abstracts of Reviews of Effects (DARE) (internet)
l Health Technology Assessment Database (HTA) (internet)
l Science Citation Index (SCI) (Web of Science)
l NIHR Health Technology Assessment Programme (internet)
Completed and ongoing trials will be identified by searches of the following resources (up to 2011):
l NIH ClinicalTrials.gov (http://www.clinicaltrials.gov/)
l Current Controlled Trials (http://www.controlled-trials.com/)
l WHO International Clinical Trials Registry Platform (ICTRP) (http://www.who.int/ictrp/en/)
l EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/)
Key conference proceedings, to be identified in consultation with clinical experts, will be screened for the
last five years. These may include the European Federation of Societies for Ultrasound in Medicine and
Biology (EFSUMB) EUROSON congress.
Identified references will be downloaded in Endnote X4 software for further assessment and handling.
References in retrieved articles and relevant systematic reviews will be checked.
Search strategies will be developed specifically for each database and the keywords associated with BAM
shall be adapted according to the configuration of each database. The main Embase search strategy for
each set of searches will be independently peer reviewed by a second Information Specialist, using the
PRESS-EBC checklist.10
No restrictions on language or publication status will be applied. Limits will be applied to remove animal
and phantom studies. Searches will take into account generic and other product names for the
intervention. Examples of the search strategies to be used are presented in Appendix 1; these will be
adapted as necessary following consultation with clinical experts.5.3. Data extraction strategy
Two reviewers will independently screen titles and abstracts of all reports identified by searches and
discrepancies will be discussed. Full copies of all studies deemed potentially relevant, after discussion, will
be obtained and two reviewers will independently assess these for inclusion; any disagreements will be
resolved by consensus or discussion with a third reviewer.
Data relating to study details, participants, intervention and comparator tests, reference standard, and
outcome measures will be extracted by one reviewer, using a piloted, standard data extraction form.
A second reviewer will check data extraction and any disagreements will be resolved by consensus or
discussion with a third reviewer.5.4. Quality assessment strategy
The methodological quality of included studies will be assessed using standard tools.7 The Cochrane
Collaboration quality assessment checklist will be used to assess the methodological quality of each
included study as detailed in Table 1.11NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 1 The Cochrane Collaboration’s Tool for Assessing Risk of Bias11
Domain Item Description
Sequence Generation Was the allocation sequence
adequately generated?
The method used to generate the
allocation sequence should be
described in sufficient detail to allow an
assessment of whether it should
produce comparable groups.
Allocation Concealment Was allocation adequately concealed? The method used to conceal the
allocation sequence should be
described in sufficient detail to
determine whether intervention
allocations could have been foreseen in
advance of, or during, enrolment.
Blinding of participants, personnel
and outcome assessors
Assessments will be made for each
main outcome (or class of
outcomes).
Was knowledge of the allocated
intervention adequately prevented
during the study?
All measures used, if any, to blind
study participants and personnel from
knowledge of which intervention a
participant received, should be
described. Any information relating to
whether the intended blinding was
effective should also be reported.
Incomplete outcome data
Assessments will be made for each
main outcome (or class of
outcomes).
Were incomplete outcome data
adequately addressed?
The completeness of outcome data for
each main outcome should be
described, including attrition and
exclusions from the analysis. The
authors should report any attrition and
exclusions, the numbers in each
intervention group (compared with
total randomized participants), reasons
for attrition/exclusions and any re-
inclusions in analyses.
Selective outcome reporting Are reports of the study free of
suggestion of selective outcome
reporting?
The study should be free of the
possibility of selective outcome
reporting.
Other sources of bias Was the study apparently free of
other problems that could put it at a
high risk of bias?
Overall, the study should be free from
any important concerns about bias (i.e.
bias from other sources not previously
addressed by the other items).
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Each study will be awarded a ‘yes’, ‘no’ or ‘unclear/unknown’ rating for each individual item in the
checklist. Any additional clarifications or comments will also be recorded.
The quality of case–control and cohort studies will be assessed using specific checklists for the
methodological quality assessment of these studies (see Appendix 2).
Quality assessment will be carried out independently by two reviewers. Any disagreements will be resolved
by consensus. The results of the quality assessment will be used for descriptive purposes to provide an
evaluation of the overall quality of the included studies and to provide a transparent method of
recommendation for design of any future studies. In addition, if enough data are available from the
included studies, each of the quality components will be included as explanatory variables in a meta-
regression analysis to investigate the association of each of these components with study results as a way
of explaining possible heterogeneity. Based on the findings of the quality assessment, recommendations
will be made for the conduct of future studies.225
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2265.5. Methods of analysis/synthesis
The results of initial scoping searches suggest that trial data and prognostic data are likely to be sparse or
non-existent. This section therefore focuses on the synthesis of data from test accuracy studies. If other
studies are identified, we anticipate that these will be summarised in a narrative synthesis.
Where meta-analysis is considered unsuitable for some or all of the data identified (e.g. due to the
heterogeneity and/or small numbers of studies), we will employ a narrative synthesis. Typically, this will
involve the use of text and tables to summarise data. These will allow the reader to consider any outcomes
in the light of differences in study designs and potential sources of bias for each of the studies being
reviewed. Studies will be organised by clinical application (diagnosis of BAM in those with chronic
diarrhoea and those with Crohn’s disease).
Any data included on the following outcome measures: effects of testing on treatment planning and/or
clinical outcome; adverse events associated with testing; acceptability to patients will be summarized
according to the size and range of the outcomes reported.
The methods used to synthesis the data will be dependent on the types of outcome data included and the
clinical and statistical similarity of the studies. Possible methods include the following types of analysis.Dichotomous outcomes
Dichotomous data will be analysed by calculating the relative risk (RR) for each trial using the random-
effects DerSimonian and Laird method and the corresponding 95% confidence intervals (CIs).12Continuous outcomes
Continuous data will be analysed by calculating the standardised mean difference (SMD) between groups
and the corresponding 95% CI, due to the different types of outcome measures. If the standard deviations
and means are not determinable, they will be estimated from the data that is provided or from a
representative value from other studies.
Systematic differences between studies (heterogeneity) are likely; therefore, the random-effects model will
be used for the calculation of relative risks or standardised mean differences. Heterogeneity will initially be
assessed by measuring the degree of inconsistency in the studies’ results (I2). This measure (I2) describes the
percentage of total variation across studies that were due to heterogeneity rather than the play of chance.
The value of I2 can lie between 0% and 100%. Low, moderate and high I2 values correspond to 25%,
50%, and 75%.
If important heterogeneity is identified, this will be formally investigated using meta-regression. In
particular, a model will be used to explore the possible modifying effects of the following pre-specified
factors: methodological quality of the primary studies, underlying illness, duration of pain, different age
groups, and gender. The coefficient describing the predictive value of each factor and the overall effect on
the main outcome will be modelled, using a fixed-effect model.
A funnel plot (plots of logarithm of the RR for efficacy against the precision of the logarithm of the RR) will
be generated in order to estimate potential asymmetry, which will be indicative of small study effects.
Treatment discontinuations will be chosen as an outcome since they are likely to be reported by the
majority of included studies. In addition, the Egger regression asymmetry test will be used in order to
facilitate the prediction of potential publication biases. This test detects funnel plot asymmetry by
determining whether the intercept deviates significantly from zero in a regression of the standardised
effect estimates against their precision.
Statistical analyses will be performed using the following software: RevMan (version 5), Comprehensive
Meta-Analyses (CMA version 2), and STATA (STATA™ for Windows, version 10, Stata Corp; College
Station, TX).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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be included, together with a description of how this may have affected the individual study results.
Recommendations for further research will be made based on any gaps in the evidence or
methodological flaws.6. Report methods for synthesising evidence
of cost-effectiveness
6.1 Identifying and reviewing published cost-effectiveness studies
Exploration of the literature regarding published economic evaluations, utility studies and cost studies will
be performed in the literature databases listed above. In addition, specific health economic databases will
be searched (e.g. NHSEED (NHS Economic Evaluation Database), and HEED (Health Economic Evaluation
Database). Searches will focus on original papers that report on cost, cost-accuracy, cost-effectiveness or
cost-utility analyses, either studying the diagnostic phase (test accuracy in terms of detecting BAM of
patients with chronic diarrhoea), therapeutic phase (patients with BAM), or a combination. For our
assessment cost studies, utility studies and full economic evaluations, i.e. those that explicitly compare
different decision options will selected. Clinical trials as well as modelling studies and cohort studies will be
relevant within the frame of our project. The intention is not to perform a systematic review, but to use
the studies identified to support the development of an economic model and estimation of model input
parameters that will aim to answer the research questions of this project.
The results and the methodological quality of the studies selected will be summarised. Assessment of
methodological quality will follow the criteria for economic evaluations in health care as described in the
NICE methodological guidance.4 Data extraction will focus on technologies compared, indicated
population, main results in terms of costs and consequences of the alternatives compared, and the
incremental cost-effectiveness, but also on methods of modelling used (if applicable), analytical methods
and robustness of the study findings.6.2 Evaluation of costs, quality of life and cost-effectiveness
Since this project aims to assess the value of SeHCAT in two different patient populations (see section 4.3
and 4.4), two separate economics models will be defined, constructed, analysed, and reported
independently. Both models will evaluate the cost-effectiveness of SeHCAT compared to no SeHCAT as
described in section 5.1. The perspective will be that of the NHS and the timeframe used will be life time.
Consequences will be expressed as number of correct diagnoses for the diagnostic phase, and (quality
adjusted) life years to also include the therapeutic phase. Any assumption used in the models and
any parameter value will be based on literature if possible and supplemented by clinical expert opinion
as required.Model structure
Published studies that measure the clinical utility of SeHCAT from initial diagnosis through to final health
outcomes have not been identified during the scoping phase. Consequently, it is likely that a linked
evidence approach will need to be used in the modelling. That is, outcomes of the diagnostic tests to be
assessed will need to be related to changes in treatment decisions, any delays in diagnosis and final
heath outcomes.
An outline of the proposed models is presented in Figure 2 and 3.
The diagnostic part of the model for population 1 is straightforward, including the outcome of SeHCAT
(positive or negative) and the true disease status (BAM positive of negative). Both true positives and true
negatives are treated according to usual management of BAM and IBS-D. Patients who tested positive for
BAM while in fact not having BAM (false positives) are assumed to receive treatment for BAM. The
important question that needs to be addressed in this study, most likely using expert opinion, is whether227
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continue BAM treatment
BAM + treat BAM
BAM –
Test –
Test +
SeHCAT test
no test – treat as IBS-D
S_D suspected population
treat BAM
BAM + treat IBS-D
BAM – treat IBS-D
BAM + treat IBS-D
BAM – treat IBS-D
continue IBS-D treatment
treat IBS-D (delayed)
treat BAM (delayed)
continue IBS-D treatment
treat BAM (delayed)
IGURE 2 Outline of model for patients presenting with chronic diarrhoea with unknown cause and symptoms
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suggestive of functional disease.
Crohn’s population
without resection
BAM +
Test +
SeHCAT test
no test –
treat as chronic diarrhoea
Test –
BAM –
BAM +
treat chronic
diarrhoea
treat chronic
diarrhoea
treat BAM
BAM – treat BAM
BAM + treat chronic diarrhoea
BAM – treat chronic diarrhoea
continue BAM treatment
continue diarrhoea treatment
continue
diarrhoea treatment
treat BAM (delayed)
treat diarrhoea (delayed)
treat BAM (delayed)
FIGURE 3 Outline of model for patients with Crohn’s disease and chronic diarrhoea with unknown cause (i.e. before
resection of the terminal ileum).(some of) these patients will be detected at some point as having IBS-D, and how long this delay will last.
Likewise, patients who tested negative for BAM while in fact having BAM (false negatives) are assumed to
receive treatment for IBS-D. Again, an important question is whether (some of) these patients will be
detected at some point as having BAM, and how long this delay will last. Also interesting in this situation
is whether some parts of IBS-D management may also be helpful to some extent in patients with BAM,
such as changes in diet.
Whether wrongly diagnosed patients will eventually receive a correct diagnosis and the duration of
the delay until correct diagnosis is expected to have an important influence on the cost-effectiveness
of SeHCAT.
If relevant, this part of the model will also take complications due to the SeHCAT test and the short and
long-term consequences into account.
The therapeutic part of the model requires modelling the life-long costs and effects of treating BAM and
IBS-D. For this, a Markov model will be developed. Until now, no modelling studies in IBS and BAM have
been identified that may be used in this study. Given the lack of data in this area, we anticipate a simple
model structure for the Markov models, using health states defined based on whether the chronic
diarrhoea is resolved or not and possibly including a health state for constipation.
For the treatment of BAM, the treatment of choice is medication with BAS. However, few published trials
exist looking at the efficacy of BAS in BAM. It has been suggested that data on efficacy of BAS in other
disease areas, such as hyperlipedemia, might be used. However, the endpoints by which the efficacy of
BAS is measured will differ between disease areas. Another issue relates to one of the important problemsNIHR Journals Library www.journalslibrary.nihr.ac.uk
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not lead to any symptoms in patients) are less willing to tolerate the side effects of BAS, merely to avoid
future cardiovascular problems. For patients with BAM, the relief from a decrease in bowel movements
might well outweigh the side effects. Thus, it is reasonable to expect that little to no data exist to
meaningful model the costs and effects of treatment of BAM.
If relevant, the impact of untreated and treated BAM and IBS-D on mortality will be taken into account.
For the treatment of IBS-D, we anticipate that more information is available on the efficacy of (some of)
the treatment options. So far, we have performed a search to obtain estimates of costs (of treatments) and
utilities in IBS-D, which retrieved 401 references, of which 27 were selected from screening title and
abstract. Some of these appear to be useful in terms of being UK based and relatively recent, although
full papers are yet to be retrieved. We also intend to perform a similar search for the Crohn’s
disease population.
For the trial-by-treatment comparator, the model may use data on effectiveness of BAS for those in the
model with BAM and assuming that those without BAM have no improvement in symptoms and the same
adverse event profiles as those with BAM.
For the second population, we will follow the same model structure. The analysis for this population is
about the efficiency of BAS causing symptom relief and avoidance of unnecessary anti-inflammatory
treatment (e.g. systemic cortico-steroids).
For this model, more information about the diagnostic part of the model needs to be collected (most
importantly from experts) in order to establish what the current approach is to chronic diarrhoea in
Crohn’s patients. And here the same questions arise as in the first population, i.e. whether (some of the)
wrongly diagnosed patients are detected and what the delay in detection will be.
The therapeutic part of the model requires modelling the life-long costs and effects of treating BAM or
chronic diarrhoea with non-BAM cause through a Markov model. Again, data on efficacy of treatments in
this population will be scarce. Although assumptions can be made, and varied in sensitivity analysis and
threshold analysis, the question is whether this will lead to any useful conclusions.
Final choices and definitions regarding the structure of the model will depend on the findings from the
literature review and consultation with clinical experts. In addition, the existence/availability of any other
electronic models that reflect the cost-effectiveness of treatment pathways for these patients, and are
representative of current care within the NHS, will be determined.
Issues relevant to analyses:
l Longer term costs and consequences will be discounted using the UK discount rates of 3.5% of both
costs and effects.
l One way sensitivity analyses will be performed for all key parameters, especially for parameters in the
models which are based on expert opinion.
l Probabilistic sensitivity analyses will be performed using parameter distributions instead of fixed values.
l Decision uncertainty regarding mutually exclusive alternatives will be reflected using cost-effectiveness
planes and cost-effectiveness acceptability curves.Health outcomes
Utility values, based on literature or other sources, will be incorporated in the economic model. When
utility values specific for BAM are not available, values for general chronic diarrhoea will be used. QALYs
will be calculated from the economic modelling.229
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Resource utilisation will be estimated for the diagnostic tests and treatments. Data for the cost analyses
will be drawn from routine NHS sources (e.g. NHS reference costs, Personal Social Services Research Unit
(PSSRU), British National Formulary (BNF)), discussions with individual hospitals and with the manufacturers
of the comparators.7. Handling of information from the companiesAll data submitted by the manufacturers/sponsors will be considered if received by the EAG no later than
05/03/2012. Data arriving after this date will not be considered. If the data meet the inclusion criteria for
the review they will be extracted and quality assessed in accordance with the procedures outlined in
this protocol.
Any ‘commercial in confidence’ data provided by manufacturers, and specified as such, will be highlighted
in blue and underlined in the assessment report (followed by company name in parentheses). Any
‘academic in confidence’ data provided by manufacturers, and specified as such, will be highlighted in
yellow and underlined in the assessment report. Any confidential data used in the cost-effectiveness
models will also be highlighted.8. Competing interests of authorsNone9. Timetable/milestonesMilestones Completion data
Draft protocol 24/11/2011
Final protocol 15/12/2011
Progress report 05/03/2012
Draft assessment report 02/04/2012
Final assessment report 21/05/201210. ReferencesNIHR1. GE Healthcare Limited. Summary of product characteristics: SeHCAT 370 kBq capsules [Portable
Document Format], 2001.
2. Thomas PD, Forbes A, Green J, Howdle P, Long R, Playford R, et al. Guidelines for the
investigation of chronic diarrhoea, 2nd edition. Gut 2003;52(SUPPL. 5):v1–v15.
3. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s guidance for undertaking
reviews in health care [internet]. York: University of York, 2009 [cited 23.11.11] Available from:
http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm
4. National Institute for Health and Clinical Excellence. Diagnostics Assessment Programme: interim
methods statement (version 2) [internet]. London: NICE, 2010 [cited 12.1.11]. 46p. Available
from: http://www.nice.org.uk/media/164/3C/DAPInterimMethodsStatementProgramme.pdfJournals Library www.journalslibrary.nihr.ac.uk
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Clinical effectiveness search
Embase search: Facet 1 combined terms for SeHCAT (lines #1-5) and Bile Acid Sequestrants (lines #6-12)
using OR in line #13 (n=33829). Facet 2 for Bile Acid Malabsorption (lines #14-20) was then combined
with facet 1 using AND in line #21 (n=3044). Line #21 was then combined with both an RCT filter and
Non-randomised studies filter and limited to remove animal studies. The final set was then limited to
Embase records only in line #37 (n=1172). For the full strategy please see below.Embase (OvidSP): 1980 to 2011 Week 46
Searched: 25.11.111. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).mp. (151)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75).mp. (765)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid).mp. (19)
4. (selenium adj3 "75").mp. (483)
5. or/1-4 (1150)
6. bile acid sequestrant/ (629)
7. ((bile adj3 acid adj3 sequestra$) or BAS).ti,ab,ot,hw,rn. (15990)
8. Colestipol/ or (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-
epichlorohydrin-copolymer or diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or
epichlorohydrin-copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a or231
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232u-26597-a or u-26597a or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6).ti,ab,ot,
hw,rn. (2486)
9. Colestyramine/ or (colestyramine or chol-less or choles or cholesthexal or cholestyramin or
cholestyramine or cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or
colestyramin or cuemid or lipocol-merz or lismol or locholest or prevalite or quantalan or questran or
resincoles-tiramina or resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6 or
58391-37-0).ti,ab,ot,hw,rn. (9021)
10. Colesevelam/ or (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-
104hb or gt31-104 or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-
44-7).ti,ab,ot,hw,rn. (693)
11. aluminum hydroxide/ or (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or
algeldraat or algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu
cap or alu-cap or alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina
trihydrate or aluminium hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum
hydrate or aluminum hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or
amphogel or amphojel or amphotabs or antiphos or bayerite or chefarox or collumina or collumol
or colodral or colugel or creamalin or cremorin or diplogel or f 1000 or f1000 or fluagel or gastracol
or gastrosetarderm or gelumina or hoemigel or hycolal or hydracoll or hydrated alumina or hydrolum
or hydronal or hydroxal or lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p or vanogel
or 21645-51-2 or brasivil or rocgel or alugel or hydrated alumina or basalgel or dialume or nephrox).ti,
ab,ot,hw,rn. (7408)
12. or/6-11 (32747)
13. 5 or 12 (33829)
14. (BAM or I-BAM or IBAM or PBAM).mp. (1952)
15. primary bile acid diarrh?ea$.mp. (4)
16. chronic diarrhea/ (2492)
17. ((chronic or watery or recur$ or persist$ or protract$ or continual$ or continuous$ or sustain$ or
constant$ or relentless$ or unrelent$ or functional or aggressive) adj2 diarrh?e$).mp. (14493)
18. (malabsorb$ or mal-absorb$ or malabsorp$ or mal-absorp$).mp. (16312)
19. ((bile or biliary) adj3 (acid$ or salt$)).mp. (31246)
20. or/14-19 (61945)
21. 13 and 20 (3044)
22. Random$.tw. or placebo$.mp. or double-blind$.tw. (835216)
23. "clinical trial (topic)"/ or "controlled clinical trial (topic)"/ or "multicenter study (topic)"/ or "phase 1
clinical trial (topic)"/ or "phase 2 clinical trial (topic)"/ or "phase 3 clinical trial (topic)"/ or "phase 4
clinical trial (topic)"/ (11859)
24. Clinical article/ or controlled study/ or major clinical study/ or prospective study/ (5272269)
25. (Cohort or compar$ or groups or multivariate).mp. (4685280)
26. or/22-25 (8026182)
27. animal/ (1661955)
28. animal experiment/ (1473625)
29. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or
ovine or monkey or monkeys).mp. (4826714)
30. or/27-29 (4826714)
31. exp human/ (12719767)
32. human experiment/ (295041)
33. or/31-32 (12721151)
34. 30 not (30 and 33) (3868516)
35. 26 not 34 (6217248)
36. 21 and 35 (1231)
37. limit 36 to embase (1172)NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61Based on Trials filter:
Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound
treatment studies in EMBASE. Journal of the Medical Library Association 2006;94(1):41-7.
&
Based on Non-randomised studies filter: Fixed method B for Embase:
Furlan AD, Irvin E, Bombardier C. Limited search strategies were effective in finding relevant
nonrandomized studies. Journal of Clinical Epidemiology 2006;59(12):1303-11. [Ovid]MEDLINE (Ovid SP): 1948 to November Week 3 2011
Searched 25.11.111. (tauroselcholic or selenohomocholyltaurine or 75018-71-2).ti,ab,ot,hw,rn. (2)
2. (SeHCAT or Se-HCAT or 75SeHCAT or Se-75 or 75-SeHCAT or SE75).ti,ab,ot,hw,rn. (274)
3. (23-seleno-25-homo-tauro-cholic acid or selenium homocholic acid taurine or 23-selena-25-
homocholyltaurine or 23-selena-25-homotaurocholate or 23- selena-25-homotaurocholic-acid or
selenium radioisotopes or tauroselenocholic acid).ti,ab,ot,hw,rn. (317)
4. (selenium adj3 "75").ti,ab,ot,hw. (143)
5. or/1-4 (639)
6. ((bile adj3 acid adj3 sequestra$) or BAS).ti,ab,ot,hw,rn. (2567)
7. Colestipol/ or (Colestipol or cholestabyl or cholestipol or colestid or diethylenetriamine-
epichlorohydrin-copolymer or diethylenetriamine-polymer-with-1-chloro-2,3-epoxypropane or
epichlorohydrin-copolymer-with-diethylenetriamine or flavored-colestid or lestid or u-26,597a or
u-26597-a or u-26597a or u-26,597a or 25085-17-0 or 37296-80-3 or 50925-79-6).ti,ab,ot,
hw,rn. (503)
8. Cholestyramine Resin/ or (colestyramine$ or chol-less or choles or cholesthexal or cholestyramin or
cholestyramine$ or cholybar or cholytar or colestepril or colestiramina or colestran or colestrol or
colestyramin or cuemid$ or lipocol-merz or lismol or locholest or prevalite or quantalan or questran$
or resincoles-tiramina or resincolestiramina or vasosan-p-granulat or vasosan-s-granulat or 11041-12-6
or 58391-37-0 or mk 135 or mk135).ti,ab,ot,hw,rn. (3234)
9. (Colesevelam or cholestagel or gt-31-104 or gt-31-104hb or gt-31-104 or gt-31-104hb or gt31-104
or gt31-104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 or 182815-44-7).ti,ab,ot,
hw,rn. (155)
10. Aluminum Hydroxide/ or (aluminum hydroxide or Ageldrate or al u creme or alcid or aldrox or
algeldraat or algeldrate or algelox or alhydrogel or alkagel or alocol or alokreem or alterna gel or alu
cap or alu-cap or alu-tab or alucol or aludrox or alugelibys or alumigel or alumina gel or alumina
trihydrate or aluminium hydroxide or aluminium hydroxide or aluminoid or aluminox or aluminum
hydrate or aluminum hydroxide gel or aluminum oxide trihydrate or aluminum trihydrate or alutab or
amphogel or amphojel or amphotabs or antiphos or bayerite or chefarox or collumina or collumol or
colodral or colugel or creamalin or cremorin or diplogel or f 1000 or f1000 or fluagel or gastracol
or gastrosetarderm or gelumina or hoemigel or hycolal or hydracoll or hydrated alumina or hydrolum
or hydronal or hydroxal or lactalumina or neutroxide or palliacol or pepsamar or ulcerin-p or vanogel).
ti,ab,ot,hw,rn. (4374)
11. or/6-10 (10353)
12. 5 or 11 (10957)
13. (BAM or I-BAM or IBAM or PBAM).ti,ab,ot,hw. (1657)
14. primary bile acid diarrh?ea$.ti,ab,ot,hw. (3)
15. diarrhea/ (35622)233
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23416. ((chronic or watery or recur$ or persist$ or protracted or continual$ or continuous$ or sustain$ or
constant$ or relentless$ or unrelent$ or functional or aggressive) adj2 diarrh?e$).ti,ab,ot,hw. (6806)
17. "Bile Acids and Salts"/ (18352)
18. (malabsorb$ or mal-absorb$ or malabsorp$ or mal-absorp$).ti,ab,ot,hw. (13612)
19. ((bile or biliary) adj3 (acid$ or salt$)).ti,ab,ot,hw. (28246)
20. or/13-19 (79804)
21. 12 and 20 (1746)
22. randomized controlled trial.pt. (322599)
23. controlled clinical trial.pt. (84057)
24. randomized.ab. (227373)
25. placebo.ab. (130354)
26. randomly.ab. (163568)
27. trial.ab. (235465)
28. groups.ab. (1082545)
29. or/22-28 (1586402)
30. Clinical Trials as Topic/ or Clinical Trials, Phase I as Topic/ or Clinical Trials, Phase II as Topic/ or
Clinical Trials, Phase III as Topic/ or Clinical Trials, Phase IV as Topic/ or Controlled Clinical Trials as
Topic/ (173991)
31. Cohort studies/ or comparative study/ or follow-up studies/ or prospective studies/ (2204429)
32. (Cohort or compar$ or groups or multivariate).ti,ab,ot,hw. (4454648)
33. or/30-32 (4921469)
34. 29 or 33 (5121407)
35. animals/ not (animals/ and humans/) (3630436)
36. 34 not 35 (4030238)
37. 21 and 36 (532)
Based on Trials filter:
Lefebvre C, Manheimer E, Glanville J. Chapter 6: searching for studies. Box 6.4.c: Cochrane Highly
sensitive search strategy for identifying randomized controlled trials in Medline: Sensitivity-maximizing
version (2008 version); OVID format. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008.
Available from www.cochrane-handbook.org
&
Based on Non-randomised studies filter: Fixed method B:
Furlan AD, Irvin E, Bombardier C. Limited search strategies were effective in finding relevant
nonrandomized studies. Journal of Clinical Epidemiology 2006;59(12):1303-11. [Ovid]Appendix 2
Checklists for the methodological quality assessment of case–control and
cohort studies:
A. Case–control studiesl Is the case definition explicit?
l Has the disease state of the cases been reliably assessed and validated?
l Were the controls randomly selected from the source of population of the cases?
l Were interventions and other exposures assessed in the same way for cases and controls?NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17610 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 61l How was the response rate defined?
l Were the non-response rates and reasons for non-response the same in both groups?
l Is it possible that over-matching has occurred in that cases and controls were matched on factors
related to exposure?
l Was an appropriate statistical analysis used (matched or unmatched)?B. Cohort studiesl Is there sufficient description of the groups and the distribution of prognostic factors?
l Are the groups assembled at a similar point in their disease progression?
l Is the intervention/treatment reliably ascertained?
l Were the groups comparable on all important confounding factors?
l Was there adequate adjustment for the effects of these confounding variables?
l Was a dose-response relationship between intervention and outcome demonstrated?
l Was outcome assessment blind to exposure status?
l Was follow-up long enough for the outcomes to occur?
l What proportion of the cohort was followed-up?
l Were drop-out rates and reasons for drop-out similar across intervention and unexposed groups?Appendix 3
NICE guidelines on interventions for the treatment of chronic diarrhoea:
None.Other relevant guidelines:l Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary
care. February 2008. Available from http://guidance.nice.org.uk/CG61
l Mowat et al. (2011) Guidelines for the management of inflammatory bowel disease in adults.
Gut;60:571–607.235
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